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Abstract
Genetic Dissection of Quantitative Trait Loci for Substances of Abuse
By Jo Lynne Harenza, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Major Director, Michael F. Miles, M.D., Ph.D., 
Professor, Pharmacology and Toxicology and Neurology
  It has been reported that an individual’s initial level of response to a drug might 
be predictive of his or her future risk of becoming dependent, thus basal gene 
expression profiles underlying those drug responses may be informative for both 
predicting addiction susceptibility and determining targets for intervention. This 
dissertation research aims to elucidate genetic risk factors  underlying acute alcohol and 
nicotine dependence phenotypes using mouse genetic models of addiction. 
Phenotyping, brain region-specific mRNA expression profiling, and genetic mapping of a 
recombinant inbred panel of over 25 mouse strains were performed in order to identify 
xxi
quantitative trait loci (QTL) harboring candidate genes that may modulate these 
phenotypes. Previous BXD (B6 x D2) behavioral studies performed in our laboratory 
identified an ethanol-induced anxiolysis-like QTL (Etanq1) in the light dark box (LDB). 
We hypothesized that genetic variation within Nin (a gene within the Etanq1 support 
interval involved in microtubule-anchoring) may modulate anxiolytic-like responses to 
acute ethanol in the LDB as well as other preclinical models of anxiety, the elevated 
plus maze (EPM), and marble burying (MB) task. Molecular studies have allowed us to 
confirm cis regulation of Nin transcript levels in the NAc. To elucidate potential 
mechanisms mediating Etanq1, the pharmacological tools, diazepam and HZ166 (a 
benzodiazepine derivative) were utilized to interrogate whether GABAA receptor 
activation modulates ethanol’s anxiety-like behaviors in the LDB. We show that the LDB 
phenotype, percent time spent (PTS) in the light following a brief restraint stress, is not 
being modulated through direct activation of GABAA α2/α3 receptor subunits. To 
genetically dissect Etanq1 as  well as parse the ethanol anxiolytic-like phenotype, we 
have assayed 8 inbred strains, selected based on genotypes at Nin, in various 
preclinical models of anxiety. Principal components analysis of these behavioral data 
suggests that the gene(s) modulating the ethanol anxiolytic-like component in the LDB 
do not overlap with similar phenotypes in the elevated plus maze (EPM), nor the MB 
phenotype. Furthermore, site-specific delivery of an sh-Nin lentivirus into the NAc of D2 
mice revealed that Nin may modulate one LDB endophenotype, latency to enter the 
light side of the LDB, which loaded as a part of the “anxiolysis” principal component. 
These data strongly imply that basal neuronal Nin expression in the NAc is important for 
acute ethanol anxiolytic-like behavior, perhaps through a novel mechanism involving 
xxii
synaptic remodeling. In separate behavioral QTL mapping studies, we hypothesized 
that genetic variation regulating expression of Chrna7 modulates the reward-like 
phenotype, conditioned place preference (CPP), for nicotine. We provide evidence for 
genetic regulation of Chrna7 across the BXD panel of mice and through 
pharmacological and genetic behavioral studies, confirm Chrna7 as a quantitative trait 
gene modulating CPP for nicotine in mice. Microarrays, followed by network analyses, 
allowed us to identify a genetically co-regulated network within the nucleus accumbens 
(NAc), differentially expressed in mice null for Chrna7, which was similarly correlated in 
the BXD panel of mice. Our network and molecular analyses  suggest a putative role for 
Chrna7 in regulating insulin signaling in the NAc, which together, may contribute to the 
enhanced sensitivity to nicotine observed in strains of mice that lack or have low mRNA 
levels  of Chrna7 in the NAc. Overall, this  research has elucidated and confirmed new 
genetic risk factors underlying alcohol and nicotine dependence phenotypes and has 
enabled a better understanding of the neurogenomic bases of alcohol and nicotine 
addiction. Future studies that further investigate the signaling pathways and/or gene 
interactions involving Nin and Chrna7 may lead the field to new candidates for 
pharmacotherapies that may be tailored for use in individuals  with susceptible 
genotypes. Supported by NIAAA grants P20AA017828 and R01AA020634 to MFM, 
NIDA T32DA007027 to WLD, and NIDA R01DA032246 to MFM and MID.
xxiii
Chapter 1 - Introduction
 Alcohol and nicotine are two of the most widely abused drugs in the world, 
accounting for nearly 8 million deaths globally and $5 million of the drug abuse-related 
socioeconomic burden of the United States each year (World Health Organization, 
2011). Risk for developing various aspects of drug addiction, such as  tolerance and 
dependence, is  determined by a combination of interactions among an individual’s 
genetic makeup, environment, and neuroadaptations that occur following acute and 
repeated drug exposure. Alcohol and nicotine dependence each have estimated 
heritabilities ranging between 30-60% (Heath, 1997; Cloninger, 1981; Swan, 1997; 
Kendler, 1999; Heath, 1993; True, 1999), thus, a strong genetic component influences 
these traits. Furthermore, these complex interactions manifest themselves 
heterogeneously among individuals, and as such, there remains a need to understand 
the biological and genetic bases of risk for developing different stages of the disease at 
the level of the individual. 
 In order to dissect neuronal and genetic mechanisms underlying substance use 
disorders, it is essential to acknowledge that drug addiction occurs through a 
progression of cycles, which lead to an evolution of neurogenomic changes that 
ultimately hijack the brain’s executive function center such that control over drug-taking 
is  lost (Koob, 2010). In one such model for the progression from acute to chronic drug 
use, the first stage begins with drug-induced activation of the mesocorticolimbic reward 
1
circuit, which consists of the ventral tegmental area (VTA), ventral striatum or nucleus 
accumbens (NAc), and prefrontal cortex (PFC). See Figure 1.1 for a schematic of the 
neurocircuitry in this pathway. Similar to natural rewards, such as food, liquids, and sex, 
most drugs of abuse, including alcohol and nicotine, increase firing of dopaminergic 
neurons from the VTA to increase synaptic concentrations of the excitatory 
neurotransmitter, dopamine, in the NAc following acute use (DiChiara, 1988). 
Interestingly, our laboratory found that in response to a single administration of a 
modest dose of ethanol in mice, over 300 genes’ expression levels were significantly 
altered in this reward circuit (Kerns, 2005), demonstrating the sensitivity of the central 
nervous system to one dose of a drug. In fact, a single exposure to cocaine in mice has 
been shown to excite dopamine neurons in the VTA and result in subsequent activation 
of AMPA and NMDA receptors which persisted for at least five days (Ungless, 2001), 
suggesting that acute drug use can result in at least short-term synaptic plasticity in the 
mesolimbic reward pathway. It follows then, that repeated drug use, which progressively 
activates this reward circuit, results  in a variety of neuroplastic changes in the VTA and 
NAc, leading to recruitment of feedback circuits  in the dorsal striatum (consisting of the 
caudate and putamen). Repeated activation of the ventral-dorsal striatal loop is thought 
to lead to habit formation and drug-seeking automaticity, which are key drivers of 
compulsive behaviors (Koob, 2010). Eventually, these neuroadaptations  may lead to 
compulsive drug use and loss of executive function maintained by the frontal cortex 
structures, leading to poor decision-making and addiction. Once in full-blown addiction, 
periods of abstinence are characterized by negative withdrawal symptoms, thought to 
2
Figure 1.1 - Neuronal projections involved in mediating effects during the acute 
and reinforcing stages of substance abuse disorders. Sagittal representation of a 
rat brain depicting the neuronal circuitry implicated the early stages of drug addiction. 
(VTA=ventral tegmental area, AC=anterior commissure, N.Acc=nucleus accumbens, 
FC=frontal cortex, C-P=caudate putamen, AMG=amygdala, BNST=bed nucleus  of the 
stria terminalis, VP=ventral palladium, ARC=arcuate nucleus, LH=lateral hypothalamus, 
Snr=substantia nigra pars  reticula, RPn=reticular pontine nucleus, LC=locus  coeruleus. 
Image adapted from (Koob, 2010).
3
result from the gain-of-function of stress systems, such as the extended amygdala 
circuit. Thus, a negative affective state caused by dysregulation of neurocircuitry often 
leads to successive episodes of drug use to curb these symptoms (Koob, 2010). 
Furthermore, in those aspiring to quit, the combination of both a loss  of control and 
enhanced negative emotional state often prevents rehabilitation, as the nervous 
systems of these addicted individuals have essentially been “re-wired” (Figure 1.2). In 
fact, 70% of adult smokers aspire to quit smoking, but only 4-7% are successful without 
medication and just 25% of those using current cessation therapies are able to abstain 
from smoking for six months (American Cancer Society, 2013). The high rates of 
relapse are thought to result from difficulty in managing cravings  and withdrawal 
symptoms (National Institutes  of Health, 2008). Additionally, alcoholics frequently self-
report anxiety as  a motive for initiation of drinking (Brown, 1991; Pohorecky, 1991) and/
or a reason for relapse. Accordingly, alcohol’s ability to relieve anxiety is  thought to 
contribute to multiple facets of the alcohol use disorder, including the initiation of 
drinking, the progression to excessive drinking by attempting to curb withdrawal-induced 
anxiety, and consequently, recidivism (Spanagel, 1995; Pandey 2003; Sloan, 2003). 
Thus, understanding the neurogenomic basis  of the acute behavioral responses  to 
drugs of abuse may be important in uncovering new drug targets and/or lead to new 
therapeutic strategies for intervention.
 The major foci of this dissertation are to genetically dissect acute behavioral 
responses to ethanol and nicotine using mouse models of ethanol-induced anxiolysis 
and nicotine reward. It is  important to note that in many cases of substance abuse 
disorders, individuals also have occurrences of psychiatric illness and/or an additional 
4
stimulant exposure. Such studies have revealed a rich
neuroplasticity associated with mesolimbic dopamine
systems and its terminal projection to the ventral striatum
(where the nucleus accumbens is located). Drugs of abuse
induce short- and long-term modifications of firing of
dopamine neurons in the VTA (Bonci et al, 2003). Studies
have shown that burst firing of dopamine neurons in the
VTA appears to be correlated with an orienting response to
a sensory stimulus (Freeman et al, 1985). A single in vivo
exposure to cocaine or amphetamine induces long-term
potentiation (LTP) of AMPA-mediated excitatory neuro-
transmission in dopamine neurons (Ungless et al, 2001).
The potentiation of synaptic AMPA responses has been
hypothesized to increase the incidence of burst firing
(Jones and Bonci, 2005). Persistent LTP lasting for 3 months
of abstinence was induced in the VTA in rats that actively
self-administered cocaine but not in passively injected rats
(Chen et al, 2008). Similar effects of induction of LTP of
glutamate transmission on dopamine neurons have been
observed with morphine and nicotine (Saal et al, 2003).
However, more chronic repeated administration of
psychostimulants failed to produce sensitization of meso-
limbic dopamine activity as measured by in vivo micro-
dialysis (Maisonneuve et al, 1995). In addition, extended
access to cocaine fails to produce locomotor sensitization
(Ben-Shahar et al, 2004) but does produce a sensitized
stereotyped behavior response (Ferrario et al, 2005).
Moreover, human cocaine abusers showed attenuated
dopamine responses when challenged with a stimulant
drug, which is opposite to that predicted by the enhanced
sensitization of mesolimbic dopamine activity (Volkow
et al, 1997b; Martinez et al, 2007).
Ventral Striatum: Incentive Salience Pathways,
Salience Attribution
Another plasticity associated with behavioral sensitization
is a persistent potentiation of nucleus accumbens excitatory
synapses that is observed after repeated drug exposure
followed by an extended drug-free period (Kourrich et al,
2007). Repeated cocaine administration increases glutamate
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Figure 5. Neurocircuitry schematic illustrating the combination of neuroadaptations in the brain circuitry for the three stages of the addiction cycle that
promote drug-seeking behavior in the addicted state. Note the activation of the ventral striatum/dorsal striatum/extended amygdala driven by cues
through the hippocampus and basolateral amygdala and stress through the insula. The frontal cortex system is compromised, producing deficits in
executive function and contributing to the incentive salience of drugs compared to natural reinforcers. Dopamine systems are compromised, and brain
stress systems such as CRF are activated to reset further the salience of drugs and drug-related stimuli in the context of an aversive dysphoric state
(modified with permission from Koob et al, 2008a).
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Figure 4. Schematic drawing describing the sequential and cumulative
effects of neuroadaptive changes hypothesized to contribute to the
neuroplasticity that promotes compulsive drug-seeking. An early neu-
roadaptation, common to all drugs of abuse and observed after a single
injection of cocaine, is increased excitability of the mesolimbic dopamine
system reflected in long-term potentiation dependent on changes in
glutamate activity. Subsequently, the activation of dopamine contributes
to increased excitability of the ventral striatum with decreased gluta-
matergic activity during withdrawal and increased glutamatergic activity
during drug-primed and cue-induced drug-seeking. The engagement of
ventral striatal-pallidal-thalamic loops is hypothesized to translate to the
dorsal striatum to contribute to engagement of habits and automaticity
that resemble compulsive-like behavior. As compulsivity evolves into full-
blown addiction, loss of function occurs in the frontal cortex systems that
control executive function, contributing to poor decision-making and gain
of function in the brain stress systems but contributing to incentive
salience for drugs over natural reinforcers.
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Figure 1.2 - Diagram illustrating one model for the progression from acute to 
chronic drug use. Neuroplastic changes occurring as a result of cute and cycles of 
repeated drug use are thought to contri ute t  compulsive drug use and ultimately lead 
to addiction. Acute drug use promotes increases in synaptic dopamine within NAc and 
with repeated use, activation of the neuronal loop between the ventral and dors l 
striatum results  in habit formation. Successive drug use leads to alteration of the frontal 
cortical circuitry, resulting in poor decision-m king and continu d use. Chronic  drug use 
ngages the extended amygdal , leading to increases in n uron l stress systems, 
which drug users attempt to counteract by increasing drug use. This cycle eventually 
leads to compulsive drug use and addiction due to a loss of control over these neuronal 
systems. Illustration adapted from (Koob, 2010).
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substance use disorder. In fact, co-morbidities  between nicotine and alcohol use 
disorders (Dani, 2005) as well as between anxiety disorders and alcohol addiction  exist 
(Swendsen, 1998). However, these interactions are beyond the scope of and were not 
assessed for this  body of work. Rather, behavioral responses and genes underlying 
each substance abuse disorder were interrogated independently. We hypothesize that 
uncovering genes modulating or altered in response to such behaviors may lead to a 
better understanding of the cycle of addiction and as will be discussed in the next 
section, may be predictive of chronic use of the same drug. The studies  herein have 
elucidated and confirmed a role for two candidate genes in these behaviors, Ninein 
(Nin) as a potential modulator of an acute ethanol anxiolytic-like phenotype, and Chrna7 
for an acute nicotine reward-like phenotype. Furthermore, each acute phenotype 
correlates to chronic behavioral responses to the same drug, suggesting that Nin and 
Chrna7 are important players  in the early cycles of alcohol and nicotine addiction, 
respectively. Additional studies described within this dissertation have investigated the 
mechanism by which the basal expression levels of each of these genes might influence 
an acute drug response in the behavioral assays tested. This work has therefore 
uncovered novel candidate genes and as will be discussed, potential signaling 
pathways underlying acute ethanol and nicotine phenotypes within the NAc, a key brain 
region involved in the acute responses to drugs. Overall, this work has elucidated two 
potential genes whose basal NAc expression levels  suggest a new pool of individuals 
who may be more sensitive than others to the acute effects  of alcohol or nicotine. Thus, 
future studies investigating the downstream molecular consequences of altered basal 
6
expression of Nin and Chrna7 may further elucidate the pharmacological mechanisms 
of acute ethanol-induced anxiolysis and nicotine reward, respectively. 
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Chapter 2 - Background and Significance
Role of acute drug responses in alcohol addiction
 Marc Schuckit, a pioneer in the alcohol field, made early observations that in 
families  with a history of alcoholism, an individual's  initial response to moderate doses 
of alcohol, measured as perceived intoxication (Schuckit, 1980) and/or the degree of 
body swaying (Schuckit, 1994), was correlated inversely with his/her later risk for 
becoming an alcoholic. Using the Subjective High Assessment Scale (SHAS), 21-25 
year-old male sons or siblings of alcoholics  were assessed for blood alcohol 
concentration (BAC) and subjective “high” at multiple time points  following consumption 
of a 20% solution of ethanol, dosed by kilogram of body weight. Although there was no 
overall difference in BAC compared to controls, males from alcoholic families reported 
significantly different feelings on 22 of the 38 subjective measures probed. Principal 
components analysis (PCA) performed using responses to both low and high doses of 
ethanol in these same groups  of men allowed identification of two major independent 
factors contributing to roughly 60% of the variance: subjective feelings on the SHAS 
after a high dose of ethanol (46%) and cortisol levels  combined with sway responses 
after both high and low doses of ethanol (14%) (Schuckit, 1988). These analyses 
reproducibly allowed the prediction of whether the subject came from a family with a 
history of alcoholism or not. Furthermore, a longitudinal study performed when these 
men were 31-35 years  of age revealed that 56% of men originally documented as 
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having low subjective responses to alcohol developed alcoholism, regardless of family 
history, compared to only 14% of those who had high initial levels of response and this 
difference was statistically significant (Schuckit, 1994). Thus, sons of alcoholics as well 
as comparison subjects  developed alcoholism, therefore, these studies suggest that 
uncovering the genetic and/or molecular mechanisms underlying the initial response to 
alcohol might allow us to predict one’s susceptibility to becoming alcoholic later in life. 
 These observations may not be unique to alcoholism. In fact, substance abuse 
studies in rodents  have begun to uncover acute phenotypic responses which may 
predict chronic drug intake. For example, a study in male Long Evans rats tested 
whether hypothermic responses to the exposure to a 3-hour vapor of the widely-abused 
inhalant, nitrous oxide (N2O), could predict later tolerance to the drug. Rats  that 
developed acute tolerance to the hypothermic effects of N2O, that is, experienced a low 
level of response to the inhalant, developed full tolerance to repeated bouts  of N2O, 
while the group that was sensitive to the acute hypothermic effects of N2O did not 
develop chronic tolerance (Ramsay, 2005). Furthermore, preliminary investigation of 
acute and chronic drug responses across a recombinant inbred panel of mice indicate 
that certain initial drug phenotypes do correlate to chronic phenotypes for the same 
drug. Additionally, these relationships are not always inverse. Specifically of note for this 
dissertation, an acute nicotine reward-like phenotype correlates positively to an 
anxiolytic-like phenotype following chronic nicotine administration (Figure 2.1, a) and an 
acute ethanol-induced anxiolytic-like phenotype was found to correlate positively to 
ethanol drinking behaviors using a two-bottle choice paradigm (Figure 2.1, b). The
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Figure 2.1 - Correlation between acute and chronic drug phenotypic responses in 
mice. Using publicly available datasets from the GeneNetwork web resource, Pearson 
correlations across the BXD RI panel reveal that acute responses to nicotine and 
ethanol might predict chronic phenotypic responses to the same drugs. Panel a, a 
nicotine preference phenotype (GN Record ID 14803) significantly correlates positively 
with a chronic nicotine anxiolytic-like response (GN Record ID 15575) as measured 
using an elevated plus maze. Pearson’s  multiple r=0.483, adjusted r=0.3801, p=0.0415, 
n=23, outliers removed. Panel b, acute ethanol’s anxiolytic-like phenotype (GN Record 
ID 10964) measured using the light-dark box shows a near significant positive 
correlation with daily ethanol consumption using a two-bottle choice paradigm (GN 
Record ID 12623). Pearson’s multiple r=0.4569, adjusted r=0.3951, p=0.0652, n=17.
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details  of these exact phenotypic responses to nicotine and ethanol will be described 
later in this section.
 Anxiety has been reported to play a key, yet complex, role in multiple aspects  of 
alcoholism, such as the initiation of drinking behavior, reinforcement, withdrawal effects, 
and relapse (Spanagel, 1995; Pandey, 2003; Pohorecky, 1991; Pohorecky, 1991; 
Colombo, 1995; Stewart, 1993). Human studies have observed a high prevalence of 
anxiety symptoms among alcohol-dependent individuals (Schuckit, 1990) and a higher 
than expected rate of anxiety symptoms in the individuals one year post-abstinence 
(Schuckit, 1990; Brown, 1991), suggesting that both genetic predisposition for higher 
anxiety levels and pharmacodynamic neuroadaptations resulting in increased anxiety 
levels  during abstinence periods following chronic use influence drinking behavior. This 
complex cycle is depicted in Figure 2.2. One human study reported that increased 
“state” anxiety (as measured by a tension-anxiety scale) was correlated with increased 
drinking behavior (Sloan, 2003). Additionally, a study in Wistar rats  reported that 
increased basal anxiety resulted in increases in drinking behavior and preference 
(Spanagel, 1995). Although a solid link between ethanol’s  acute anxiolytic effect and 
later drinking behavior has  not been established in rodent models, genetic correlations 
we have performed do suggest a possible link. Thus, there remains a need for 
understanding the complex relationship between anxiety and alcohol. 
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Figure 2.2 - Model of the involvement of anxiety in alcohol addiction disorders. 
Flow diagram depicting the multiple stages of alcohol use in which anxiety levels play a 
role in drinking behaviors. An individual may be genetically predisposed to high basal 
anxiety levels, leading to initiation of and social drinking behaviors. Alternatively, 
engaging in social and/or intermittent drinking behaviors to relieve anxiety may promote 
detrimental pharmacodynamic effects  in the brain of susceptible individuals. Both 
possibilities may lead to continued drinking, followed by abstinence periods in which 
anxiety levels  rise and drinking is  repeated to relieve anxiety. Repetition of this  cycle 
results in neuroadaptations, leading to chronic drinking and when compulsion and loss 
of control ensue, addiction. Adapted from (Pandey, 2003).
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Brain regions and neurotransmitters involved in “anxiety”.
! Anxiety is often diagnosed clinically as a sense of apprehensiveness or panic 
despite the absence of an immediate threat (Lieb, 2005) and many forms of anxiety 
disorders exist. Functional MRI (fMRI) studies performed on human subjects diagnosed 
with anxiety disorders confirmed two brain regions commonly associated with anxiety as 
it relates to fear response and suppression, the amygdala and ventral prefrontal cortex 
(vPFC), respectively (Indovina, 2011). The amygdala receives sensory input from the 
hippocampus, thalamus, and executive cortices (eg, PFC) through its basolateral and 
lateral nuclei, termed the basolateral amygdala (BLA), and subsequently, integrates this 
information into a signal which it sends to the central amygdala (CeA), bed nucleus of 
the stria terminalis (BNST), and NAc via glutamatergic efferents (McCool, 2010). 
Collectively, the CeA, BNST, and NAc are referred to as the “extended amygdala”. 
Furthermore, optogenetics studies in mice have recently dissected the microcircuitry of 
the amygdala to find that activation of BLA glutamatergic terminals in the CeA result in a 
reversible anxiolytic-like response in the elevated plus maze and open field preclinical 
anxiety tests, while inhibition of this projection produced an anxiogenic-like response in 
the same assays (Tye, 2011). Thus, the involvement of the amygdala in anxiety-related 
emotional states is well-accepted.
! Interestingly, fMRI studies in which personalized stressful imagery relating to past 
experiences was shown to healthy  subjects, revealed significant increases in activation 
of the medial prefrontal cortex (mPFC), anterior cingulate, striatum, substantia nigra, 
thalamus, caudate, putamen, and hippocampus (Sinha, 2004), indicating a role for the 
striatal-limbic-prefrontal circuits in response to emotional distress. In support of this, 
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eQTL mapping studies in the Miles laboratory  implicate genes within the nucleus 
accumbens (NAc) as potential modulators of anxiolytic-like phenotypes following acute 
ethanol administration (Putman, 2008; Wolen, 2012). Though generally thought to be 
the “reward” and reinforcement” center of the brain, rather than perceiving “anxiety”, 
studies have shown a neuroanatomical circuit link between the amygdala and the NAc. 
As mentioned earlier, the NAc is a component of the extended amygdala circuit. In fact, 
in monkeys and mice, the amygdala was found to contain projections to multiple regions 
of the striatum, including the NAc (Russchen, 1985; Novejarque, 2011). Thus, activation 
of these projections in response to an anxiogenic-like or anxiolytic-like stimulus, such as 
a saline or ethanol injection, likely  triggers signaling events in the NAc, which may have 
been captured by microarray gene expression profiling performed following behavioral 
testing in the LDB (Putman, 2008). 
! Alcohol has numerous molecular targets in the central nervous system, many of 
which have also been linked strongly to anxiety, making it difficult to dissect ethanol’s 
anxiolytic mechanism. These include many of the systems discussed below, but a larger 
weight has been placed on the gamma-aminobutyric acid receptor subunit A (GABAA) 
system, as that is the focus of Chapter 5.
Gamma-aminobutyric acid (GABA)
 It has been well-established that ethanol, similar to benzodiazepines, 
barbiturates, anesthetics, and neurosteroids, is  a positive allosteric modulator of GABAA 
receptors, potentiating GABAergic neurotransmission (Sieghart, 1994; Rudolph, 1999; 
Kumar, 2004). Since cross-tolerance exists  between chronic ethanol and 
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benzodiazepines or barbiturates and these classes of drugs are often used to treat 
alcohol withdrawal and anxiety (Kumar, 2004), GABAA receptors have long been 
implicated in the interplay between alcohol and anxiety (Enoch, 2008; Ducci, 2007; Low, 
2000; Griebel, 2000; Buck, 2001). GABAA receptors are heteropentameric ligand-gated 
ion channels most commonly comprised of 2α, 2 β, and 1ϒ subunits. Diazepam has 
been the prototypical anxiolytic used in research because of its anxiolytic effects 
observed clinically (Chouinard, 1983). Diazepam act as an agonist at α1, α2, α3, α5, β, 
and ϒ2 subunits of GABAA receptors with comparable affinities (Mohler, 1977; 
Braestrup, 1977). Studies using mice with a point mutation in the α1 subunit (H101R), 
rendering the subunit diazepam-insensitive (Rudolph, 1999), revealed that the α1 
subunit controls the sedation and anti-convulsant effects of diazepam (Rudolph, 1999), 
but not anxiolytic effects. Later, studies linked the α2 subunit to anxiolysis through 
generation of two additional GABAA subunit mutants, the α2(H101R) or α3(H126R), 
rendering them diazepam-insensitive (Low, 2000; Crestani, 2001). PTS in the light side 
of a LDB increased dose-dependently versus control following low doses of diazepam 
(0.5, 1, and 2 mg/kg, p.o.) in both WT and α3 mutants, but not α2 mutants. PTS in the 
open arms of the EPM following a low dose of diazepam (2mg/kg, p.o.) was  significantly 
increased in WT and α3 mutants, but not α2 mutants, suggesting that diazepam’s 
anxiolytic effect is  mediated through GABAA α2 subunits, but not α3 (Low, 2000). 
However, TP003, a GABAA α3 selective agonist, produced anxiolytic-like effects  in a rat 
unconditioned model and a non-human primate conditioned model of anxiety, 
demonstrating that α3 subunits  do play a role in anxiolysis (Dias, 2005). In rhesus 
monkeys, the specific GABAA α2/α3 agonist, HZ-166, produced an anti-conflict 
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response similar to diazepam without locomotor suppression effects  (Fischer, 2010). 
Furthermore, multiple human studies, through the Collaborative Study on the Genetics 
of Alcoholism (COGA) dataset and independent samples, have identified strong 
evidence of association between alcohol dependence and Gabra2, the gene encoding 
the GABAA α2 subunit (Edenberg, 2004; Pierucci-Lagha, 2005; Covault, 2004; Dick, 
2006; Fehr, 2006; Lappalainen, 2005; Soyka, 2008). Therefore, we chose to interrogate 
the GABAA receptor system, hypothesizing that ethanol might be eliciting its anxiolytic-
like effects, PTS and PDT in the light side of the LDB, through this system.
Corticotrophin-releasing hormone (CRH)
 A large body of literature consists of evidence of the involvement of the “stress” 
hormone, corticotrophin-releasing hormone, CRH (aka, corticotrophin releasing factor, 
CRF), in both anxiety and alcohol use disorders. CRH, secreted by the hypothalamus in 
response to a stress stimulus, activates its  receptors, Crhr1 and Crhr2, on the anterior 
pituitary glands. This triggers the release of a second neurohormone, adreno-
corticotrophic hormone, ACTH, which binds to and activates  its receptors on the adrenal 
glands, finally leading to the release of the neurosteroid, cortisol in humans or 
corticosterone in rodents. Cortisol has widespread effects on the body, but its major role 
is  to counteract the stress response and attempt to return the body to homeostasis. 
Once this is  achieved, cortisol can negatively regulate its  own production through 
inhibitory feedback loops at the level of secretion of both CRH and ACTH. This 
biochemical pathway is  known as the hypothalamic-pituitary-adrenal (HPA) axis. Mice 
lacking a functional Crhr1 gene displayed dampened HPA axis activation to acute stress 
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and showed significant decreases in latency to enter and increases in time spent in the 
center of an open field compared to wild-type mice, indicating overall decreases in basal 
anxiety-like levels in these mice (Smith, 1998; Timpl, 1998). Furthermore, these same 
Crhr1 knockout mice demonstrated a significantly reduced anxiogenic-like phenotype 
following withdrawal from a forced ethanol-drinking paradigm, as indicated by more time 
spent in the light side of the LDB compared to wild-type mice (Timpl, 1998). Additionally, 
administration of the pharmacological Crhr1 antagonist, CP-154,526, in the Balb/c 
mouse strain resulted in significant increases in time spent in the light side of the LDB 
compared to vehicle-treated mice, however, did not cause increases in percent time 
spent in the open arms of the EPM (Griebel, 1998). In contrast to these studies which 
generally support a role for Crhr1 in anxiety-like behaviors, experiments targeting Crhr2 
suggest that it has  a role in mediating anxiolytic-like responses. Following LDB and 
EPM testing, Kishimoto and colleagues found that Crhr2 knockout mice spent less time 
in both the light and open arms, respectively, compared to their wild-type counterparts 
(Kishimoto, 2000). Furthermore, Crhr2 knockout mice showed hypersensitive stress 
responses, as evidenced by significantly higher levels of plasma corticosterone after 
both 2 and 10 minutes of restraint stress (Bale, 2000). Pharmacogenetic experiments, in 
which antisense mRNA oligonucleotides, designed against either Crhr1 or Crhr2, were 
infused into the lateral ventricle of male Wistar rats, revealed some interesting findings 
related to the role of these receptors in stress- and anxiety-related behaviors. Four days 
following infusion, mice were immersed into a social defeat challenge to engage 
anxiogenic-like behaviors and immediately tested in the EPM. Infusion of the Crhr1 
antisense sequence resulted in increases in anxiolytic-like responses, supporting 
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aforementioned observations, however infusion of the Crhr2 antisense sequence did not 
alter defeat-induced anxiogenic-like responses (Liebsch, 1999). Following a forced-
swim test, used to assess stress-coping behavior, rats  with the Crhr2 antisense 
oligonucleotides showed increased immobility, but no differences were found in rats 
infused with the Crhr1 antisense sequence (Liebsch, 1999). The authors concluded that 
perhaps Crhr1 is involved in mediating the affective aspect of stress, while Crhr2 is 
involved in stress-coping mechanisms. 
 In addition to its role in stress and anxiety, genetic variation within the CRH 
system has been associated with alcohol addiction phenotypes. Genome-wide 
association studies using the COGA dataset have identified a single nucleotide 
polymorphism (SNP) in Crhr1 that is significantly associated with alcohol dependence 
(Chen, 2010). Another study found that increased incidences of stressful life events in 
individuals with homozygous  C alleles for the Crhr1 SNP, rs1876831, were significantly 
associated with an earlier age of drinking initiation and higher consumption of alcohol 
when exposed to stress. Additionally, individuals with an A allele for rs242938 also 
showed significantly higher levels of alcohol consumption following stress (Schmid, 
2010). Thus, the CRH system is not only involved in stress and anxiety emotional 
states, but also may be important in modulating responses to both acute and chronic 
ethanol.
Neuropeptide Y (NPY)
 NPY is an endogenous  36 amino acid peptide found at its highest CNS 
concentrations in the basal ganglia, amygdala, and nucleus accumbens, suggesting its 
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importance in motor function and/or anxiety-related emotion (Adrian, 1983). NPY acts at 
four different receptors, NPY Y1, NPY Y2, NPY Y3, and NPY Y5, but its anxiolytic-like 
properties are thought to be elicited through the NPY Y1 receptor (gene name, Npy1r). 
Early studies by Markus Heilig and colleagues showed that infusion of low doses of 
NPY into the lateral ventricle of male albino rats  significantly increased preference for 
the open arms of the EPM following the Montgomery conflict test, which was used to 
raise anxiety levels  prior to testing (Heilig, 1989). As expected, high doses of NPY 
resulted in decreases in locomotor activity. Additional intracerebroventricular (i.c.v.) 
infusion studies in rodents found that NPY produced anxiolytic-like responses in 
punished responding (Heilig, 1992) and fear-potentiated startle (Broqua, 1995) anxiety 
models. NPY knockout mice displayed anxiogenic-like phenotypes in the open field test 
and acoustic startle tests (Bannon, 2000), further supporting the notion that NPY 
promotes anxiolytic-like behaviors. Intra-amygdalar infusions of NPY into the basolateral 
(BLA), but not central (CeA), amygdala resulted in anxiolytic-like response in the social 
interaction test. Furthermore, the BLA anxiolytic-like effect was reversed with an NPY 
Y1-selective antagonist but not its inactive enantiomer (Sajdyk, 1999).
 Genetic variation within the NPY gene and its receptors have been associated 
with alcohol dependence phenotypes in both model organisms and human studies. For 
example, loss-of-function of Npr-1 (an NPY-like receptor gene) in the nematode model 
organism, Caenorhabditis elegans, resulted in a faster rate of development of an 
ethanol acute functional tolerance phenotype (Davies, 2004). In humans, two SNPs 
upstream of the Npy2r gene, rs4425326 and rs6857715, were significantly associated 
with alcohol dependence and two intronic and one promoter SNP within Npy5r were 
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significantly associated with withdrawal-induced seizures using the COGA dataset 
(Wetherill, 2008). Overall, this subset of the many studies investigating the NPY system 
not only demonstrates  its involvement in anxiety-related behaviors and ethanol-
responsive phenotypes, but also suggests that the interactions are complex.  
Cannabinoid (CB) Receptors.  
 Evidence exists linking the endogenous cannabinoid (EC) system with both 
anxiety as  well as the rewarding and reinforcing aspects of drugs of abuse, including 
ethanol. The EC system consists of two receptors, CB1 and CB2, activated by the 
endogenous cannabinoids, anandamide (AEA) and 2-arachidonylglycerol (2-AG) 
(Rinaldi Carmona, 1996). Specifically, the CB1 receptor (gene name, Cnr1) has been 
implicated in anxiolytic-like as  well as ethanol-responsive behaviors in rodent and 
human studies. Hungund and colleagues reported differences in both CB1 receptor 
density and affinity in the brains of C57BL/6J and DBA/2J mice, strains  which display 
multiple divergent responses to ethanol. B6 mice exhibit a 25% lower density, but 
greater affinity of CB1 receptors than D2 mice (Hungund, 2000). As B6 mice voluntarily 
consume ethanol and D2 mice typically avoid it (McClearn, 1959), these results may 
suggest a relationship between CB1 signaling and drinking behavior. Moreover, Cnr1 
knockout mice display reduced ethanol self-administration (Wang, 2003) and preference 
(Vinod, 2008), but increased basal anxiogenic-like phenotypes in the LDB, EPM, and 
social interaction assays (Uriguen, 2004). Cnr1 knockouts also failed to display 
increases in anxiolytic-like responses the clinically-prescribed anxiolytics, bromazepam 
(a benzodiazepine) and buspirone (a 5HT1A partial agonist), compared the wild-type 
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strains in the LDB test (Uriguen, 2004). Behavioral pharmacology studies targeting the 
CB1 receptor reported an increased anxiogenic-like phenotype in the an outbred strain 
of mice, CD-1, tested in the EPM, open field (OF), and elevated T-maze models of 
anxiety following administration of a low dose of CB1-selective antagonist, SR141716 
(Thiemann, 2009). These findings may suggest a role for activation of CB1 receptors in 
mediating acute anxiolytic-like phenotypes and/or chronic ethanol drinking behaviors.
Behavioral models for assessing acute phenotypic responses to drugs
Preclinical anxiety assays
! The rodent model of anxiety from which this project stemmed is  the light-dark box 
(LDB) due to its predictive validity in assessing select benzodiazepines known to be 
anxiolytic in humans (Crawley, 1980; Borsini, 2002; Hart, 2010). Mice have an innate 
aversion to light, so when faced with a choice between light (or white) and dark (or 
black) chambers (diagrammed in Appendix A1), they spend more time (Costall, 1989) 
and travel a greater distance (Onaivi, 1989) in dark side of the LDB. Conversely, 
following administration of clinically-prescribed anxiolytic drugs such as benzo-
diazepines, mice will spend significantly more time or explore more in the light side of 
the box, thus this  preference for the light side is routinely interpreted as anxiolytic-like 
(Crawley, 1980; Blumstein, 1983). In support of this, when given an acute dose of 
ethanol, a drug known to cause anxiolysis in humans, mice spend a significantly greater 
amount of time and travel a greater distance in the light side of the LDB compared to 
mice pretreated with saline. Accordingly, our laboratory has identified that these two 
phenotypic responses to ethanol, percent time spent (PTS) and percent distance 
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traveled (PDT) in the light are complex traits which are tightly genetically correlated to 
each other (Putman, 2008) and a major portion of this dissertation focused on 
elucidating the genetic variants underlying these phenotypes in mice. 
 A second major preclinical model of anxiety utilized throughout the experiments  
presented herein is  the elevated plus maze (EPM), in which four arms in the shape of a 
cross, two with walls and two without walls, are elevated from the ground (diagrammed 
in Appendix A2). In this  assay, clinically efficacious anxiolytic drugs which increase in 
the time spent on the open arms and/or number of entries into the open arms have 
given the EPM predictive validity as an assay measuring “anxiety” (Pellow, 1985; Hart, 
2010). However, alternative interpretations of phenotypic responses in this assay 
include measurement of fear-related, avoidance, conflict, and/or risk-taking behavior. 
Furthermore, this particular assay may measure some aspect of stress, as mice 
exposed to only the open arms of the maze show increases of plasma corticosterone 
levels  (Fernandes, 1996), a hormone produced in response to stress-induced activation 
of the hypothalamic pituitary adrenal axis. Additionally, male DBA/2J mice exposed to 
social defeat stress show decreases in time spent in the open arms (Rodgers, 1993). 
 A third experimental model utilized in a portion of the experiments is marble 
burying (MB) behavior, however, its translation to a particular affective human condition 
is  widely debated. In this assay, a cage is  filled with bedding and 20 marbles are placed 
in an evenly-spaced grid and the number of marbles buried during a test session is 
recorded. The earliest record of this test reported its  utility in discriminating major versus 
minor tranquilizers such that administration of major tranquilizers resulted fewer marbles 
buried, likely due to locomotor suppression effects (Broekkamp, 1986). Later, the test 
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was suggested to model anxiety under the premise that rodents tend to bury novel or 
noxious objects using both conditioned and unconditioned methods. For example, rats 
buried novel glass marbles (Poling, 1981) as well as drinking spouts containing tobasco 
sauce, but not those containing water or a palatable saccharin solution (Wilkie, 1979). 
Additionally, the clinically-prescribed anxiolytics, diazepam, alprazolam, chlor-
diazepoxide, and buspirone, all decreased marble burying at doses that did not 
suppress locomotor activity in C57BL/6J mice (Njung'e, 1991; Nicholas, 2006), 
supporting its predictive validity in assessing anxiolytic-like phenotypes in rodents. 
Interestingly, marble burying was also significantly reduced following anti-depressant 
(paroxetine, fluoxetine, and citalopram), anti-psychotic (haloperidol and chlor-
promazine), opiate (morphine), stimulant (D-amphetamine), and muscarinic AChR 
antagonist (atropine) administration at doses which did not significantly decrease 
locomotor activity (Nicholas, 2006). These studies suggest that the marble burying test 
might be measuring some factor common to each of the affective states mentioned.  
 As suggested above, “anxiety” is not a unitary phenomenon, but rather, is  
comprised of multiple dimensions including, but likely not limited to, fear, suppression of 
novelty-seeking, general activity, avoidance, stress, and/or decision-making when faced 
with conflict (Henderson, 2004; Turri, 2001; Clement, 2007; Brigman, 2009; Rodgers, 
1995), making interpretation and generalization of phenotypic responses across assays 
challenging. Furthermore, it has been shown that the phenotypes measured by each 
behavioral assay are made up of unique combinations of these dimensions (Turri, 
2001), contributing to the overall phenotypic response. Even more striking, an early 
factor analysis study determined that anxiolytic-like activity on the open arms of the 
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EPM with ledges loaded onto one factor, while activity on arms without ledges loaded 
onto another (Fernandes, 1996). Thus, the genetic variants driving these complex 
phenotypes are highly sensitive to the assay, its  construction, environmental factors, 
and dimensions of multiple assays may both overlap and be distinct.
 
Rodent models of reward
 As described earlier, most substances of abuse activate the mesolimbic 
dopamine pathway, which results in rises in extracellular dopamine levels to promote 
signaling events leading to the perception of reward. One way this is  modeled in rodents 
is  through a Pavlovian conditioned stimulus  choice test, known as conditioned place 
preference (CPP). The premise behind CPP is that pairing a rewarding drug with one 
type of environment, called the conditioned stimulus, would result in an increased 
preference for that environment in the absence of the drug. This  test has  been used in 
animals since the early 1940s to model the appetitive reward-like properties of drugs of 
abuse (Spragg, 1940; Rossi 1976). It is important here to note that although originally 
morphed together, “reward” and “reinforcement” are independent stages of the drug 
addiction cycle. In fact, CPP and drug self-administration were originally thought to be 
isomorphic models  of drug reward, however, that idea is  no longer generally supported. 
Rather, it is commonly accepted that self-administration models  “reinforcement” and 
CPP models “reward” (and may be influenced by other factors  such as novelty-seeking 
and memory), thus each assay measures different components of drug preference or 
drug-seeking behavior in animals (Bardo, 2000). As mentioned in the previous section, 
multiple factors play a role in rodent phenotypic responses and CPP is  especially 
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sensitive to environmental influences (Buccafusco, 2009). In the CPP paradigm used 
herein, mice received cage enrichment every other day during the week prior to testing. 
The apparatus  consists  of white and black chambers differing in floor texture, either 
white mesh or black rod, representing two different environments (for a schematic, see 
Appendix A3). For three days, drug injections are paired with one chamber and vehicle 
injections are paired with the other and on the fourth day, mice are placed into the 
apparatus and preference to the drug is interpreted as an increase in time spent in the 
compartment previously paired with the drug (Kota, 2007). A portion of this  dissertation 
work utilizes the CPP paradigm to genetically map nicotine preference phenotypes 
across a recombinant inbred panel of mice. We hypothesize that elucidating the genetic 
underpinnings of nicotine CPP may lead to discovery of novel neural pathways that play 
a role in reward (Bardo, 2000).
Quantitative Trait Loci (QTL) Mapping
 Two of the most commonly used and fully sequenced inbred strains of mice are 
C57BL/6J (B6) and DBA/2J (D2) due to excellent breeding ability, heartiness, and 
longevity (Silver, 1995). Inbred strains are powerful genetic tools because of their 
homozygosity at all loci, allowing behavioral and molecular investigation and trait 
comparisons between laboratories and/or several years apart, ceteris paribus (Crabbe, 
1999). B6 and D2 mice are highly polymorphic, containing over 4 million single 
nucleotide polymorphisms (SNPs) between the two strains  alone (Walter, 2007; Walter, 
2008), and they show divergent phenotypic responses to multiple drugs of abuse 
(Jackson, 2009; Elmer, 2010; Fish, 2010; Van der Veen, 2007). Therefore, the B6 and 
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D2 strains were used as progenitors  of the BXD recombinant inbred (RI) panel for use 
in genetic mapping of quantitative traits. Briefly, B6 and D2 mice were outcrossed to 
produce an obligate heterozygous F1 generation. F1 siblings were intercrossed to 
produce an F2 generation in which B6 and D2 alleles recombine at random loci across 
the genome. F2 siblings were intercrossed and the progeny of this mating were inbred 
for 20+ generations to create a mosaic of B6 and D2 haplotypes along every 
chromosome with homozygosity at nearly every locus (Taylor, 1978). Each resulting 
BXD RI strain has a unique, fixed combination of B6 and D2 haplotype blocks, in which 
over 14,000 polymorphic SNP and microsatellite markers have been extensively 
genotyped (Williams, 2001; Wang, 2003). To nearly double the number of recombination 
events per strain and subsequently, the resolution of mapping, advanced-intercross  RI 
(ARI) strains were developed by randomly intercrossing (non-brother-sister and non-
cousin matings) mice starting with BXD F2 mice for 9-14 generations, followed by at 
least 20 generations of inbreeding (Peirce, 2004). Thus, the BXD panel of mice provides 
a powerful tool for quantitative trait loci (QTL) analysis and has been used extensively to 
map QTL for genetically-driven traits, such as ethanol-responsive phenotypes (Buck, 
2001; Demarest, 1999; Phillips, 2010; Grisel, 2002; Christensen, 1996; Crabbe, 1999; 
Yoneyama, 2008; Crabbe, 1998; Radcliffe, 2000), physiological measures (Grisel, 2002 
Porcu, 2011; Jellen, 2012; Kirstein, 2002), as well as anxiety-related phenotypes 
(Bailey, 2008; Yalcin, 2004), for example. In addition to B6 and D2, most of the inbred 
mouse strains in use today have been SNP-typed and indel-typed (insertion/deletion) by 
multiple groups (Frazer, 2007; Yalcin, 2011; Keane, 2011) within the past few years, 
making mice a valuable tool in the genetics field.
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Using expression genomics in drug abuse research
 By obtaining phenotype data (behavioral or other) from BXD RI and ARI panels 
of mice, QTL can be quickly mapped using the online resource, WebQTL (Wang, 2003). 
Like behavioral traits, mRNA (or even protein) expression levels, if genetically driven, 
can be mapped as quantitative traits  (Damerval, 1994; Schadt, 2003). These are 
referred to as expression QTL (eQTL) and are predicted to underlie complex traits 
(Damerval, 1994; Sladek, 2006). Genetic regulation of eQTL may be either cis (local) or 
trans (distal), such that genes with eQTL regulated in cis map to a location within 20Mb 
(~10cM) of the eQTL peak and those regulated in trans map elsewhere in the genome 
(Doss, 2005; Sladek, 2006). Thus, cis eQTL result from genetic variation such as  SNPs 
or structural variants within or near the gene itself and as such, are thought to be the 
primary drivers of complex traits (Doss, 2005; Sladek, 2006; Fehrmann, 2011). For 
example, cis-modulation of hippocampus mRNA expression of the Per3 gene in the 
BXD panel was found to be the result of an indel variant within the Per3 gene which 
controls its transcript abundance by altering the binding of a transcription factor at that 
site (Wang, 2012). Another study discovered that tandem repeat variation within the 
promoter region of the CTSB gene was causative for its  cis-regulation in neurons and 
white blood cells (Borel, 2012). Other possibilities include variation within the 3‘UTR 
leading to increased or decreased miRNA binding at the seed region, intronic or exonic 
variation at splicing, enhancer, or insulator sites leading to altered alternative splicing or 
altered promotor activity. Alternatively, trans eQTL result from genetic variation at a 
locus distal to the eQTL peak, for example, variation within a transcription factor or distal 
enhancer or miRNA, and may represent secondary or tertiary effects that may converge 
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on downstream genes or pathways (Fehrmann, 2011). Thus, by correlating behavioral 
QTL (bQTL) with eQTL from the same samples, candidate quantitative trait genes 
(QTGs) can be prioritized for testing if a cis eQTL is  present in the same tissue where 
the gene’s expression significantly correlates  to the phenotype (Sladek, 2006; 
Hitzemann, 2004). The major premise of this dissertation utilizes  this integration of 
phenotypic data from BXD RI strains and corresponding genomic data, termed 
“genetical genomics”, in such a way to identify and test QTGs influencing acute ethanol 
and nicotine traits. This approach is illustrated in Figure 2.3.
Acute ethanol-induced anxiolysis QTL 1, Etanq1 
 The ethanol studies  discussed herein originated from work performed by Dr. 
Alexander Putman from the Miles Laboratory. Using the LDB preclinical model of 
anxiety, 27 BXD strains were tested for an anxiolytic-like response to acute ethanol, 
measured as  PTS or PDT in the light. Nearly every strain tested showed significant 
increases in these phenotypes compared to saline treatment, indicating that these 
phenotypes contribute to the anxiolytic-like properties of ethanol. Furthermore, the strain 
distributions for these phenotypes  were continuous, indicative of quantitative traits. QTL 
mapping of these two acute ethanol phenotypes identified overlapping significant 
behavioral QTL (bQTL) on chromosome 12 and suggestive QTL on chromosome 1, 
suggesting that the major gene(s) influencing PTS and PDT might lie on chromosome 
12. The support interval for the bQTL on chromosome 12, deemed Etanq1 (ethanol-
induced anxiolysis QTL 1), ranged from 53.9–71.6Mb and contained over 100 genes 
(Putman, 2008). As it is impractical to test such a large number of genes in the mouse, 
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Figure 2.3 - Flowchart of the “genetical genomics” approach to identifying 
quantitative trait genes. For this dissertation work, genetic mapping of an acute 
nicotine reward-like phenotype across the BXD RI panel was performed. Expression 
data from the mesolimbic dopamine reward pathway (PFC, NAc, and B) were used for 
eQTL analysis and correlations to bQTL in order to prioritize candidate genes. For the 
acute ethanol anxiolytic-like phenotype, previous studies from our laboratory took this 
approach and candidate genes were narrowed to four, one of which will be a focus this 
dissertation.
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Dr. Aaron Wolen from the Miles  Laboratory sought to narrow this support interval by 
testing additional strains from the ARI BXD population. As mentioned previously, these 
BXD strains  were created in such a way to introduce significantly more recombination 
events  than existed in the original panel of BXDs. By selecting strains with 
recombinations within the original support interval, Dr. Wolen successfully narrowed the 
Etanq1 support interval to a 3.5Mb region on chromosome 12, 69.1–72.6Mb, thus 
reducing the number of candidate genes for investigation to 48 genes (Wolen, 2012). 
 Four hours  following behavioral testing of each cohort of BXDs, mice were 
sacrificed and brain regions from the mesolimbic dopamine reward pathway, VMB, NAc, 
and PFC, were used for mRNA expression profiling by microarrays (Wolen, 2012). 
Previous studies performed by our laboratory have shown that this four hour time point 
captures a genomic profile of signal transduction events that occurred in response to 
drug administration (Kerns, 2005). At this  time point, an array of early, intermediate, and 
late gene expression changes in response to ethanol can be detected. Additionally, 
neuroadaptations occurring in response to the behavioral testing may also be captured. 
These expression data were then subjected to eQTL analysis and by using a genetical-
genomics approach to identify relationships between bQTL and eQTL, candidate genes 
were characterized and prioritized for interrogation. Chapter 5 focuses on the 
interrogation of one such gene, Ninein.
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Chapter 3 - Etanq1 Correlation with Anxiolytics Targeting GABAA
Introduction
 Risk for developing alcoholism is determined by the combination of genetic 
predisposition, environment, and neuroadaptations that occur following acute and 
chronic exposure to alcohol. Early twin studies estimated heritability for alcohol 
dependence risk ranging around 60% (Heath, 1997), thus a significant genetic 
component determines one’s susceptibility to this disease. Human studies have also 
observed a high prevalence of anxiety symptoms among alcohol-dependent individuals 
(Schuckit, 1990) and a higher than expected rate of anxiety symptoms in the individuals 
one year post-abstinence (Schuckit, 1990; Brown, 1991). In fact, one study reported 
that increased “state” anxiety (as measured by a tension-anxiety scale) was correlated 
with an increase in drinking (Sloan, 2003). In support of this, a study in Wistar rats 
reported that increased basal anxiety resulted in increases in drinking behavior and 
preference (Spanagel, 1995). As  alcoholics frequently report anxiety as motivation for 
drinking (Koob, 1997; Brown, 1991; Schuckit, 1990), we hypothesize that alcohol’s 
ability to relieve anxiety may contribute to initiation of drinking behavior and/or relapse in 
an attempt to curb withdrawal-induced anxiety. However, the genes and receptor 
systems involved in ethanol-induced anxiolysis are poorly understood, thus, there 
remains a need for understanding this complex interplay between anxiety and alcohol 
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so that future preventions and/or treatments might aid in the treatment of alcohol use 
disorders. 
 Our laboratory has previously identified and confirmed a quantitative trait locus 
(QTL), Etanq1, across the BXD genetic mapping panel of mice for two anxiolytic-like 
phenotypes following acute ethanol administration (for background, see Chapter 2). 
These phenotypes, percent time spent (PTS) and percent distance traveled (PDT) in the 
light side of a light-dark box (LDB) have been used preclinically to predict the efficacy of 
anxiolytic drugs (Crawley, 1980; Blumstein, 1983). Thus, this model for measuring 
anxiolytic-like behavior in rodents  is well-accepted. We sought to determine whether 
acute ethanol is mediating this anxiolytic-like response through the GABAA system, a 
receptor system known to be involved in both anxiolysis and alcohol use disorders (See 
Chapter 2). We asked whether the commonly prescribed anxiolytic agent and known 
target of the GABAA receptor system, diazepam, would produce similar responses to 
ethanol in BXD strains in the LDB paradigm used herein. Since the BXD strains showed 
a continuous distribution for the Etanq1 phenotypes, we predicted that strains with 
extreme phenotypes for their ethanol responses would have similar responses to 
diazepam if Etanq1 was being elicited through direct activation of GABAA α1, α2, α3, α5 
receptors. Additionally, as  it is  believed that the GABAA system elicits its anxiolytic 
responses through agonism of GABAA α2/α3 subunits of the receptor, we utilized a 
selective GABAA α2/α3 agonist, HZ166 (a benzodiazepine derivative) in the same way. 
We hypothesized that if Etanq1 is being modulated through direct agonism of GABAA 
α2/α3 subunits, PTS and PDT in the light following HZ166 administration would result in 
a mimicking of ethanol’s responses  observed in selected BXD strains. Surprisingly, we 
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show that the LDB phenotypes, PTS and PDT in the light following ethanol treatment 
are not being modulated through direct activation of GABAA α1, α2, α3, α5 receptors. 
Thus, the PTS and PDT phenotypes might result from activation of an alternate receptor 
system known to be involved in anxiolysis or Etanq1 may be acting through a novel 
mechanism.
Materials and Methods
! Mice and Husbandry Conditions. For all studies, male mice were used, housed 
2-4 per cage, and allowed at least a one-week acclimation period to the vivarium 
following shipment to Virginia Commonwealth University (VCU). Mice were maintained 
on a 12-hour light/dark cycle with ad libitum access  to standard rodent chow (Harlan, 
7012) and tap water. All mice were 8-12 weeks old at time of testing. C57BL/6J and 
DBA2/J mice were obtained from Jackson Laboratories (Bar Harbor, ME) and Hsd, ICR 
(CD-1) mice were obtained from Harlan Laboratories (Indianapolis, IN). Mice were 
housed with Teklad aspen sani-chip  (Harlan, 7090A) or Teklad corn cob  (Harlan, 7092) 
bedding, where noted. 
! Drugs. For LDB studies, a 1.8g/kg of ethanol dose was administered using a 
10% ethanol (w/v) stock solution dissolved in a 0.9% physiological saline vehicle. This 
dose was chosen based on previous LDB studies in our laboratory (Putman, 2008). 
Diazepam dose response curves were performed using the following doses, 0, 0.5, 1.0, 
5.0, and 10.0 mg/kg in a vehicle of 5% Tween 80 in 0.9% saline. HZ-166 ((8-ethynyl-6-
(2’-pyridine)-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester) dose 
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response curves were performed using the following doses, 0, 0.3, 1.0, 3.0, 10.0, and 
30.0 mg/kg in a vehicle of 0.5% methylcellulose in 0.9% saline. For pain-stimulated 
stretching experiments, 0.56% acetic acid was administered in 0.9% saline, ibuprofen 
was administered at a dose of 30mg/kg in 0.9% saline, and HZ-166 was administered at 
16mg/kg in 0.5% methylcellulose. Diazepam, HZ-166, acetic acid, ibuprofen and their 
respective vehicles were all administered at a volume of 0.1mL per 10g of mouse mass 
and all drugs, including ethanol, were administered intraperitoneally. Diazepam was 
obtained from Sigma Aldrich and HZ-166 was obtained from the University of Wisconsin 
(Di Lio, 2010; Cook, 2009). 
! Light Dark Box. In order to determine whether the Etanq1 phenotypes, PTS and 
PDT in the light side of the LDB, are driven by activation of receptor subunits known to 
be involved in anxiolytic phenotypes observed in humans, we first performed dose-
response curves in the LDB in both B6 and D2 mice for the GABAA α1, α2, α3, α5- 
agonist, diazepam, and the GABAA  α2/α3-selective agonist, HZ-166. We hypothesized 
that if in B6 and D2 mice, ethanol’s phenotypes, PTS and PDT in the light, were being 
mediated primarily through activation of one or more of these receptor subunits, that for 
one or more of these drugs, one of the doses tested would also produce significant 
increases in PTS and PDT in the light compared to vehicle-treated mice in the same 
mouse strains, B6 and D2. Next, studies comparing ethanol’s phenotypic responses in 
BXD strains with high and low PTS/PDT in the light to those same phenotypes following 
administration of a dose of diazepam or HZ-166 which significantly increased these 
phenotypes in B6 and D2 mice would allow us a better understanding of which receptor 
systems through which Etanq1 may be acting.
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! One hour prior to behavioral testing, mice were moved to the behavior room, 
cages were changed, and the light-dark box chambers were turned on, such that mice 
were allowed to habituate to the testing environment. For those mice receiving restraint 
stress, mice were placed into a 50mL conical tube on top  of a full cage of bedding for 15 
minutes. For ethanol positive control studies, immediately following the restraint stress, 
mice were injected i.p. with either ethanol, saline, or another vehicle, returned to their 
home cage for 5 minutes, and then placed into center of the LDB, facing the dark side, 
and allowed to roam for 10 minutes. Studies used either house lights (100mA) or 
stimulus lights (170mA) within the light-dark box and are indicated for each experiment. 
Due to the longer half-lives of diazepam and HZ-166, mice received an i.p. injection of 
one of these drugs or their respective vehicles, 15 minutes later, were placed into tubes 
for a 15 minute restraint stress, and then immediately placed into the center of the LDB, 
facing the dark side, and allowed to roam for 5 minutes. A brief stress was performed to 
both ensure that all mice were at similar baseline “anxiety” levels at the start of 
behavioral testing and to minimize within-group variability. All light-dark box experiments 
were performed during the light cycle between the hours of 0800 and 1300.
! Acetic Acid Pain-Stimulated Stretching. In order to determine whether HZ-166 
was pharmacologically  active, we tested the compound in an acute model of 
inflammatory pain in D2 mice. Previous studies have reported its efficacy in other 
models of inflammatory and neuropathic pain (DiLio, 2010), thus we hypothesized that it 
would decrease the number of pain-stimulated stretches following an acetic acid 
stimulus. Ibuprofen, a non-steroidal anti-inflammatory drug, was used as a positive 
control.
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! Mice were administered a blinded pretreatment of methylcellulose (MeC), saline 
(Sal), ibuprofen (Ibu), or HZ-166 (HZ), and 30 minutes later, injected with 0.56% acetic 
acid (AA). The number of pain-stimulated stretches was tallied over 20 minutes and 
percent inhibition of stretching was calculated by  setting the average number of 
stretches for the Sal group  to 100%. All stretching behavioral experiments were 
performed during the light cycle between the hours of 1000 and 1500.
! Statistical Analyses. All data are presented as the mean ± SEM. Oneway 
ANOVAs testing treatment as the factor were performed. A Tukey’s HSD post-hoc at an 
alpha=0.05 determined statistical significance between two groups. For LDB and AA 
experiments, only differences between vehicle and any doses were reported.
Results
Acute ethanol produces significant increases in PTS and PDT in the light side of the 
LDB in B6, D2, and CD-1 (ICR) mice without decreasing locomotor activity.
! Previous dose-response studies in our laboratory have determined that restraint 
stress, followed by a 1.8g/kg dose of ethanol administered 5 minutes prior to testing, 
elicited a significant increase in PTS and PDT in the light without decreasing TLA in both 
B6 and D2 mice. Figure 3.1, a-c, depicts replication of these studies in B6 and D2 mice 
housed on sani-chip bedding, and expansion to the outbred strain, CD-1 (ICR) housed 
on corncob  bedding. Additionally, in B6 mice, ethanol significantly decreased the latency 
to enter the light and increased the total number of transitions between the light and 
dark compartments, supporting historical criteria for an “anxiolytic-like” drug in the LDB.
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Figure 3.1 - Ethanol-responsive behaviors in the light dark box in B6, D2, and ICR 
mice. Following a brief restraint stress, acute ethanol significantly increased the PTS 
(a) and PDT (b) in the light side of the LDB compared to within-strain saline-treated 
mice in all three strains tested, validating the LDB model of anxiolytic-like behavior for 
ethanol in these strains  of mice. Ethanol significantly decreased both jumping behavior 
(j) and the latency to enter the light (i) in B6 and ICR mice and showed a trend for 
decreased latency in D2 mice. All three strains also showed significant increases in the 
percent stereotypies in the light (g), even though ICR mice demonstrated fewer overall 
stereotypies following ethanol treatment (f). Only D2 and ICR mice showed significant 
increases in TLA (c) and percent rearing in the light (e). Ethanol-treated B6 mice 
demonstrated fewer total rears (d), but a greater number of transitions  between the light 
and dark compartments (h). Finally, ethanol-treated ICR mice had fewer transitions in 
between the light and dark compartments (h) and an overall lower mean speed (k) 
(*p<0.05, oneway ANOVA, n=5-8/gp). 
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Furthermore, although the total number of rears was significantly  decreased in ethanol-
treated B6 mice, there was a non-significant trend for an increase in percent of rears in 
the light, suggesting that the majority of the exploratory rearing behavior occurred in the 
light, supporting the notion of increased exploration in the light in B6 mice treated with 
acute ethanol. In D2 mice, ethanol significantly increased TLA and both the percent 
stereotypic counts and percent rears in the light, and showed a trend for decreasing 
latency to enter the light compared to vehicle-treated mice. In the ICR mice, ethanol 
significantly affected all measures tested. Ethanol significantly increased PTS, PDT, 
TLA, percent rearing in the light, percent stereotypies in the light, and significantly 
decreased total transitions, total stereotypies, jumps, speed, and latency to enter the 
light compared to vehicle-treated mice.
Acute diazepam treatment does NOT mimic acute ethanol phenotypes elicited by B6 
and D2 mice in the LDB. 
! An initial diazepam dose-response using restraint stress and house lights was 
performed in D2 mice housed on sani-chip  bedding (Figure 3.2). Doses lower than 2mg/
kg were chosen because previous studies in our laboratory  had observed locomotor 
suppression in D2 mice at 2mg/kg (data not shown). Doses of 1.0, 1.25, and 1.5mg/kg 
significantly decreased the latency to enter the light compared to vehicle-treated mice, 
which supports what “anxiolytic” doses of drugs routinely show in the LDB. No other 
significant differences were found between vehicle and diazepam treatments even 
though there are trends for increased PTS and PDT at the aforementioned doses.
38
010
20
30
40
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
M
ea
n 
S
pe
ed
 (
cm
/s
) Dose
0
0.5
1
1.25
1.5
0
20
40
60
80
100
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
P
T
S
 i
n
 L
ig
h
t 
(s
e
c
)
0
20
40
60
80
100
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
P
D
T
 i
n
 L
ig
h
t
0
500
1000
1500
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
T
o
ta
l 
D
is
ta
n
c
e
 T
ra
v
e
le
d
 (
c
m
)
0
10
20
30
40
50
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
T
ot
al
 N
um
be
r 
of
 R
ea
rs
0
20
40
60
80
100
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
P
er
ce
nt
 R
ea
rin
g 
in
 L
ig
ht
0
200
400
600
800
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
T
ot
al
 S
te
re
ot
yp
ic
 C
ou
nt
s
0
20
40
60
80
100
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
P
er
ce
nt
 S
te
re
ot
yp
ic
 C
ou
nt
s 
in
 L
ig
ht
0
10
20
30
40
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
M
ea
n 
N
um
be
r 
of
 T
ra
ns
iti
on
s
0
50
100
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
La
te
nc
y 
to
 E
nt
er
 L
ig
ht
 (
se
c)
0
5
10
15
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
T
ot
al
 N
um
be
r 
of
 J
um
ps
0
10
20
30
40
0 0.5 1 1.25 1.5
Dose of Diazepam (mg/kg)
M
ea
n 
S
pe
ed
 (
cm
/s
)
 d                           e                              f                           g                  
                                a                             b                          c                  
 h                            i                                j                          k                  
* *
Figure 3.2 - Diazepam light-dark box dose-response curve in D2 mice that 
underwent a brief restraint stress. At the doses tested, diazepam failed to produce 
significant increases in PTS and PDT traveled in the light side of the LDB in D2 mice (a-
b). The only phenotypes which doses of diazepam significantly differed vehicle were 
latency to enter the light (i) and speed (k). At 0.5, 1.0, and 1.25 mg/kg diazepam, D2 
mice demonstrated significantly lower latencies to enter the light and the 1.25mg/kg 
dose of diazepam significantly lowered speed (*p<0.05, oneway ANOVA, Tukey’s HSD, 
n=4-7/gp).
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! A diazepam dose-response in B6 mice housed on corn cob bedding using 
restraint stress and house lights revealed that 5 and 10mg/kg of diazepam significantly 
decreased TLA, total transitions, TotRears, and jumps compared to vehicle-treated 
mice. Also in B6 mice, 5mg/kg diazepam significantly decreased the percent of rears in 
the light and 10mg/kg significantly decreased mean speed compared to the vehicle 
group, suggesting an overall decrease in general activity, perhaps due to the sedative 
effects of diazepam at these higher doses (Figure 3.3). Under these same conditions in 
D2 mice, diazepam significantly  increased PTS in the light at 5mg/kg (Figure 3.4), but 
significantly decreased TLA and total stereotypies at 10mg/kg and showed a trend for 
decreased TLA at 5mg/kg, suggesting possible sedative effects at the 5 and 10 mg/kg 
doses as observed in B6 mice.
Restraint stress does not mask the ability to detect anxiolytic-like phenotypes of 
diazepam in the LDB.
! Since our LDB protocol utilizes a brief restraint stress unlike common protocols in 
the literature, we attempted to produce diazepam dose-response curves without 
restraint stress, with stimulus lights, in D2 mice housed on corn cob bedding. Diazepam 
significantly decreased multiple locomotor phenotypes, TLA, total transitions, total 
stereotypies, jumps, and mean speed at both 5 and 10mg/kg and also significantly 
decreased percent rearing in the light at 10mg/kg. Diazepam did not significantly 
increase any phenotype compared to vehicle-treated D2 mice, thus, collectively, these 
data suggest that diazepam is causing locomotor suppressing effects at high doses (5 
and 10mg/kg), thereby masking our ability to detect “anxiolytic-like” effects as defined 
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Figure 3.3 - Diazepam light-dark box dose-response curve in B6 mice that 
underwent a brief restraint stress. At the doses tested, diazepam failed to produce 
significant increases in PTS and PDT traveled in the light side of the LDB in B6 mice (a-
b). The doses of 5 and 10 mg/kg significantly decreased multiple phenotypes  (denoted 
with *), indicative of overall suppression of activity (*p<0.05, oneway ANOVAs, Tukey’s 
HSD, n=8/gp).
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Figure 3.4 - Diazepam light-dark box dose-response curve in D2 mice with and 
without restraint stress. At the doses tested, diazepam produced a significant 
increases in PTS, but not PDT traveled in the light side of the LDB in only D2 mice 
undergoing restraint (a-b). The doses of 5 and 10 mg/kg significantly decreased multiple 
phenotypes (denoted with *), indicative of overall suppression of activity (*p<0.05, 
oneway ANOVAs, Tukey’s HSD, n=8/gp).
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by increases in PTS and PDT in the light at the doses tested (Figure 3.4).
Acute HZ-166 treatment does NOT mimic acute ethanol phenotypes elicited by B6 and 
D2 mice in the LDB. 
! An initial HZ-166 dose-response in B6 mice using restraint stress, house lights, 
and a 5 minute homecage period, failed to produce significant changes all LDB 
phenotypes compared to vehicle-treated mice (Figure 3.5). In fact, vehicle-treated mice 
showed high mean PTS and PDT (38% and 36%, respectively). Therefore, in attempt to 
increase the “stress”/”anxiety” of the light side to avoid ceiling effects, dose-response 
studies were performed in B6 and D2 mice with stimulus lights and without the 5 minute 
homecage period. As shown in Figure 3.6, these experimental manipulations did not 
lower vehicle levels for PTS and PDT in the light and additionally, failed to produce 
significant within-strain differences from vehicle-treated mice at all doses tested. 
Interestingly, vehicle levels for mean PTS and PDT in B6 mice increased to 49% and 
42%, respectively, suggesting no preference for either side of the light-dark box prior to 
drug treatment.
HZ-166 pretreatment attenuates pain-stimulated stretching in a model of acute 
inflammatory pain.
! At a dose of 16mg/kg, HZ166 significantly decreased pain-stimulated stretching 
behavior compared to its vehicle group (Figure 3.7). At a dose of 30mg/kg, the positive 
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Figure 3.5 - HZ166 light-dark box dose-response curve in B6 mice with restraint 
stress and house lights. At the doses tested, HZ166 did not alter any of the 
phenotypes measured. There was a trend for the 0.3mg/kg dose to decrease the 
number of transitions in between the light and dark compartments, but it was non-
significant with a Tukey’s HSD post-hoc test (n=4/gp).
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Figure 3.6 - HZ166 light-dark box dose-response curve in B6 and D2 mice with 
restraint stress and stimulus lights. At the doses tested, HZ166 did not alter any of 
the phenotypes measured (n=3-8/gp).
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Figure 3.7 - HZ166 significantly decreases acid-stimulated stretching. 
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its vehicle, saline (*p<0.01, oneway ANOVAs, Tukey’s  HSD, n=6-7/gp). Pretreatment 
with 16mg/kg HZ166 significantly decreased acetic acid-stimulated stretching (a) or 
significantly increase the percent inhibition of stretches (b) compared to its vehicle, 
0.5% methylcellulose/0.9% saline (*p<0.05, F[3,24]=7.9107 for number of stretches and 
F[3,24]=12.2186 for percent inhibition, oneway ANOVAs, Tukey’s HSD, n=7-8/gp). 
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control, ibuprofen, significantly decreased writhing behavior compared to its vehicle 
group. 
! Based on these initial dose-response experiments, diazepam and HZ-166 were 
not tested in BXD strains in the LDB. Furthermore, literature studies do not provide 
strong evidence of the behavioral efficacies of acute diazepam in B6 mice in the light-
dark box assay, as variety of factors differ among studies, including, strain, age, light-
dark box construction, pretreatment time, dose, vehicle, and phenotype interpreted as 
anxiolytic-like. Thus, inter-laboratory comparisons are quite difficult.
Discussion
! In the present studies, we sought to determine whether Etanq1 was acting 
through activation of the GABAA α1, α2, α3 α5 or GABAA α2, α3 by comparing 
phenotypes produced by acute ethanol in the LDB to those produced by diazepam, and 
HZ-166, respectively. Since acute ethanol produced phenotypes in the LDB predictive of 
its role as an “anxiolytic” drug, other known anxiolytic drugs whose mechanisms of 
anxiolytic action have been discovered were chosen for comparison. Diazepam is used 
clinically to treat anxiety and anxiety disorders, while HZ-166 was chosen based on 
literature studies providing preclinical evidence that agonism of the GABAA α2, α3 
subunits  reduces anxiogenic-like behaviors in multiple models of anxiety in multiple 
species (Fischer, 2010; Atack, 2006). Surprisingly, however, we were unable to attain 
dose-response curves for PTS and PDT in the light for any of the three drugs in B6 and 
D2 strains of mice using our light-dark box protocol. 
47
 A number of studies have demonstrated an “anxiolytic-like” effect for diazepam in 
multiple preclinical models of anxiety, especially in C57BL/6J mice. However, each 
study may use a different experimental design, a different substrain of C57BL/6 mice, a 
different drug vehicle, as well as report different phenotypes which they consider to be 
“anxiolytic-like”, thus  making inter-laboratory comparisons  quite difficult. Bouwknecht 
and Paylor argue that in addition to monitoring an increase in time spent in an aversive 
area (eg, light side of the LDB, open arms of the EPM, center of the OF), one must also 
monitor locomotor measures such as total distance traveled, number of transitions, etc 
(Bouwknecht, 2004). Here, we demonstrate that acute ethanol significantly increased 
PTS and PDT in the light without decreasing total distance traveled. Perhaps most 
importantly, ethanol decreased the latency to enter the light in all three strains, 
suggesting that ethanol is acting as an anxiolytic-like drug in the LDB. 
 Furthermore, it has been well-established that the starting position of the animal 
greatly affects  the PTS in the light outcome, yet little attention is  given to these details in 
publications. For example, placing two different groups (treatments or genotypes) of 
mice into the light side of the LDB can cause one of two responses, freezing, which 
would increase time spent in the light (in an “anxious” strain) or an immediate escape to 
the dark side but then explores readily, thereby decreasing percent time spent in the 
light (in a “non-anxious” strain). However, when starting the same mice in their “safe 
zone”, the mouse that previously froze in the light chooses to spend more time in the 
dark side and the mouse that immediately escaped to the dark still spends the same 
amount of time in the light. Thus, it is  recommended that a mouse always be started in 
its “safe zone” when assaying anxiety-related behaviors (Bouwknecht, 2004), which is 
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what was done herein. In fact, the premier papers describing the LDB and its predictive 
validity for assessing diazepam’s anxiolytic-like properties started B6 mice in the light 
side and used activity counts  and the number of transitions to draw conclusions  about 
anxiolytic-like properties of the drug (Crawley, 1980; Blumstein, 1983). These measures, 
one can argue, may actually represent exploratory/locomotor-related phenotypes, rather 
than anxiolytic-like phenotypes.
 One very intriguing reason for the lack of increase in PTS and PDT in the light 
following diazepam observed in our studies may be the result of a novel polymorphism 
in the gene for the GABAA α2 subunit, Gabra2, in B6 mice that occurred sometime 
between 1976 and 1990. Gabra2 expression is cis-modulated across multiple brain 
regions (hippocampus, amygdala, striatum, and cortex) and platforms (microarray and 
RNA-Seq), with low expression always associated with the B allele in multiple RI 
crosses (Mulligan, 2012). Between B6 and D2 mice, the Gabra2 locus is identical by 
descent except for eight indels  and nine SNPs within intronic or intergenic regions, thus 
it is likely that one or more of these variants is responsible for the large differences in 
expression observed (Mulligan, 2012). The publications  reporting phenotypes that 
support diazepam’s anxiolytic-like actions in B6 mice in preclinical assays of anxiety 
were largely published in the 1970s and 1980s. From these studies, one would predict 
that D2 mice would be responsive to the anxiolytic-like effects of diazepam. In our 
studies, we showed that diazepam in D2 mice did not produce significant increases in 
PTS or PDT in the light under the conditions of enhanced lighting without restraint 
stress and while we did observe significant increases in PTS in the light with restraint 
stress, we saw concurrent locomotor suppression, thus the sedative side effect of 
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diazepam complicated interpretation of these results. Interestingly, our first D2 
diazepam dose-response study showed trends for increased PTS and PDT in the light 
without locomotor suppression effects, yet at some of these same doses in the later 
study, this was not observed. The only difference in these two studies  was the type of 
bedding on which mice were housed. To date, no one has studied the effects of different 
bedding types on the anxiolytic-like responses of diazepam in preclinical models of 
anxiety and often, the type of bedding is  not reported. However, it has been reported 
that changing an animal’s bedding and essentially its  environment for all, if not most, of 
its adult life, does alter behavioral outcomes (Blom 1996; Ras, 2002; Homma, 2009). 
Perhaps testing a larger number of mice, housed on sani-chip bedding, may reveal 
significant increases in PTS and PDT at some of the lower doses (0.5-1.5mg/kg) of 
diazepam in D2 mice. 
 Finally, most published studies on diazepam use a vehicle containing between 
2-10% ethanol, which we have shown produces significant increases in PTS and PDT in 
the light along with decreased latency to enter the light on its own. Thus, we argue that 
those studies be interpreted with caution. 
 In an attempt to bypass the locomotor sedative effects of diazepam due to 
agonism at the GABAA α1 subunit, we tested both B6 and D2 mice with a GABAA α2, α3 
- selective agonist, HZ-166. Based on the Gabra2 expression studies mentioned earlier, 
we predicted to see increases in PTS and PDT in the light in D2 mice following 
administration of HZ-166. However, we failed to produce dose response curves  in either 
strain with this drug. Testing HZ-166 in a pain-stimulated stretching assay validated that 
the drug does have pharmacological activity at both the time-point and within the dose 
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range tested. Interestingly, PTS and PDT in the light levels in vehicle-treated mice 
ranged from 36-49%, suggesting that 0.5% methylcellulose treatment lowered basal 
“anxiety” levels to a point where mice did not prefer one side over the other, thus leaving 
a small window of detection for possible increases in PTS and PDT in the light. 
Interpretation of these studies may be compromised due to a ceiling effect of the 
vehicle, thus more experiments, perhaps utilizing an alternate vehicle, would need to be 
performed in order to draw conclusions about the anxiolytic-like action of HZ-166. 
! Overall, although the dose-response studies were largely negative in of 
themselves, they do provide insight for mechanism of action of Etanq1. First, Etanq1 is 
genetically  driven by acute ethanol’s ability to significantly  increase PTS and PDT in the 
light side of the LDB, but not genetically driven by locomotor activating effects of ethanol 
across the BXD panel. Second, diazepam, HZ-166, and buspirone, drugs whose 
specific mechanisms of anxiolytic action have been well-documented, failed to produce 
coincident increases in PTS and PDT in the light. Therefore, we can conclude that 
Etanq1 is not being driven primarily through activation of one of the following receptor 
subunit systems alone, GABAA α1, α2, α3 α5 or GABAA α2, α3. It is  entirely possible 
that small effects at one or more of these subunits  may have a cumulative effect on PTS 
and PDT in the light, however, mixed dosing regimens would need to be performed in 
order to answer those questions. The more likely scenario is that Etanq1 may be acting 
through another receptor system known to be involved in eliciting anxiolytic responses, 
such as the CRF, neuropeptide Y, the endocannabinoid system, or through a novel 
mechanism yet to be discovered. 
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 Alternatively, these studies may imply that ethanol’s influence on the PTS and 
PDT phenotypes is  not driven primarily by “anxiolysis”. The LDB gained predictive 
validity for assessing anxiolytic drugs based on the ability of clinically known anxiolytics 
to significantly increase the time spent in the light, increase exploratory behaviors  in the 
light such as rearing, and/or decrease the latency to enter the light (Crawley, 1980; 
Blumstein, 1983; Costall, 1989). Perhaps PTS and PDT are measuring something other 
than “anxiolysis” in these strains of mice, such as disinhibition or risk-taking behaviors. 
Nonetheless, these studies demonstrate the complexity of Etanq1 and beg for additional 
experiments to interrogate its mechanism of action.
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Chapter 4 - Etanq1 Correlation with Other Behavioral Models of “Anxiety”
Introduction
 Risk for developing alcoholism is determined by the combination of genetic 
predisposition, environment, and neuroadaptations that occur following acute and 
chronic exposure to alcohol. Due to the complex and heterogenous nature of 
alcoholism, there is a need to understand the biological and genetic bases of risk for 
disease-related endophenotypes. Alcoholics frequently report anxiety as motivation for 
drinking and we hypothesize that alcohol’s ability to relieve anxiety may contribute to 
initiation of drinking behavior. However, the genes and receptor systems involved in 
ethanol-induced anxiolysis are poorly understood, as ethanol acts at multiple receptor 
systems in the central nervous system (Spanagel, 2009). A number of previous studies 
have attempted to “genetically dissect” endophenotypes across multiple preclinical 
assays measuring basal “anxiety” levels (Flint, 2003; Henderson, 2004; Fernandez, 
2002; Turri, 2001; Clement, 2007; Brigman, 2009; Rodgers, 1995) in order to genetically 
map loci underlying “anxiety”. With these studies, it has become clear that the 
responses measured in behavioral assays are made of multiple components and thus 
influenced by multiple genes. As such, phenotypic responses to drugs which have 
considerable heritability are expected to be influenced polygenically. The studies by 
Flint, Turri, and others cited above provide evidence that studying “anxiety” is rodents  is 
complex and when adding a new variable such as a drug, it may be necessary to 
53
dissect phenotypic responses to drugs in the same way in order to elucidate genes 
modulating these behaviors.
 Our laboratory has previously identified and confirmed a quantitative trait locus 
(QTL) across the BXD panel for the percent time spent (PTS) and percent distance 
traveled (PDT) phenotypes in the light-dark box (LDB), deemed Etanq1 (Putman, 2008). 
We hypothesized that acute ethanol might be mediating its anxiolytic-like responses 
through the same mechanism across the LDB and EPM, as we show that it reproducibly 
produces significant increases in PTS and PDT in the light and open arms in multiple 
strains of mice and both assays are constructed such to test unconditioned responses 
to a drug. To dissect Etanq1 as well as parse the ethanol anxiolytic-like phenotype, we 
have assayed six BXD strains (and their progenitors, B6 and D2), selected based on 
haplotypes within the Etanq1 support interval, and eight inbred strains in various 
preclinical models of “anxiety”. Principal components  analysis of these behavioral data 
suggests that the gene(s) modulating the ethanol anxiolytic-like component in the LDB 
do not overlap with those same phenotypes  in the elevated plus  maze (EPM), nor a 
marble burying (MB) phenotype. Dissecting complex phenotypes may allow us to 
uncover novel genes and/or mechanisms, thus  leading to new targets for alcohol use 
disorders.
Materials and Methods
! Mice and Husbandry Conditions. For all studies, male mice were used, housed 
2-4 per cage, and allowed at least a one-week acclimation period to the vivarium 
following shipment to Virginia Commonwealth University (VCU). Mice were maintained 
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on a 12-hour light/dark cycle with ad libitum access  to standard rodent chow (Harlan, 
7012) and tap water. All mice were 8-12 weeks old at time of behavioral testing, each of 
which were performed during the light cycle between the hours of 0800 and 1300. 
C57BL/6J, DBA2/J, AKR/J, NOD/ShiLtJ, 129S1/SvImJ, C3H/HeJ, and Balb/cByJ mice 
were obtained from Jackson Laboratories (Bar Harbor, ME) and BXD mice were 
obtained from the University of Tennessee Health Sciences Center (Memphis, TN). Mice 
were housed with Teklad aspen sani-chip  (Harlan, 7090A) or Teklad corn cob (Harlan, 
7092) bedding, where noted. 
! Drugs. For all behavioral studies, a 1.8g/kg of ethanol dose was administered 
intraperitoneally  (i.p.) using a 10% ethanol (w/v) stock solution dissolved in a 0.9% 
physiological saline vehicle. This dose was chosen based on previous LDB studies in 
our laboratory (Putman, 2008).
! Restraint Stress. For the majority of studies herein, a brief (15 minute) restraint 
stress was performed to both ensure that all mice were at similar baseline “anxiety” 
levels at the start of behavioral testing and to minimize within-group variability.
! Light Dark Box. The LDB (Med-Associates, St. Albans, VT) consists transparent 
square box of dimensions 10.75" L x 10.75" W x 8" H with a black insert which divides 
the chamber into two equally sized chambers. The entire apparatus is contained within 
a sound-attenuating chamber. Mice were placed into a 50mL conical tube on top of a full 
cage of bedding for 15 minutes. Immediately following the restraint stress, mice were 
injected i.p. with either ethanol or saline, returned to their home cage for 5 minutes, and 
then placed into center of the LDB, facing the dark side, and behaviors were recorded 
for 10 minutes. Studies used house lights (100mA) within the light-dark box.  
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! Elevated Plus Maze. The EPM (Hamilton Kinder, San Diego, CA) consists of four 
black arms in a cross shape raised 30.5” from the ground. Each arm is 15” L x 2” W and 
the apparatus contains with center section measuring 2” L x 2” W. The closed arms 
have 6” black walls and the open arms do not have walls. For mice receiving restraint 
stress, mice were placed into a 50mL conical tube on top  of a full cage of bedding for 15 
minutes. Immediately following the restraint stress, mice were injected i.p. with either 
ethanol or saline, returned to their home cage for 5 minutes, and then placed into center 
of an EPM, facing one of the open arms, and allowed to roam for 5 minutes. The open 
arm that each mouse faced to begin the assay  was randomized and balanced within 
treatment groups. If mice did not receive restraint stress, they were administered either 
ethanol or saline i.p., placed into their home cage for 5 minutes, and then placed into 
the center of the EPM and allowed to roam for 5 minutes. If a mouse fell or jumped off 
of the maze, it was placed back into the center facing the opposite open arm from which 
it fell. The number of falls was counted as a separate phenotype. 
! Marble Burying Task. A large rat cage was filled 1/3 with sani-chip  bedding and 
cages were shaken such that the surface of the bedding was flat. 20 marbles were 
arranged evenly into a matrix of 5 rows x 4 columns (See Appendix A3). Mice received a 
15 minute restraint stress (as described previously), were injected i.p. with either 
ethanol or saline, returned to their home cage for 5 minutes, then were placed in the 
cages below the grid  in the middle of grid and allowed to roam for 5 minutes. Marbles 
must have been buried at least 50% with bedding in order to be counted in  the total 
number of marbles buried. The total number of marbles buried was converted to a 
percent of marbles buried. 
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! Statistics. Using JMP and/or R, A twoway ANOVA, followed by a Tukey’s HSD 
post-hoc was performed for all behavioral studies to determine the presence of main 
and/or interaction effects of treatment and either strain or haplotype, where applicable. 
For HMDP experiments, Pearson’s product moment correlations were performed and 
using the psych package (Revelle, 2012) in R, principal components analysis (PCA) 
was performed on varimax-rotated correlation matrices. The number of principal 
components was determined by examining scree and parallel analysis plots as well as 
performing chi square analyses.
! Experiment 1. To validate the anxiolytic-like responses of acute ethanol in the 
EPM, we performed experiments with and without restraint stress in B6 and D2 mice 
following the protocol listed above. 
! Experiment 2. In order to determine whether the Etanq1 locus may modulate 
acute ethanol phenotypes observed in another preclinical model of “anxiety”, the EPM, 
we selected BXD strains with either high or low ethanol-induced PTS/PDT in the LDB 
whose haplotypes were either B6 or D2 across the Etanq1 support interval on 
chromosome 12, 69.1-72.6Mb (Wolen, 2012). We hypothesized that if the Etanq1 locus 
modulated PTS/PDT in the open arms of the EPM following acute ethanol, then when 
collapsed by  the Etanq1 haplotype, strains having the B6 haplotype would show a 
higher PTS/PDT than those having the D2 haplotype, without a significant difference 
between saline groups. In other words, we predicted a significant haplotype x treatment 
interaction, in which having the B6 haplotype would increase the ethanol-responsive 
phenotype. To avoid possible interaction effects of a separate suggestive QTL locus for 
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Etanq1, genotypes were clamped (all D2) at the peak marker on distal chromosome 1, 
located at 165.32Mb.  
! Experiment 3. Next, we selected eight inbred strains from the hybrid mouse 
diversity panel (HDMP) to test in the LDB, EPM, and MB tasks in the order depicted in 
Figure 4.1. Since the LDB and EPM assays are computerized, the number of 
phenotypes resulting from each test is quite large. Collecting all of this data allowed us 
to perform principal components analysis (PCA), which enabled the reduction of 
phenotypes into principal components. We hypothesized that the genetic architecture 
underlying ethanol’s anxiolytic-like effects across preclinical models of anxiety  may be 
detectable through correlation analysis of these principal components across assays. 
Results
Eight strains selected for their Etanq1 haplotype provide sufficient power to detect 
haplotype x treatment interactions for LDB phenotypes. 
! After selecting BXD strains differing by Etanq1 haplotype (BXD11, 32, 66, 67, 90, 
and 98), we performed twoway ANOVAs on this same subset of BXDs previously  tested 
in the LDB by Dr. Putman in the Miles Laboratory to ensure that we had sufficient power 
with eight BXD strains to detect haplotype x treatment interactions with the EPM 
experiments. His studies were able to detect a significant haplotype x treatment 
interaction across the original panel of 27 BXD strains (Putman, 2008), thus, we 
hypothesized that selecting a subset of these strains, in which the interaction remains 
significant, would allow us to interrogate the effect of the Etanq1 haplotype in the EPM. 
Figure 4.2 shows that indeed, we were able to detect a significant haplotype x treatment 
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Figure 4.1 - Timeline for testing ethanol phenotypes in eight inbred strains across 
three preclinical models of anxiety. Eight strains from the hybrid mouse diversity panel 
(HMDP) were used for high-throughput phenotyping of ethanol-responsive behaviors in the 
light dark box (LDB), elevated plus maze (EPM), and marble burying (MB) task. In between 
assays, mice were given a two-week test-free period. Mice receiving ethanol in the LDB 
received saline in the EPM and vice versa. For the MB assay, treatment groups were re-
randomized within each strain. 
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Figure 4.2 - Eight selected strains of mice provide adequate power for measuring 
haplotype x treatment interactions in the LDB following acute ethanol. When 
collapsed by their Etanq1 haplotype, a subset of BXD strains tested by Dr. Putman 
(BXD11, 32, 66, 67, 90, and 98) (Putman, 2008) demonstrated significant effects of 
treatment, haplotype, and haplotype x treatment interactions for both PTS and PDT 
(p<0.01, twoway ANOVA), in the light side of the LDB following restraint stress and acute 
ethanol administration, but not TLA. (Panels  a-c, with the progenitor strains, B6 and D2 
(n=32-25/group) and d-f, without progenitor strains (n=17-19/group). Panel f also 
revealed a near significant interaction of haplotype x treatment for TLA in the BXD only 
subset (p=0.09782).
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interaction for the acute ethanol phenotypes, PTS and PDT in the light, with the B6 
haplotype significantly increasing PTS and PDT in the light following ethanol treatment 
compared to the D2 haplotype. The interactions remained significant even following the 
removal of the progenitor strains, B6 and D2, suggesting that this number of and these 
particular strains are sufficient.
Restraint stress alters acute ethanol phenotypes in B6 and D2 mice using the EPM 
assay. 
! As observed in the LDB, a 1.8g/kg dose of acute ethanol was effective in the 
EPM for significantly increasing the PTS and PDT in the open arms in B6 mice with and 
without restraint stress (Figure 4.3, a-b, f-g). However, D2 mice showed significant 
increases in PTS, but not PDT, in response to ethanol only after undergoing restraint 
stress (Figure 4.3, f-g). Under conditions with and without restraint stress, D2 mice 
exhibited a similar locomotor activation response following a 1.8g/kg dose of ethanol 
(Figure 4.3, c,d) as is routinely seen in the LDB, further validating the efficacy of ethanol 
in this assay. Interestingly, restraint stress had no effect on the mean number of fine 
movements (eg, grooming behaviors, Figure 4.3, d, i); there was a significant strain x 
treatment interaction for this phenotype under both conditions. Finally, restraint stress 
elucidated a near significant trend for the mean entries into the center compartment of 
the EPM (Figure 4.3, j) that is not present without restraint stress (Figure 4.3, e). The 
remaining phenotypes recorded, mean transitions between arms, mean entries into the 
open arms, and mean pokes into the open arms, did not show significant strain x 
treatment interactions. Overall, these data suggest that experimental parameters, here 
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specifically, restraint stress, are important in determining phenotypic outcomes in 
preclinical behavioral assays of anxiety. 
PTS and PDT phenotypes in the EPM show significant interactions between ethanol 
and the Etanq1 haplotype in select BXD strains following restraint stress.
! Testing of six BXD strains selected for having either a B6 or D2 Etanq1 
haplotype, BXD11, 32, 66, 67, 90, and 98, revealed significant interactions between 
haplotype and treatment for PTS, PDT, and total distance traveled (Figure 4.4, a-c) 
following an brief restraint stress. Strikingly, these interactions were not detected upon 
testing of the same strains without restraint stress (Figure 4.4, d-f). However, PTS, PDT, 
and TLA did show significant effects of ethanol treatment when restraint stress was not 
present. Together, these findings implicate the Etanq1 haplotype as a modulator of the 
restraint stress-induced acute ethanol phenotypes, PTS and PDT in open arms as well 
as total distance traveled in the EPM, however, these interactions provide additional 
evidence to support the dramatic effect of restraint stress on ethanol responses in 
preclinical behavioral assays of anxiety.
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Figure 4.4 - Testing a subset of BXDs with and without restraint in the EPM 
revealed different haplotype x treatment interaction effects. When collapsed by their 
Etanq1 haplotype, a subset of BXD strains (BXD11, 32, 66, 67, 90, and 98) demonstrated 
a significant main effect of treatment and significant haplotype x treatment interactions  for 
both PTS and PDT, in the open arms of the EPM (p<0.05, twoway ANOVA), and TLA 
(p<0.01, twoway ANOVA) following restraint stress and acute ethanol administration. 
(Panels  a-c, n=6-18/group). Conversely, acute ethanol administration without restraint 
stress only reveals significant effects of treatment (all p<0.01, oneway ANOVA), but not 
haplotype x treatment interactions for PTS (p=0.8679), PDT (p=0.7370), or TLA 
(p=0.5639, panels d-f, n=8-9/group). 
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Figure 4.5 - HMDP strain distributions for PTS, PDT, and TLA in the LDB and EPM. Nearly 
all strains tested demonstrated a significant increase in PTS and PDT in the light side of the 
LDB following acute ethanol (p<0.05, oneway ANOVA, Tukey’s HSD post-hoc, n=8-11/group, 
panels a-b). Conversely, only B6, D2, and NOD strains demonstrated significant increases in 
PTS in the open arms of the EPM (d-e). Panels c and f show TLA measures for both assays, 
with D2 mice displaying a significant increase in TLA following acute ethanol, as expected. 
Acute ethanol treatment resulted in significant increases in time spent in the light side of 
the light dark box in nearly all HMDP strains tested, but these phenotypes did not 
translate to the elevated plus maze.
! Following a brief restraint stress, acute ethanol significantly  increased PTS and 
PDT in the LDB in all strains except C3H (Figure 4.5, a-b). Additionally, A/J, AKR, Balb/
c, C3H, and D2 strains showed significant increases in TLA following ethanol (Figure 
4.5, c), while 129S and B6 mice demonstrated significant decreases in TLA. There were 
significant main effects of strain any of these three phenotypes. On the other hand, in 
the EPM, only B6, D2, and NOD strains showed significant increases in PTS in the 
open arms and only  NOD mice also showed significant increases in PDT in the open 
arms following acute ethanol treatment. (Figure 4.5, d-e). 129S, AKR, C3H, and D2 
mice showed significant locomotor activation with acute ethanol (Figure 4.5, f). Of these 
4 strains, AKR and D2 mice also had significant increases in total transitions, open arm 
entries, and entries into the center. Interestingly, 129S mice showed a significant 
decrease in total transitions, open arm entries and fine motor movements, even though 
that strain had a significantly greater TLA following ethanol, suggesting that ethanol 
activated locomotion, but not exploratory activity. 129S, AKR, B6, Balb/c, C3H, and 
NOD mice all fell/jumped off of the open arms a significantly  greater number of times 
than their within-group saline mice. 
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Ethanol significantly reduced digging behavior in the marble burying task
! In all strains tested, acute ethanol significantly reduced or abolished digging 
behavior (Figure 4.6). More recent reports in the literature indicate that this behavior is 
genetically  regulated, persists over multiple testings, but may be more indicative of 
perseverance or  repetitive behavior, rather than anxiety-related or fear or novel objects 
(Thomas, 2009). 
Multiple saline and ethanol endophenotypes within the LDB and EPM correlate with 
each other.
 Figure 4.7 depicts Spearman correlation matrices for saline (a) and ethanol (b) 
phenotypes in the LDB. Regardless of saline or ethanol treatment, PTS, PDT, and 
percent stereotypies  in the light significantly correlate to each other, however, when 
ethanol is administered, latency to enter the light also significantly correlates  with these 
phenotypes. Interestingly, following saline administration, TLA correlates significantly 
with the number of transitions, jumps, and speed. However, following ethanol 
administration, the number of transitions, jumps, and speed correlate more strongly to 
each other than to TLA.
 Figure 4.8 depicts Spearman correlation matrices for saline (a) and ethanol (b) 
phenotypes in the EPM. As observed in the LDB, PTS and PDT are tightly significantly 
correlated following both saline and ethanol. With the exception of the number falls  or 
jumps off of the maze, the remaining phenotypes, TLA, fine movements, center entries, 
open arm entries, open arm pokes, and number of transitions largely correlate with each 
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Figure 4.7 - Correlation matrices for saline and ethanol LDB phenotypes. 
Correlation scattergrams (left of diagonal), univariate density plots  (in white, along the 
diagonal), and Spearman’s rho values (right of diagonal) are displayed for saline (a) and 
ethanol (b) phenotypes for the LDB. For the correlation scattergrams, each point 
represents a strain mean with linear fits  plotted in red. A blue rho values denotes a 
significant correlation, while grey rho values are non-significant at an alpha = 0.05. 
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Figure 4.8 - Correlation matrices for saline and ethanol EPM phenotypes. 
Correlation scattergrams (left of diagonal), univariate density plots (in white, along the 
diagonal), and Spearman’s rho values (right of diagonal) are displayed for saline (a) and 
ethanol (b) phenotypes for the EPM. For the correlation scattergrams, each point 
represents a strain mean with linear fits plotted in red. A blue rho values denotes a 
significant correlation, while grey rho values are non-significant at an alpha = 0.05. 
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Figure 4.9 - Principal components analysis of saline phenotypes in the LDB and 
EPM. Scree plots and biplots from the of principal components analysis of saline-
responsive phenotypes in the LDB (a-b) and the EPM (c-d) following varimax rotation 
of correlation matrices. For the LDB, scree plots, parallel analyses, and chi-square 
analyses revealed that two principal components (PC) were sufficient (p<0.05, n=8, 
df=8), whereas for the EPM, the chi-square analysis revealed that one PC was 
sufficient (p<0.05, n=8, df=8). 
other following saline administration. However, following ethanol administration, the 
number of falls significantly correlates with PTS and PDT and with the number of open 
arm pokes.
Principal components analysis and correlation analysis reveal that the anxiolytic-like 
components of the LDB and EPM are not being regulated by common genes. 
 Principal components analysis (PCA) of saline phenotypes revealed two principal 
components in the LDB (Figure 4.9, a-b), contributing to 84% of the total variance, but 
only one principal component in the EPM (Figure 4.9, c-d), contributing to 47% of the 
overall variance. Previous BXD studies in our laboratory showed that PTS and PDT are 
tightly genetically correlated (Putman, 2008) and since an n=8 strains were used for 
PCA, only 7 phenotypes could be assessed, thus, PDT was  not used in the LDB PCAs. 
Factor loadings for the saline LDB phenotypes, Table 4.1, revealed that PTS, percent 
rears in the light, and percent stereotypies in the light are most strongly correlated with 
PC1, while TLA and total transitions are most strongly correlated with PC2. For the 
EPM, saline phenotypes did not separate into multiple components. These results may 
indicate that in general, the LDB may be a better assay for interrogating anxiolytic drugs 
in mice, as locomotor-related and exploratory behaviors may be parsed.
 Principal components analysis of ethanol phenotypes revealed two principal 
components for the LDB (Figure 4.10, a-c), contributing to 84% of the total variance, 
and two principal components in the EPM (Figure 4.10, d-f), contributing to 87% of the 
overall variance. Factor loadings for the ethanol LDB phenotypes, Table 4.2, revealed 
that PTS, percent rears in the light, and percent stereotypies in the light are most 
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Figure 4.10 - Principal components analysis of ethanol phenotypes in the LDB and 
EPM. Scree plots and biplots  from the of principal components analysis of ethanol-
responsive phenotypes in the LDB (a-c) and the EPM (d-f) following varimax rotation of 
correlation matrices. For both assays, scree plots, parallel analyses, and chi-square 
analyses (p<0.05, n=8, df=8) revealed that two principal components (PC) were sufficient. 
For each assay, PC1 contains  locomotor endophenotypes, while PC2 represents the 
anxiolytic-like endophenotypes. Interestingly, latency to enter the light loads onto both 
PC1 and PC2 in the LDB, revealing a possible additional endophenotype of Etanq1. In the 
EPM, the number of falls  loaded with the anxiolytic-like component, PC2, while pokes into 
the open arms loaded onto both PCs. (PCA was not performed on the MB assay since 
only one phenotype was measured).
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strongly correlated with PC1, while TLA and total transitions are most strongly correlated 
with PC2. 
 In order to determine whether the genes underlying ethanol’s  anxiolytic-like 
responses can be generalized across preclinical anxiety assays, PC1 and PC2 resulting 
from the LDB ethanol phenotypes were correlated with all of ethanol phenotypes from 
the EPM as well as ethanol’s  marble burying phenotype (Figure 4.11). As expected, the 
largely locomotor-related PC1 from the LDB significantly correlated with multiple 
locomotor-related phenotypes part of PC1 in the EPM,  transitions, open arm entries, 
entries into the center, number of falls of of the maze. Additionally, the percent of 
marbles buried significantly correlated to the LDB’s PC1. Strikingly, PC2 from the LDB, 
which was contained the PTS and PDT in the light phenotypes, did not correlate with 
any ethanol endophenotype in the EPM, nor the marble burying task, indicating that 
Etanq1 is not generalizable across these two assays. 
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Discussion
! Here, we sought to determine whether genes underlying the behavioral QTL, 
Etanq1, could be generalized across other preclinical models of anxiety, the EPM and 
MB task. Acute ethanol significantly  increased PTS and PDT in the open arms and 
decreased the percent of marbles buried, two phenotypes routinely interpreted in the 
literature as “anxiolytic-like”, thus we hypothesized that Etanq1 might modulate 
anxiolytic-like responses across assays. 
! Upon testing BXD strains selected for Etanq1 haplotypes in the EPM with acute 
ethanol, we only observed haplotype x treatment interactions when restraint stress was 
used prior to ethanol administration, strongly  suggesting that restraint stress is 
necessary to detect significant interactions between the Etanq1 haplotype and ethanol 
treatment for PTS and PDT in the open arms of the EPM. Interestingly, these 
interactions were abolished when testing was done in the absence of restraint stress. 
Furthermore, these BXD studies do suggest that the Etanq1 locus may be influencing 
the ethanol responses, PTS and PDT, across both the LDB and EPM assays. One 
limitation of these studies is that the BXDs grouped based on Etanq1 haplotypes have 
additional locations across their genomes in which they group in the same manner, thus 
the test for significant interactions would show the same results at each of these loci as 
well. Upon searching for locations in which the six BXD strains grouped by haplotype 
similarly to Etanq1 haplotype grouping (Supplemental Table S1), additional loci were 
found on chromosomes 3, 7, 10, 12, and X. Within these haplotype blocks, we searched 
for genes with non-synonymous exon SNPs between the B6 and D2 strains 
(Supplemental Table S2) and correlated each of genes with the phenotypes driving 
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Etanq1. Of the 150 genes with SNPs, only 10 showed significant correlations between 
basal NAc expression, a brain region we think is important for Etanq1 (Chapter 7), and 
PTS and PDT in the light side of the LDB (Supplemental Table S3), three of which, Nin, 
Pygl, and Atp5s, lie within the Etanq1 support interval. The fact that the expression of 
very  few genes at the other loci where the BXD strains grouped by haplotype correlate 
significantly to Etanq1 adds confidence in our results, which suggest that genetic 
variation within a gene (or genes) in the Etanq1 support interval modulates both PTS 
and PDT in the LDB and EPM.
! Next, we used principal components analysis across the phenotypes from three 
preclinical models of anxiety, LDB, EPM, and MB tasks, to determine whether the 
genetic components of ethanol’s responses overlap across assays. We found that both 
saline and ethanol responses in the LDB and EPM were largely locomotor-driven as 
evidenced from their first principal components. This was expected, as multiple 
literature studies have reported the locomotor-dependence of these assays (Clement, 
2007; Henderson, 2004; Turri, 2001; Flint, 2003). Interestingly, the MB phenotype 
correlated significantly  with the locomotor PC from the LDB, suggesting that this 
phenotype may not reflect anxiolytic-like behavior in mice. In both PCAs performed on 
the ethanol phenotypes, PC2 for each assay contained the PTS and PDT phenotypes, 
however, upon correlation of these phenotypes with each other, we found that they  were 
genetically  correlated. In contrast to our BXD studies, the HMDP studies suggest that 
the same genetic loci do not influence PTS and PDT across the LDB and EPM. There 
may be multiple reasons for the conflicting results. First, perhaps the PCA and 
correlation analyses were underpowered with an n=8. However, early PCA across 
79
preclinical anxiety  assays have been performed using just two inbred strains of mice 
(Clement, 2007). Second, the strains used are all inbred, thus a limited genetic diversity 
may have masked our ability to detect the relationships between ethanol responses in 
these assays if the driver loci or variants were not present. Lastly, maybe these ethanol 
responses are so complex that Etanq1 does play a role in both the EPM and LDB, but 
its effect is major in the LDB, but minor in the EPM. 
! Overall, these studies have provided evidence of the complexity of acute ethanol-
responsive phenotypes in unconditioned preclinical models of anxiety, thus 
interpretation and interrogation of genetic loci influencing these traits is not trivial. 
Future, controlled studies should be performed with an expanded panel of mice across 
additional unconditioned preclinical anxiety  assays, such as the elevated zero maze 
and/or open field test, in order to continue to parse ethanol’s endophenotypes. Such 
studies may allow us to “genetically dissect” the mechanism of ethanol-induced 
anxiolysis, which has important implications in the future treatment of alcohol use 
disorders.
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Chapter 5 - Ninein as a Candidate Gene for Etanq1
Introduction and Preliminary Studies
 Risk for developing various aspects of alcoholism is determined by a combination 
of an individual’s genetic makeup, environment, and neuroadaptations that occur 
following acute and chronic exposure to alcohol. These complex interactions manifest 
themselves heterogeneously among individuals, thus there remains a need to 
understand the biological and genetic bases of risk for developing different stages of the 
disease. Alcoholics frequently self-report anxiety and stress as motives for drinking 
(Brown, 1991; Schuckit, 1990) and it has been hypothesized that alcohol’s ability to 
relieve stress may contribute to initiation of drinking, development of excessive drinking, 
and/or its reinforcing effects and relapse (Spanagel, 1995). Thus, one focus of my thesis 
is  to elucidate the genetic architecture underlying the acute anxiolytic-like response to 
ethanol. Previously, Dr. Putman, of the Miles Laboratory, utilized two parental inbred 
strains of mice, C57BL/6J (B6) and DBA2/J (D2) and BXD (B6 x D2) recombinant 
inbred (RI) strains. Following an acute dose of saline or ethanol, mice were assayed in 
the light-dark box (LDB) preclinical model of “anxiety” and genetic mapping of an acute 
anxiolytic-like phenotype was performed. Those studies identified and confirmed a 
behavioral quantitative trait locus (bQTL) for both PTS and PDT in the light, on 
chromosome 12, deemed Etanq1 (ethanol-induced anxiolysis QTL 1), shown in Figure 
5.1 (Putman, 2008). Using advanced-intercross recombinant inbred (ARI) strains 
81
containing additional recombination events within the Etanq1 suport interval, Dr. Wolen, 
from the Miles laboratory, was able to refine the support interval from a 17.74Mb region 
containing 106 genes to a 3.4Mb region containing 48 genes, spanning 69.1-72.6Mb on 
distal chromosome 12 (Wolen, 2012). Four hours following behavioral testing, tissue 
from the mesolimbic dopamine reward pathway, nucleus accumbens (NAc), medial 
prefrontal cortex (mPFC), and ventral midbrain (VMB) of each BXD mouse was 
harvested. Affymetrix M430 2.0 chips were used to conduct gene expression analysis of 
39,000 transcripts  across the genome captured by 45,000 probesets of over 34,000 
well-characterized genes. Transcript levels at this timepoint are thought to be a 
surrogate measure of signal transduction events that occurred as a result of earlier drug 
administration and behavioral testing (Kerns, 2005). Following cis expression QTL (cis 
eQTL) analysis across  these brain regions, it was found that of the 48 genes within the 
Etanq1 support interval, four (Nin, Atp5s, Sos2, and Trim9) have putative cis eQTL in 
the NAc, which overlap with Etanq1, Figure 5.2. Furthermore, the basal expression of 
each gene within the NAc significantly correlates to Etanq1, making Nin, Atp5s, Sos2, 
and Trim9 top-priority quantitative trait genes (QTGs), Figure 5.3. 
 Although Sos2 and Trim9 both contain cis eQTLs overlapping with and correlated 
to Etanq1, they do not contain non-synonymous exon or untranslated region (UTR) 
polymorphisms differing between the B6 and D2 mouse strains, which are the most 
common variants predicted to underlie cis eQTL (Schadt, 2005). The number of genes 
passing each criterion are pictured in Figure 5.4. It is  entirely possible that non-
synonymous intra- or intergenic SNPs may lie within regions containing enhancer 
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Figure 5.1 Significant behavioral QTL for PTS and PDT in the light dark box 
phenotypes resulted following acute ethanol administration. Strain-mean interval 
mapping using 2000 permutations generated signifiant behavioral QTL on chromosome 
12 and suggestive QTL on distal chromosome 1 for the acute ethanol-induced 
anxiolytic-like responses, PTS in the LDB, a, Suggestive LRS≥10.84, LOD≥2.36, 
p≤0.63, Significant LRS≥18.18, LOD≥3.96, p≤0.05 and PDT in the LDB (GN Record ID 
12632), b, Suggestive LRS≥10.93, LOD≥2.34, p≤0.63, Significant LRS≥17.89, 
LOD≥3.85, p≤0.05 (GN Record ID 10964). Grey lines denote suggestive LOD scores 
and red lines denote significant LOD scores.
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Figure 5.2 - Significant cis eQTL overlap with the PTS bQTL, Etanq1, for 
candidate genes, Nin, Atp5s, Trim9, and Sos2. Strain-mean interval mapping of 
NAc saline RMA data using 1000 permutations resulted in identification of signifiant 
cis  eQTL on chromosome 12 for Nin (a), Atp5s (b), Trim9 (c), and Sos2 (d) for the 
probesets indicated in each legend. 
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Figure 5.3 - Nin, Atp5s, Trim9, and Sos2 mRNA expression in the NAc 
significantly correlate with the PTS and PDT LDB phenotypes. Correlation 
scattergrams (left of diagonal), univariate density plots (in white, along the diagonal), 
and Pearson’s r values (right of diagonal) are displayed. For the correlation 
scattergrams, each point represents a strain mean with linear fits  plotted in red and 
95% confidence intervals plotted in blue. Blue r value denote a significant correlation 
at an alpha = 0.05. 
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Figure 5.4 - Venn diagram of characteristics of quantitative trait genes for Etanq1. 
Of the 48 genes within the Etanq1 support interval on chromosome 12, 69.1-72.6Mb, 29 
genes contain SNPs between B6 and D2 strains, 4 of which are missense SNPs. 14 
genes have either cis or trans eQTL which overlap  with Etanq1, and 24 genes show 
significant correlations to PTS and PDT (p(Pearson’s r) <0.01) across the NAc, mPFC, 
and/or VMB. Of note, only 4 genes possess cis eQTL, all of which are in the NAc, and 
only two of these contain missense coding SNPs, Nin and Atp5s.
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binding-sites, which in turn, may cause cis-regulated expression, however, enhancer 
regions within the mouse genome are poorly mapped at present. With the advent of 
next-generation sequencing, regulatory regions such as these are currently being 
identified in human cells using chromatin profiling (Ernst, 2011). Thus, without the 
availability of this information in the mouse, we further narrowed down our candidate 
gene list to Nin and Atp5s on the basis of possessing non-synonymous exon SNPs. 
 Quantitative, real-time PCR (qRT-PCR) performed from B6 and D2 NAc tissue for 
all four genes containing cis eQTL and allele-specific sequencing of Nin from B6D2F1/J 
tissue confirmed cis regulation of basal Nin transcript levels in the NAc, resulting in 
significantly higher Nin expression in D2 mice compared to B6 mice. Next, analysis of 
putative splice sites  has revealed that two of the missense coding SNPs within the Nin 
gene, but not Atp5s are predicted to enhance alternative splicing at those locations in 
D2 mice. Finally, we have shown that in the NAc, D2 mice have significantly higher 
levels  of two protein isoforms likely resulting from increased alternative splicing 
compared to B6 mice. Taken together, this  aim has largely focused on interrogating the 
role of Nin in modulating phenotypic responses to ethanol in LDB and EPM. Through 
behavioral testing of hybrid mouse diversity panel (HMDP) strains selected for 
possessing either B6 or D2 missense exon SNPs as well as D2 mice in which Nin was 
knocked down via lentiviral delivery into the NAc, we have discovered that Nin may 
modulate one endophenotype of the LDB’s PC2, latency to enter the light side of the 
LDB. Overall, these studies provide evidence for basal Nin levels in modulating one 
component of acute ethanol anxiolytic-like behavior, perhaps through a novel 
mechanism. Confirmation of candidate genes involved in acute responses to ethanol in 
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rodents, such as Nin, may lead to discovery of new and important molecules to further 
research or target pharmcotherapies which may ultimately aid in the treatment of 
alcohol addiction disorders in relevant populations.
Materials and Methods
! Mice and husbandry conditions. Male C57BL/6J, DBA/2J, B6D2F1/J, AKR/J, 
NOD/ShiLtJ, 129S1/SvImJ, C3H/HeJ, and Balb/cByJ mice were obtained at 7-8 weeks 
of age from the Jackson Laboratories (Bar Harbor, ME). Mice were housed 4/cage and 
allowed to habituate to the animal vivarium for two weeks following shipment to Virginia 
Commonwealth University (VCU). Mice were maintained on a 12-hour light/dark cycle 
with ad libitum access to standard rodent chow (Harlan, 7012) and tap water. All mice 
were 8-12 weeks old at time of behavioral testing. All behaviors were assayed during 
the light cycle between the hours of 0800 and 1300. Mice used only for molecular 
studies were housed with Teklad aspen sani-chip  (Harlan, 7090A) and mice undergoing 
behaviors were housed on Teklad corn cob (Harlan, 7092) bedding. 
! Drugs. For all behavioral studies, a 1.8g/kg of ethanol dose was administered 
intraperitoneally  (i.p.) using a 10% ethanol (w/v) stock solution dissolved in a 0.9% 
physiological saline vehicle. This dose was chosen based on previous LDB studies in 
our laboratory (Putman, 2008). For stereotaxic surgeries, mice received ad libitum 
access to 0.188mg/mL cherry-flavored children’s ibuprofen in their drinking water from 
day prior to surgery until 48 hours after surgery. Mice were anesthetized with 5% 
isoflurane and 7L O2 per minute and maintained sedated with 2-3% isoflurane/7L O2 per 
minute. For local anesthesia, 0.1mL of 0.25% bupivacaine, was administered at the 
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incision site. Lentivirus at a titer of 1.0x107 pg p24 per mL was used for in vivo infection. 
This  titer was  chosen based on previous studies showing behavioral alterations  using 
shRNA lentiviruses (Lasek, 2007; Lasek, 2008; Lasek, 2010).
! Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR). For 
molecular studies  using mouse tissue, single nucleus accumbens (NAc) samples from 
9-week old, untreated B6 and D2 mice were micro-dissected on ice and immediately 
flash-frozen in liquid nitrogen using a protocol described previously (Kerns, 2005). 
Samples were homogenized with a Polytron® (Kinematica AG) and RNA extracted 
using a guanidine/phenol/chloroform method (STAT-60, Tel-Test, Inc.). Each RNA liquid 
layer was added to an RNeasy Mini Column (Qiagen) for cleanup and elution of total 
RNA. For studies using cell lysates, cells  were pelleted and washed three times with 1X 
sterile PBS. Cells were lysed using Buffer RLT and RNA was extracted following the cell 
culture protocol from the RNeasy Mini kit (Qiagen). RNA quality and purity was 
determined using an Experion Automated Electrophoresis  Station (Bio-Rad) and a 
Nanodrop 2000 (Thermo Scientific). 1µg of RNA was converted to cDNA using Bio-
Rad’s  iScript cDNA synthesis kit containing random hexamers according to 
manufacturer’s  instructions. For qPCR, primer efficiencies were between 90-110% and 
each primer set resulted in only one PCR product. Primer sequences, Tm’s, amplicon 
sizes, and cDNA dilutions used for each gene are listed in Table 7.1. Data analysis was 
performed using the 2-[∆∆CT] method (Heid, 1996). Statistical analysis of qRT-PCR data 
was performed using a Student’s t-test between the two strains tested. 
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 Cis-trans test via pyrosequencing. Single nucleus accumbens (NAc) samples 
from 9-week old, untreated B6D2F1/J hybrid mice were micro-dissected on ice and 
immediately flash-frozen in liquid nitrogen using a protocol described previously (Kerns, 
2005ks). Samples were homogenized with a Polytron® (Kinematica AG) and RNA 
extracted using a guanidine/phenol/chloroform method (STAT-60, Tel-Test, Inc.). Each 
RNA liquid layer was added to an RNeasy Mini Column (Qiagen) for cleanup and elution 
of total RNA. RNA quality and purity was determined using an Experion Automated 
Electrophoresis  Station (Bio-Rad) and a Nanodrop 2000 (Thermo Scientific). 1µg of 
RNA was  converted to cDNA using Bio-Rad’s iScript cDNA synthesis kit containing oligo 
dT’s according to manufacturer’s  instructions. End-point PCR was performed using the 
primers listed in Table 5.2, which were designed around two of the four non-
synonymous coding SNPs present between B6 and D2 mice, dbSNPs rs29192398 and 
rs29159683, creating a 413bp amplicon for sequencing. These primer sequences were 
also extended with a unique identifier (MID) sequence such that all samples  could be 
multiplexed during pyrosequencing. PCR products  were sequenced on the Roche 454 
instrument and then analyzed for SNP allele frequency.
! Immunoblotting. Single nucleus accumbens from untreated B6 and D2 mice were 
microdissected and flash-frozen in liquid nitrogen as described above. Samples were 
triturated in 100uL of cold 1X LDS (Life Technologies, Grand Island, NY) containing 2X 
Halt protease and phosphatase inhibitor cocktail and 10mM EDTA (Thermo Fisher 
Scientific). Each sample was passed through a 28g syringe until brain tissue was no 
longer visible upon quick spin centrifugation. Protein concentrations on the whole 
sample homogenates were determined using the bicinchoninic acid assay (Thermo 
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Fisher Scientific). Samples were balanced with 1X LDS, reduced with 50mM 
dithiothreitol and boiled for 10 minutes. For each antibody used herein, it was 
determined that 17.5µg of protein lie within the linear range of detection, thus 17.5µg of 
protein were loaded per lane on a 3-8% Tris-acetate gel (Life Technologies). Using a 1X 
tris-acetate running buffer, electrophoresis was performed at 150V. The gel was 
transferred to a 45µm PVDF membrane at 10V for 24 hours using a freshly prepared 
transfer buffer containing 10% methanol. Coomassie staining of the gel and Ponceau 
staining of the membrane indicated efficient and even transfer. Prior to each primary 
antibody incubation, the membrane was blocked with 5% nonfat milk in 1X wash buffer 
(TBS-T containing 0.2% Tween 20 and 1M NaCl) for 30 minutes at room temperature. 
For ACTB, Primary and secondary antibody catalog numbers, dilutions, and incubation 
times are provided in Table 3.2. For NIN, 1, 1000 of rabbit primary (Bethyl Laboratories, 
Montgomery, TX, Cat# A301-504) and 1, 2000 of donkey anti-rabbit (Table 6.2) were 
used. Immunoblots were imaged on Kodak film using the chemiluminescent ECL prime 
reagent (GE Healthcare Life Sciences) and quantitated using ImageJ processing and 
analysis software (National Institutes of Health). All proteins were normalized to the 
loading control, β-actin (ACTB).
! Plasmids. Bacterial glycerol stocks for five Ninein (Nin) and one b-actin (Actb) 
shRNA-containing plasmids and DNA for a plasmid containing a non-mammalian target 
scrambled shRNA sequence (denoted sh-scram) were obtained from Sigma Aldrich 
(Table 5.3). The shRNAs were previously cloned into the pLKO.1-puromycin plasmid 
backbone immediately downstream of the U6 promoter. Bacterial slabs of second 
generation lentiviral plasmids, psPAX2 (Plasmid 12260) and pMD2.G (Plasmid 12259), 
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were obtained from Addgene (Cambridge, MA). For positive control studies requiring the 
GFP reporter protein, the pLL3.7 plasmid (Rubinson, 2003) (Plasmid 11795) was 
obtained. All plasmid maps are pictured in the appendix (A4). Bacterial glycerol 
stocks were streaked onto sterile 1.5% luria agar plates infused with 100µg/mL 
ampicillin. 0.01ng of the sh-scram plasmid were transformed into Stabl (Invitrogen) E. 
coli using the manufacturer’s protocol. 10, 20, and 100µL of the transformation solution 
was spread onto sterile 1.5% luria agar plates infused with 100µg/mL ampicillin. All 
plates were incubated at 37°C overnight. No more than 16 hours later, single colonies 
were picked into 3mL of either sterile Luria Broth (LB) containing with 10g NaCl or 
Terrific Broth (TB) containing 100µg/mL ampicillin in 15mL cell culture tubes. Tubes 
were shaken at 2000rpm and 37°C for 8h, after which the 3mL was poured into 500mL 
of sterile broth containing 100µg/mL ampicillin in a 1L erlenmeyer flask. The flasks were 
shaken under the same conditions overnight for no more than 16h. Following the 
incubation, bacterial glycerol stocks were made using 500µL of bacteria and 500µL of 
50% sterile glycerol. Stocks were frozen at -80°C. Bacteria were pelleted by 
centrifugation at 6000 rpm at 4°C  for 10 minutes. Pellets were either frozen at -80°C 
until harvesting or immediately lysed. Lysis, cleanup, and DNA precipitation were 
performed using the endotoxin-free Qiagen MegaPrep kit according to the 
manufacturer’s instructions. The purity  and integrity  of plasmid DNA were determined by 
NanoDrop 2000 (ThermoScientific) analysis, restriction enzyme digestion, and agarose 
gel electrophoresis (Figure A5). 
 In vitro transfection. Mouse fibroblast cells, NIH3T3, maintained in high-glucose 
DMEM containing 10% FBS, 2mM L-glutamine, and 50U/mL penicillin/streptomycin, 
95
(complete media) were used for all transfection experiments. Prior to transfection, a 
puromycin kill curve was performed in NIH3T3 cells, which determined that 2µg/mL was 
the optimal concentration of puromycin required to kill 100% of this cell type within 48 
hours. The afternoon prior to transfection, 0.25x106 cells were plated in 6 -well dishes. 
The morning of transfections, media was removed and replaced with 400µL Opti-MEM. 
3µL of X-tremeGENE 9 transfection reagent was diluted into 96µL Opti-MEM and 1µL of 
1µg/µL plasmid DNA was added to the solution, mixed, and incubated at room 
temperature for 20 minutes. DNA-lipid complexes were added drop-wise to each dish, 
dishes were swirled, and placed into a humidified 37°C/5% CO2 incubator overnight. 24 
hours later, media was replaced with complete media containing 2 µg/mL puromycin. 
(Prior studies testing multiple ratios and seeding densities determined that the optimal 
transfection reagent to DNA ratio was 3µL, 1 µg using 0.25x106 cells  seeded the 
afternoon prior to transfection). Cells were harvested at 48 and 72 hours post-
transfection. 
! Lentivirus Production and Titering (adapted from Dr. Amy Lasek, University of 
Illinois - Chicago). HEK293FT cells were obtained from Invitrogen and maintained 
according to the manufacturer’s instructions. Upon thawing, cells were passaged at 
least three times before use in viral production. On the afternoon prior to transfection, 
for each construct, 3-15cm dishes 16x106 HEK293FT cells were seeded in 20mL of 
room-temperature media without Geneticin (G418), such that cells were 80-90% 
confluent for transfection. 16 hours following cell seeding, media was removed and 
replaced with 13mL of fresh, room-temperature media without G418. For each dish, 
12µg of psPAX2, 5µg of pMD2.G, and 15µg of either the sh-Nin or sh-scram plasmid 
96
were combined in 3.5mL of Opti-MEM and incubated at room temperature for 5 minutes. 
In a separate 3.5mL of Opti-MEM, 80µl of Lipofectamine 2000 (Invitrogen) was added 
and placed at room temperature for 5 minutes. Next, the 3.5mL of media containing the 
DNA was added to the 3.5mL of media containing Lipofectamine and incubated for 20 
minutes at room temperature. The 7mL mixture was then added drop-wise a 15cm dish, 
swirled, and placed into a humidified 37°C/5% CO2 incubator overnight. The  following 
morning,  the media was removed and replaced with 22mL of fresh, room-temperature 
Opti-MEM. 48 hours following transfection, media was removed from the cells, 
transferred into a 50mL conical tube, and spun at 1200rpm for 5 minutes at 4°C. Media 
was poured into a 45µm Steriflip filter unit (Millipore), transferred into ultraclear 38.5mL 
tubes (Beckman), and qs’d to 30mL with cold Opti-MEM. Tubes were massed and 
balanced prior to centrifugation. Using an SW  32 Ti rotor, tubes were spun at 26,000rpm 
for 90 min. at 4°C. After centrifugation, the supernatant was discarded and 20µL of 
sterile, 1X PBS was added to the bottom of the tube without disturbing the pellet. The 
pellet was resuspended by gentle pipetting 10 times and the virus from 3 tubes (3 
transfection dishes) was combined, mixed, and then distributed into 10µL aliquots. 
Aliquots were frozen on dry ice and stored at -80°C until titering. Viral titers were 
determined using the HIV-1 p24 ELISA (ZeptoMetrix Corporation, Buffalo, NY).
 In vitro viral transduction (adapted from Sigma Aldrich). Mouse fibroblast cells, 
NIH3T3, maintained in high-glucose DMEM containing 10% FBS, 2mM L-glutamine, 
and 50U/mL penicillin/streptomycin, were used for all transduction experiments. The 
afternoon prior to transduction, 0.1x105 cells were plated in 96-well dishes. The morning 
of transduction, media was removed and replaced with 100µL of media containing 8µg/
97
mL hexadimethrine bromide (polybrene) and viruses  at a concentration sufficient for a 
multiplicity of infection (MOI) of either 0.5, 1.0, 2.0, or 5.0 were added drop-wise to each 
well. Plates were swirled and placed into a humidified 37°C/5% CO2 incubator 
overnight. 24 hours  later, cells were transferred to 6-well plates and at 48 hours, 
lentivrus-containing media was replaced with media containing 2µg/mL puromycin. At 
96 hours, puromycin-containing media was replaced to continue selection. At 140-144 
hours post-transduction, cells were harvested. 
 In vivo viral infection via stereotaxic delivery. 8-week old D2 mice received ad 
libitum access to 0.188mg/mL cherry-flavored children’s ibuprofen in their drinking water 
from day prior to surgery until 48 hours  after surgery. Prior to surgery, mice were 
anesthetized with 5% isoflurane and 7L O2 per minute and maintained sedated with 
2-3% isoflurane/7L O2 per minute. Scalps were shaved, wiped with isopropanol to 
remove hair, mice were placed in the stereotaxic rig, earbars were inserted to 
immobilize the head, and the head was adjusted to be level. Ophthalmic ointment 
(Henry Schein) was applied generously to each eye, the incision site was cleaned with 
ethanol, betadine, ethanol, and then a 0.1mL of 0.25% bupivacaine, was  injected at the 
incision site. An anterioposterior (AP) incision was made to expose the skull and 
needles were centered at bregma. If necessary, the animal’s head was adjusted to be 
within the same AP and mediolateral (ML) planes as bregma. AP and ML coordinates 
from bregma were recorded. NAc coordinates (A,  +1.7mm, L,  +1.4mm, V,  -4.1mm) 
were added/subtracted from those recorded at bregma and A and L coordinates 
adjusted. Needles were lowered to the surface of the skull , where marks were made for 
drilling. Holes were drilled through the skull and needles were rinsed with water, 
98
ethanol, and water before loading them with virus. Needles were placed at the edge of 
the skull and dorsal readings were taken. Ventral coordinates were subtracted and 
needles were lowered to the NAc. 0.1 µL of virus was injected every minute for a total of 
1µL of virus injected bilaterally. Needles were allowed to sit at the injection site for 10 
minutes and then slowly  removed and cleaned. Incisions were sealed with Vetbond 
(3M) and mice were placed into a clean cage on a heating pad until coming out from 
under anesthesia. Sterile technique was maintained throughout the surgery and the 
absence of a toe pinch reflex was recorded at 15 minute intervals. Behavioral studies 
were performed three weeks following viral injections, as previous studies have 
demonstrated maximal lentiviral expression occurs at two weeks  following injection and 
is maintained for at least one year following infection (Baekelandt, 2002).
 Light Dark Box. The LDB (Med-Associates, St. Albans, VT) consists transparent 
square box of dimensions 10.75" L x 10.75" W x 8" H with a black insert which divides 
the chamber into two equally sized chambers. The entire apparatus is contained within 
a sound-attenuating chamber. Mice were placed into a 50mL conical tube on top of a full 
cage of bedding for 15 minutes. Immediately  following a 15-minute restraint stress, mice 
were injected i.p. with either ethanol or saline, returned to their home cage for 5 
minutes, and then placed into center of the LDB, facing the dark side, and behaviors 
were recorded for 10 minutes. Studies used house lights (100mA) within the light-dark 
box.  
! Elevated Plus Maze. The EPM (Hamilton Kinder, San Diego, CA) consists of four 
black arms in a cross shape raised 30.5” from the ground. Each arm is 15” L x 2” W and 
the apparatus contains with center section measuring 2” L x 2” W. The closed arms 
99
have 6” black walls and the open arms do not have walls. Mice were placed into a 50mL 
conical tube on top of a full cage of bedding for 15 minutes. Immediately following the 
restraint stress, mice were injected i.p. with either ethanol or saline, returned to their 
home cage for 5 minutes, and then placed into center of an EPM, facing one of the 
open arms, and allowed to roam for 5 minutes. The open arm that each mouse faced to 
begin the assay was randomized and balanced within treatment groups. If mice did not 
receive restraint stress, they were administered either ethanol or saline i.p., placed into 
their home cage for 5 minutes, and then placed into the center of the EPM and allowed 
to roam for 5 minutes. If a mouse fell or jumped off of the maze, it was placed back into 
the center facing the opposite open arm from which it fell. The number of falls was 
counted as a separate phenotype.
 Statistics. Using JMP and/or R, appropriate Student’s t-tests or oneway ANOVAs, 
followed by Tukey’s HSD post-hocs were performed for all cellular and molecular 
studies, as noted where applicable. A twoway ANOVA, followed by a Tukey’s HSD post-
hoc was performed for all behavioral studies to determine the presence of main and/or 
interaction effects of treatment and genotype. Pearson’s or Spearman’s correlations, 
where appropriate, were performed using the psych package in R (Revelle, 2012). 
Results
! Functional analysis of non-synonymous exonic SNPs within Nin and Atp5s 
revealed that two of the four SNPs within the Nin gene overlap with exonic splicing 
enhancer (ESE) sequences, while the single missense coding SNP within the Atp5s 
100
N
in
 rs
32
22
53
58
 (C
/T
)
B
6
D
2
N
in
 rs
29
19
23
98
 (C
/T
)
B
6
D
2
D
2 B
6
D
2
N
in
 rs
29
15
96
83
 (G
/T
)
N
in
 rs
29
14
90
25
 (T
/C
)
B
6
D
2
A
tp
5s
 M
R
S
34
53
06
1 
(G
/A
)
B
6
D
2
a 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  b
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 c
   
   
   
   
   
   
   
   
d 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
e
Fi
gu
re
 5
.5
 - 
Tw
o 
of
 N
in
’s
 m
is
se
ns
e 
SN
P
 a
lle
le
s 
in
 t
he
 D
2 
st
ra
in
 r
es
ul
t 
in
 a
lte
ra
tio
n 
of
 o
r 
cr
ea
tio
n 
of
 e
xo
n 
sp
lic
e 
en
ha
nc
er
  s
eq
ue
nc
es
. E
xo
ni
c 
sp
lic
in
g 
en
ha
nc
er
 (
E
S
E
) a
na
ly
si
s 
of
 B
6D
2 
S
N
P
s 
w
ith
in
 th
e 
N
in
 a
nd
 A
tp
5s
 g
en
es
 re
ve
al
ed
 
th
at
 th
e 
D
2 
al
le
le
 fo
r 
rs
29
19
23
98
 (
b,
 p
os
iti
on
 1
01
 o
n 
th
e 
di
ag
ra
m
) 
is
 p
re
di
ct
ed
 to
 c
au
se
 a
n 
E
S
E
 h
ex
am
er
 b
in
di
ng
 s
ite
, 
w
he
re
as
 th
e 
B
6 
al
le
le
 d
oe
s 
no
t. 
A
dd
iti
on
al
ly,
 N
in
 S
N
P 
rs
29
15
96
83
 a
lte
rs
 th
e 
E
S
E
 b
et
w
ee
n 
B
6 
an
d 
D
2 
st
ra
in
s 
(c
). 
N
in
 
S
N
P
s 
rs
32
22
53
58
 (
a)
 a
nd
 r
s2
91
49
02
5 
(d
) 
w
er
e 
no
t 
pr
ed
ic
te
d 
to
 c
re
at
e 
E
S
E 
si
te
s.
 F
or
 A
tp
5s
, 
th
e 
m
is
se
ns
e 
S
N
P,
 
M
R
S
34
53
01
6 
(p
os
iti
on
 1
14
 o
n 
th
e 
di
ag
ra
m
), 
is
 n
ot
 p
re
di
ct
ed
 t
o 
cr
ea
te
 a
n 
E
S
E 
si
te
 (
e)
. 
A
rr
ow
s 
de
no
te
 S
N
P 
al
le
le
s.
 
(S
cr
ee
ns
ho
ts
 a
da
pt
ed
 fr
om
 th
e 
R
E
S
C
U
E
-E
S
E
 o
nl
in
e 
to
ol
 (Y
eo
, 2
00
4)
). 
101
gene does not (Fairbrother, 2002; Yeo, 2004), Figure 5.5. Furthermore, the Nin SNP, 
rs29192398, was predicted to create an ESE site in the presence of the D2 T allele, 
which is not present with the B6 C allele in the same position, suggesting that D2 mice 
might have increased splicing of Nin transcripts  at this location, which may lead to 
different pools of NIN protein isoforms, and consequently, NIN function between the two 
strains. In fact, two alternatively-spliced variants which are translated into two protein 
isoforms of NIN have been discovered in the mouse genome (Figure 5.6).
Basal transcript levels of Ninein in the NAc are cis-regulated.
! qRT-PCR analysis of NAc samples from untreated B6 and D2 mice only 
confirmed differential mRNA expression of Nin, but not Atp5s, Sos2, nor Trim9 (Figure 
5.7, a), the four candidate QTGs possessing cis eQTL in the NAc. The expression of 
Nin was significantly  greater in the NAc of D2 mice compared to B6 mice. Thus, 
pyrosequencing was performed on only  Nin. In the NAc of untreated B6D2F1/J mice, 
allele-specific pyrosequencing of missense SNPs within the Nin gene revealed a 
significantly greater frequency of the D2 SNP alleles compared to B6 alleles, confirming 
cis regulation of Nin in the NAc (Figure 5.7, b).
Basal NINEIN protein isoforms in the NAc are differentially regulated between B6 and 
D2 mice.
! Immunoblotting confirmed significantly higher basal levels of two protein isoforms 
in the NAc of D2 mice compared to B6 mice (Figure 5.8). If either one or both SNPs, 
rs29192398 and rs29159683, result increased splicing out of exon 16 in D2 mice, the 
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Figure 5.7 - Confirmation of cis regulation of Ninein. (a) Basal mRNA levels 
of Nin in NAc of D2 mice were found to be significantly greater than levels  in B6 
mice (*p<0.01, n=8 per group) as confirmed by qRT-PCR. However, basal 
mRNA levels  of Sos2, Atp5s, and Trim9 were not found to be different between 
B6 and D2 mice in NAc as measured by qRT-PCR. (b) Pyrosequencing of 
B6D2F1/J hybrid mice for an amplicon of Nin containing two SNPs between B6 
and D2 mice (rs29192398 and rs29159683 at 71.144373 and 71.144376 Mb of 
mouse build mm9, respectively) confirmed a higher D2 allele frequency in NAc 
compared to B6 allele frequency (*p<0.01, n=2 pooled per sample, n=3 per 
group, n>4000 reads per group) for those SNPs.
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Figure 5.8 - Immunoblotting confirms differential regulation of NIN protein 
isoforms in the NAc between B6 and D2 mice. Immunoblotting of single NAc tissue 
from untreated B6 and D2 mice revealed significantly higher levels  of the provisional 
NIN4 and NIN5 isoforms in D2 compared to B6 mice (*p<0.05, Student’s t-test, n=5/gp). 
Panel a, blot images and panel b, quantitation of 10 NIN isoforms. D2 mice also show a 
trend for higher levels of NIN6, NIN8, and NIN10 isoforms (p=0.1703, p=0.0589, and 
p=0.1516, respectively, Student’s t-test). NIN levels were normalized to ACTB protein 
levels. 
 
 
Page 2
Directions 
The HiMark™ Pre-Stained HMW Protein Standard is supplied in a 
ready-to-use format. There is no need to heat or add reducing agent.  
Load the standard using the loading volumes listed below to obtain the 
best results. Use an appropriate percentage of the gel to resolve proteins. 
 Gel Electrophoresis/Blotting 
Mini-Gel (1.0 mm thick, 10-well) 10 Pl 
Mini-Gel (1.5 mm thick, 10-well) 12 Pl 
To obtain good resolution of all 9 bands of the protein standard, run the 
gel until the phenol red tracking dye reaches the bottom of the gel. 
Note: The HiMark™ Pre-Stained HMW Protein Standard is designed for 
use with NuPAGE® Novex Tris-Acetate Gels, NuPAGE® Novex Bis-Tris 
Gels, or Tris-Glycine Gels. 
After electrophoresis, you should observe the protein standard bands as 
shown on the next page. 
Blotting: To obtain higher transfer efficiency during the transfer of high 
molecular weight proteins, follow the recommendations below. For a 
detailed blotting protocol, refer to the NuPAGE® Large Protein Analysis 
System manual available from our web site at www.invitrogen.com or by 
contacting Technical Service. 
Nitrocellulose Membranes 
Perform transfer with 1X transfer buffer with 10% methanol using the 
recommended transfer conditions based on the gel type. Use 1:1000 
NuPAGE® Antioxidant for efficient transfer of reduced proteins. 
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The apparent molecular weight of protein bands in the 
HiMark™ Pre-Stained HMW Protein Standard in several buffer 
systems is shown below. The protein bands have different 
mobilities in various SDS-PAGE buffer systems.  
An example of 10 Pl HiMark™ Pre-Stained HMW Protein 
Standard analyzed on a NuPAGE® Novex 3-8% Tris-Acetate 
Gel is shown below.  
Apparent Molecular Weight (kDa) 
Band 
No. 
NuPAGE® 
Tris-Acetate 
NuPAGE® 4-12% 
Bis-Tris/MOPS 
4% Tris-
Glycine 
 
1
2
3
 
4
5
6
 
7
8
9
1 
2 
3 
4 
5 
6 
7 
8 
9 
460 
268 
238 
171 
117 
71 
55 
41 
31 
420 
247 
214 
160 
107 
64 
51 
39 
28 
500 
279 
251 
164 
121 
-- 
-- 
-- 
-- 
Product Qualification 
The HiMark™ Pre-Stained High Molecular Weight Protein 
Standard is qualified on a NuPAGE® Novex 3-8% Tris-Acetate 
Gel. After electrophoresis, 9 sharp protein bands of the 
appropriate molecular weight must be observed. 
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resulting protein isoforms would be predicted to be ~150 and ~160KDa (Figure 5.6).  In 
fact, compared to B6 mice, the two provisional isoforms significantly increased in D2 
NAc are NIN4 and NIN5, with predicted molecular weights between 117-171KDa. These 
data support the hypothesis of enhanced splicing activity in D2 mice as a result of an 
additional and/or altered ESE sequence in exon 16, resulting in a greater pool of these 
smaller isoforms in D2 mice. These differences in protein isoforms may suggest 
functional differences in NIN between B6 and D2 mice.
HMDP strains selected for Nin SNPs show multiple genotype x treatment interactions in 
the LDB and EPM, but not the marble burying task.
! In order to determine whether Nin is influencing ethanol-responsive phenotypes 
in the LDB and EPM, strains from the mouse hybrid diversity panel (HMDP) were 
selected on the basis of possessing either the B6 or D2 alleles for the four non-
synonymous coding SNPs within the Nin gene. Table 5.4 lists the HMDP strains 
selected. We hypothesized that if Nin is modulating Etanq1 through differences in one 
or more of these missense SNPs, and its effect is large, then we may be able to detect 
significant genotype x treatment interactions for the anxiolytic-like phenotypes 
measured in the LDB and/or EPM. To avoid possible interaction effects of a separate 
suggestive QTL locus for Etanq1, genotypes were clamped (all B6) at the peak marker 
on distal chromosome 1, located at 165.32Mb. 
! In the LDB, Figure 5.9, MDP strains show significant genotype x treatment 
interaction effects  for TLA, total transitions, percent rearing in the light, jumps, and a 
trend for stereotypic counts (p=0.0533) in the LDB, but not PTS, nor PDT in the light. 
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Table 5.4 - Hybrid Mouse Diversity Panel strains of mice chosen based on Nin 
missense exon SNPs. Nin contains 4 non-synonymous coding SNPs between B6 
and D2 mice, two of which are predicted to alter protein function. 129S1/SvImJ, AKR/
J, and NOD/ShiLtJ strains possess  B6 SNP alleles and A/J, Balb/cByJ, and C3H/HeJ 
strains possess D2 SNP alleles. Mice were obtained from the Jackson Laboratory. 
Chr
Location+(Mbp)+
mouse+build+37 12
9S
1/
Sv
Im
J
AK
R/
J
N
O
D/
Sh
iL
tJ
C5
7B
L/
6J
DB
A/
2J
A/
J
Ba
lb
/c
By
J
C3
H/
He
J
+dbSNP+rs
12 71.144164 C C C C T T T T rs32225358
12 71.144373 C C C C T T T T rs29192398
12 71.144376 G G G G T T T T rs29159683
12 71.144902 T T T T C C C C rs29149025
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Additionally, there was a significant main effect of the Nin genotype for transitions and a 
near significant effect of genotype for latency to enter the light (p=0.0721).
 In the EPM, Figure 5.10, MDP strains  show significant genotype x treatment 
interaction effects for PDT, total transitions, fine movements, entries into the center, and 
near significant trends for TLA (p=0.0533) and number of falls (p=0.0750) off of the 
maze.
! There was no significant interaction between the Nin genotype and ethanol 
treatment in the marble burying assay across the MDP strains tested. However, there 
are significant main effects of genotype, treatment, and a significant genotype x saline 
treatment interaction only, Figure 5.11.
The NAc expression of Nin is significantly correlated with PDT in the open arms of the 
EPM, shows a near significant correlation with the number of falls and trends toward a 
significant correlation with latency to enter the light.  
! A separate cohort of the same HMDP strains were used for qRT-PCR analysis of 
basal Nin levels in the NAc. Figure 5.12 depicts correlations with basal Nin expression 
and several ethanol-responsive phenotypes from the LDB and EPM. As the interaction 
effect plots failed to show genotype x treatment interaction for PDT in the light (Figure 
5.9, b), we also failed to observe a significant correlation between Nin expression and 
PDT in the light following ethanol (Figure 5.12, a). However, in support of the significant 
interaction effect observed for PDT in the open arms (Figure 5.10, b), we observed a 
significant inverse correlation between Nin expression in the NAc and PDT in the open 
arms of the EPM (Figure 5.12, b). Additionally, we observed a near significant 
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Figure 5.11 - Interaction effect plot for the Nin genotype and treatment across 
eight inbred strains tested in the marble burying assay. When collapsed by Nin 
genotype, there are significant main effects of genotype, 1.8g/kg ethanol treatment, and 
a significant genotype x saline treatment interaction (all p<0.01, twoway ANOVA, 
n=36-40/genotype).
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Figure 5.12 Correlations between the Nin mRNA levels in the NAc and ethanol 
responses in the LDB and EPM across eight HMDP strains. Correlation of basal 
NAc Nin levels  measured by qRT-PCR with ethanol responses in the LDB and EPM 
revealed a lack of correlation for PDT in light side of  the LDB (a), but a significant 
correlation for PDT in the open arms of the EPM (b). Additionally, there were near 
significant correlations between Nin transcript levels  and the number of falls (c) off of 
the EPM and the latency to enter the light side of the LDB (d). Spearman’s rho with their 
p-values are noted (n=8 strains, n=8 per strain). Actual values are plotted in the 
correlation matrices. Nin was normalized to the housekeeping gene, Ppp2r2a.
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correlation with the number of falls off of the maze (Figure 5.12, c), consistent with the 
near significant interaction in Figure 5.10, h). Finally, we observed a trend for a 
correlation between basal Nin levels and the latency to enter the light side of the LDB, 
another phenotype that loaded onto PC2 of the LDB, along with PTS and PDT. We did 
not observe significant correlations between Nin expression and the marble burying 
phenotype following ethanol administration (data not shown). 
Lentiviral plasmids containing Actb or Nin shRNAs were able to significantly decrease 
Actb or Nin mRNA levels in mouse NIH3T3 cells following transfection.
! In order to more directly  interrogate the role of Nin in the NAc of mice, a 
approach was taken to knock down Nin levels using short-hairpin RNAs (shRNAs). 
Lentiviral plasmids containing the shRNA sequences for the positive control, sh-Actb, 
the negative control scrambled RNA sequence, sh-scram, or sh-Nin were obtained and 
transfected into the mouse embryonic fibroblast cell line, NIH3T3. 
! Figure 5.13 depicts two positive controls used to test transfection efficiency and 
shRNA plasmid mRNA knockdown efficiency. Transfection of an shRNA plasmid 
containing an eGFP reporter, pAAV-U6-sh-scram-CMV-eGFP, demonstrated that 48 
hours following transfection, roughly 40-50% of cells  contained the plasmid (Figure 
5.13, a). The positive shRNA plasmid control for Actb, pLKO.1-U6-sh-Actb-CMV-puro, 
was able to significantly decrease Actb  mRNA levels in NIH3T3 cells at 48 hours post-
transfection (Figure 5.13, b).
! Next, five pLKO.1-U6-shRNA-CMV-puro plasmids containing different Nin 
shRNA sequences were transfected into NIH3T3 cells, but only two, sequences 1763 
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Figure 5.13 - Positive controls confirm both transfection and shRNA efficiency. 
The pAAV-U6-sh-scram-CMV-eGFP plasmid (Vector Biolabs) transfected into NIH3T3 
cells shows roughly 40-50% of cells containing the plasmid by 48 hours. Transfection of 
the pLKO.1-U6-sh-Actb-CMV-puro plasmid (Sigma Aldrich) into NIH3T3 cells was able 
to significantly decrease Actb  mRNA levels compared to a scrambled control at 48 
hours post-transfection (*p<0.01, F[2,6]=35.2814, oneway ANOVA, Tukey’s HSD post-
hoc, n=3 biological replicates, n=technical replicates). Actb expression levels were 
normalized to Ppp2r2a. 
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and 924, showed significant knockdown of Nin mRNA levels at both 48 and 72 hours 
post-transfection, Figure 5.14. 
In vitro transduction of pLL3.7 lentivirus confirms viable lentivirus production using 
second generation plasmids.
! Using second generation packaging plasmids in the protocol described to make 
lentivirus, subsequent transduction of the pLL3.7-U6-sh-CMV-eGFP virus into NIH3T3 
cells  confirmed that the lentivirus produced was indeed viable, Figure 5.15.
In vitro transduction of lentivirus containing Nin shRNA was able to knock down mRNA 
levels of Nin in NIH3T3 cells.
! Using second generation packaging plasmids in the protocol described to make 
lentivirus, subsequent transduction of the pLKO.1-U6-shNin-CMV-puro virus into 
NIH3T3 cells at MOIs of 2.0 and 5.0 was able to knock down Nin mRNA levels 
compared to the plasmid containing the scrambled shRNA control (Figure 5.16).  
Site-specific delivery of Nin shRNA lentivirus in the NAc of D2 mice significantly altered 
the latency to enter the light side of the LDB.
! Three weeks following viral injection of lentiviruses expressing either Nin or 
scrambled shRNA into the NAc (Figure 5.17), D2 mice, the strain with higher basal NIN 
levels in the NAc, were tested for ethanol-responsive behaviors in the LDB and EPM. Of 
all of the phenotypes tested in the LDB, only one, latency to enter the light, was altered 
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Figure 5.14 - mRNA knockdown of Ninein via transfection. Transfection of two 
pLKO.1-U6-sh-Nin-CMV-puro plasmids, 1763 and 924, into NIH3T3 cells was able to 
significantly decrease Nin mRNA levels at 48 hours post-transfection (*p<0.01, 
F[4,8]=13.2761, oneway ANOVA, Tukey’s  HSD post-hoc, n=3 biological replicates, n=3 
technical replicates) and transfection of three of the plasmids, 1763, 5335, and 924, 
significantly decreased Nin mRNA expression at 72 hours (*p<0.05, F[6,12]=6.1310, 
oneway ANOVA, Tukey’s HSD post-hoc, n=3 biological replicates, n=3 technical 
replicates) compared to the scrambled shRNA control plasmid. Nin expression levels 
were normalized to the housekeeping gene, Ppp2r2a.
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a                                                                       b                                                                            
Figure 7.15 - Transduction of pLL3.7 lentivirus into NIH3T3 cells confirms 
successful lentiviral production. Bright field (a) and 488nm field (b) views of NIH3T3 
cells 48 hours following transduction with pLL3.7 lentivirus made with the second 
generation plasmids, psPAX2 and pMD2.G.
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Figure 5.16 - Successful knockdown of Nin mRNA with pLKO.1-U6-sh-Nin-CMV-
puro lentivirus. Viral transduction of pLKO.1-U6-sh-Nin-CMV-puro plasmids, 924, into 
NIH3T3 cells  was able to significantly decrease Nin mRNA levels at 144 hours post-
infection (*p<0.05, F[4,10]=23.9992, oneway ANOVA, Tukey’s HSD post-hoc, n=3 
biological replicates, n=3 technical replicates) compared to the scrambled shRNA 
control plasmid. Nin expression levels  were normalized to the housekeeping gene, 
Ppp2r2a. Multiplicities of infection used were either 2.0 or 5.0, as noted.
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Figure 5.17 - Verification of stereotaxic injection into the NAc. Three weeks following 
injection of pLL3.7-CMV-eGFP lentivirus into the NAc of an 8-week old DBA/2J mouse, 
brains were perfused in 4% paraformaldehyde, sliced at 20µm thickness, and imaged 
using confocal microscopy. Brain slice image of DBA/2J mouse, section 13, A: + 1.7mm 
from bregma, from the Mouse Brain Library Database (Rosen, 2000). The blue arrow 
denotes the approximate injection site. Coordinates are listed to the right. Inset, confocal 
image of a slice showing eGFP-positive cells, confirming viral infection. (Mouse injected 
by Julie (So Hyun) Park and confocal image taken by Dr. Yun Kyung Hahn).
Veriﬁca(on+of+len(viral+injec(on+into+the+NAc
A:  +1.7mm
L:  +1.4mm
V:  -4.1mm
Mouse Brain Library, DBA/2J mouse, Section 13.
Photo credit: Yun Kyung Hahn
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by knockdown of Nin, shown in Figure 5.18. None of the EPM phenotypes 
demonstrated significant genotype x treatment interactions (Figure 5.19), suggesting 
that Nin modulates one endophenotype of the LDB PC2, latency to enter the light, and 
this regulation by Nin is not generalizable to ethanol anxiolytic-like responses in the 
EPM.
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Discussion
! In this chapter, we sought to determine whether the QTG, Ninein, plays a role in 
Etanq1’s behavioral responses to ethanol. Although the literature on the function of Nin 
is limited, it has been shown to play a role in anchoring microtubules in the centrosome 
(Bouckson-Castaing, 1996; Mogensen, 2000). In mice, the Nin gene produces two 
known transcript variants (TV1, 9.7Kb and TV2, 7.6kb) and two major protein isoforms 
(244 KDa and 235 KDa). These protein isoforms share an overall ~78% sequence 
similarity  to the human NIN protein and similarity  at most protein domains is largely 
homologous. The GTP-binding domains share 90% homology, the four leucine zippers 
share 69%, the C-terminal domains share 54%, while very little homology is shared at 
the N-terminal domains, 20% (Hong, 2000). Interestingly, a phosphorylation binding site 
for Gsk3b (Glycogen synthase kinase 3 beta), an ethanol-responsive gene (Wolen, 
2012; French, 2009), was found within an 81 amino acid portion of the C-terminal 
domain of human Nin (2010-2090) (Howng, 2004). Furthermore, this 81 amino acid 
sequence is 94% identical to the homologous region in the mouse NIN protein 
sequence (Appendix A6, adapted from the NCBI blast resource (Boratyn, 2013)), 
suggesting conserved regulation of Nin by Gsk3b in mice, which may be important for 
ethanol-responsive behaviors.
! Here, we provide evidence of cis-regulation of Nin transcript levels in the NAc, 
leading to differential protein abundance between B6 and D2 mouse strains. This data 
supports an early finding suggesting transcriptional regulation of Nin, in which 
correlations between Nin mRNA levels and immunohistochemical labeling were found in 
cell culture and across tissues (Bouckson-Castaing, 1996). 
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! Previous studies conducted by Dr. Putman in our laboratory have mapped 
Etanq1 on chromosome 12 as being comprised of the PTS and PDT in the light 
phenotypes (Putman, 2008), thus we hypothesized that Nin may modulate these 
phenotypic responses to ethanol. However, upon testing HMDP strains in the LDB, we 
did not observe significant Nin genotype x ethanol treatment interactions, perhaps for a 
number of reasons. First, the number or strains tested was only eight, and although this 
number gave us enough power to detect significant interactions in the BXD experiments 
in Chapter 6, we have introduced additional genetic variance by using the HMDP 
strains, thus increased the likelihood of epistatic, or gene-gene, interactions. In fact, our 
laboratory has recently  elucidated an epistatic interaction across the BXD panel 
between a chromosome 12 marker which lies within Etanq1, rs3716547 (68.67Mb), and 
a chromosome 1 marker, rs13474399 (182.53Mb) (Putman, et al, in preparation). This 
epistatic interaction masks an Etanq1 haplotype x ethanol treatment interaction when 
the genotype at the chromosome 1 marker is B6. Incidentally, contrasted to the BXD 
strains chosen in chapter 6 having a D2 genotype at rs13474399, the HMDP strains 
chosen for the studies herein were all the B6 genotype at rs13474399, thus it likely that 
epistasis between loci on chromosome 12 and 1 may have masked our ability  to detect 
significant interactions between the chromosome 12 locus and ethanol treatment for 
PTS and PDT in the light dark box. 
! Behavioral studies for ethanol-responsive behaviors across the HMDP strains in 
the EPM elucidated a number of significant interaction effects which were not present 
upon testing of BXD strains selected based on Etanq1 haplotypes (Chapter 4). 
Interactions between the Nin genotype and ethanol treatment were present for PDT in 
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the open arms, total transitions, fine movements, entries into the center compartment 
and near significant trend for total distance traveled and the number of falls off of the 
maze. Observation of significant Nin genotype x treatment interaction effects for 
endophenotypes of both principal components of the ethanol responses in the EPM 
contradicts the principal components analysis data in Chapter 4, suggesting that PC2 
from the LDB does not correlate with any ethanol-responsive EPM phenotype. However, 
the significant interaction effect for PDT in the open arms and near significant interaction 
effect of the number of falls, together with correlations to Nin mRNA levels do suggest a 
common regulation across assays. There are at least two explanations for these data. 
First, the genetic correlations performed in Chapter 4 may have been underpowered 
without representative D2 genotypes at the chromosome 1 marker, rs13474399, leading 
to a lack of correlation between anxiolytic-like phenotypes in the LDB and EPM since 
the chromosome 1 locus is important for the LDB phenotypes, PTS and PDT. If this is 
true, the significant interactions observed in the EPM suggest that the chromosome 1 
locus is not important for detection of a significant genotype x treatment interaction on 
chromosome 12. Perhaps Nin commonly regulates these two phenotypes, but another 
gene is also contributing to the PTS/PDT LDB phenotypes and not the PTS/PDT EPM 
phenotypes, as evidenced by the additional QTL peak on chromosome 1. Second, due 
to the genetic variation across the HMDP strains not present between B6 and D2 mice, 
it is entirely possible that additional epistatic interactions are present in this panel of 
mice which may be responsible for the genotype x treatment interactions we have 
observed in the EPM. Additionally, the strain groupings are not unique for only  the Nin 
genotype. In fact, mining multiple available whole genome sequence datasets for 
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missense SNPs within the exons of other genes revealed that these groups also have at 
least 729 missense SNPs common to their genotype groupings (See Supplemental 
Table S1). Of particular interest, these strains group based on missense SNPs for the 
cannabinoid receptor 1 (Cnr1) and the corticotropin releasing hormone receptor 2 
(Crhr2), both of which have also been implicated in playing a role in anxiety-related 
behaviors (Rubio, 2008; Kishimoto, 2000; Thiemann, 2009; Uriguen, 2004). Thus, there 
remains the possibility that one or more of the significant interactions observed across 
the HMDP panel may be mediated through one of these genes, rather than Nin. 
! In order to directly interrogate the role of NAc Nin in ethanol’s anxiolytic-like 
phenotypes, we have produced and delivered a lentivirus expressing a Nin shRNA into 
the NAc of DBA/2J mice. We hypothesized that if Nin is regulating Etanq1, we would 
observe significantly  greater PTS and PDT in the light side of the LDB compared to D2 
mice injected with a virus expressing a scrambled shRNA. Interestingly, we did not 
observe differences in PTS, nor PDT. However, we observed a significant genotype x 
treatment interaction for latency to enter the light side of the LDB. The principal 
components analysis across the HMDP strains reported in Chapter 6 allowed 
elucidation of additional endophenotypes of Etanq1’s PC2, which contained PTS and 
PDT. Of note, PC2 contained the latency to enter the light phenotype, which was not 
previously measured in the original QTL mapping study. These studies suggest that 
basal NAc levels of Nin may play a role in modulating Etanq1, through the latency to 
enter the light phenotype. As such, low basal levels of Nin in the NAc may be a risk 
factor for acute responses to ethanol by a novel mechanism possibly involving 
microtubule dynamics at or near the synapse. Alternatively, higher levels of a splice 
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variant which does not include exon 16 of the Nin gene may be protective. Furthermore, 
recent studies have reported an association between genetic variation within the Nin 
gene or altered expression patterns of Nin with a number of diseases and genetic 
disorders, including breast cancer (Olson, 2011), a type of skeletal dysplasia (Grosch, 
2013), microencephalic primordial dwarfism (Dauber, 2012), polycystic ovary syndrome 
(Baranova, 2013), and non-alcoholic fatty liver disease (Baranova, 2013), suggesting 
that certain genetic variants of Nin might be a risk factor for multiple disease 
phenotypes. Overall, these studies have uncovered the first role for Nin in an acute 
response to ethanol in mice and future studies investigating its neuronal mechanism 
may lead to a better understanding of the genetic targets of acute ethanol in the central 
nervous system, and ultimately allow for the design of new pharmacotherapies for 
alcohol addiction in those with susceptible genotypes. 
!
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Chapter 6 - Acute Nicotine Behavioral QTL
Introduction
 Nicotine dependence as a result of tobacco use is  the leading cause of 
preventable death in the world, contributing to 90% of lung cancer cases in the United 
States and 49,400 deaths from second-hand smoke per year (National Institutes of 
Health, 2012). Several studies have demonstrated that genetic influences on nicotine 
addiction and dependence exist, with trait heritabilities between 46-84% (Swan, 1997; 
Kendler, 1999; Heath, 1993; True, 1999). Although roughly 70% of adult smokers aspire 
to quit smoking, only 4-7% are successful without medication and only 25% of those 
using current cessation therapies are able to abstain from smoking for six months 
(American Cancer Society, 2013). The inability to quit smoking is thought to be due to 
high rates of relapse from difficulty in managing cravings and withdrawal symptoms 
(National Institutes of Health, 2008), thus, more effective treatments are needed. 
 It has been hypothesized that associative cues in smokers can maintain drug-
seeking behavior and reinforcement, even in the absence of nicotine (Rose, 1997t; 
Caggiula, 2001). A conditioned stimulus choice test, conditioned place preference 
(CPP), has been used in animals since the early 1940s to model appetitive reward-like 
properties of drugs of abuse (Spragg, 1940; Rossi, 1976). Thus, using CPP to test an 
animal’s drug-free response to contextual cues associated with nicotine may lead to 
discovery of neural pathways that play a role in nicotine reward and reinforcement 
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(Bardo, 2000). 
 Behavioral genetics studies in animal models have been widely used to study the 
role of specific nicotinic subunits or other genes in nicotine’s reward-like properties  or 
other behaviors (Changeux, 2010). Additionally, several human studies have associated 
the genetic variation within multiple nicotinic acetylcholine receptor (nAChr) genes with 
different nicotine dependence phenotypes (Ehringer, 2007; Bierut, 2007; Saccone, 
2007; Zeiger, 2008; Amos, 2008; Berrettini, 2008; Hung, 2008; Saccone, 2010). 
However, few forward genetics approaches have been used to identify novel targets for 
intervention in nicotine behaviors. Modern genetic panels, together with high-density 
genotyping and use of expression genetics, have improved the prospects for using 
forward genetics to identify gene networks modulating complex traits such as nicotine 
dependence (Hitzemann, 2004; Carlborg, 2005).
 To identify gene networks involved in nicotine dependence, we used a 
combination of behavioral genetics and pharmacological studies in mice, together with 
genetic analysis of gene expression. Our results implicate genetic variation in Chrna7 
mRNA expression and its potential regulation of insulin signaling as  modulators of 
nicotine conditioned place preference. These studies may have important implications 
for understanding and treating nicotine dependence in humans.
Materials and Methods
 Mice. For all studies, male mice were housed 3-5 per cage and allowed at least a 
one-week acclimation period to the vivarium following shipment to Virginia 
Commonwealth University (VCU). Mice were maintained on a 12-hour light/dark cycle 
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with ad libitum access  to food and water. Adult mice were tested or had tissues 
harvested between 7-12 weeks of age. C57BL/6J (B6, Stock No. 000664), DBA/2J (D2, 
Stock No. 000671), and BXD mice were obtained from Jackson Laboratories (Bar 
Harbor, ME). Chrna7 knock-in, gain-of-function (α7 KI) mice (Chrna7 L250T +/-) were 
obtained from Baylor College of Medicine (Houston, TX) (Broide, 2002). Chrna7 
homozygous knock-out (α7 KO) mice (B6.129S7-Chrna7tm1Bay/J, Stock No. 003232) 
were either obtained from Jackson Laboratories or breeding pairs  were obtained and 
KO mice were bred and genotyped at VCU. Both α7 KI and α7 KO mice were 
backcrossed to the background strain, C57BL/6J, for an additional 8-10 generations and 
wild-type littermates (α7 WT) were used as controls. The animal facility was approved 
by the Association for Assessment and Accreditation of Laboratory Animal Care. 
Experiments were performed during the light cycle and approved by the Institutional 
Animal Care and Use Committee of VCU.  
 Drugs and Chemicals. (-)-Nicotine hydrogen tartrate salt and methyllycaconitine 
citrate (MLA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). PHA-543613 
[N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide] and cocaine 
hydrochloride were obtained from the Drug Supply Program of the National Institute on 
Drug Abuse (Rockville, MD). All drugs were dissolved in a vehicle of physiological saline 
(0.9% sodium chloride), filter sterilized, and administered at a volume of 0.1mL per 10g 
of mouse mass. Nicotine, PHA-543613, and MLA were administered subcutaneously 
(s.c.), while cocaine was given intraperitoneally (i.p.). All doses are expressed as the 
free base of the drug. 
 Conditioned Place Preference (CPP) Experiments. For all CPP experiments with 
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BXD strains, α7 KO, KI, and WT mice, a five-day paradigm was performed as described 
previously (Kota, 2007), Figure 6.1. Each animal received cage enrichment and on 
Wednesday, Thursday, and Friday of the week prior to CPP testing, each mouse was 
handled by the experimenter for approximately two minutes. The CPP apparatus (Med-
Associates, St. Albans, ENV3013) consisted of white and black chambers (20 x 20 x 20 
cm each), which differed in floor texture (white mesh and black rod). The chambers 
were separated by a smaller grey chamber with a smooth PVC floor and partitions that 
allowed access to the black and white chambers. Briefly, on Day 1 (pre-conditioning 
day), mice were placed in the center chamber for 5 minutes, partitions were lifted, and 
mice were allowed to roam freely for 15 minutes. The times spent in the white and black 
chambers were used to establish baseline chamber preferences, if any. Mice were 
separated into vehicle and drug groups such that initial chamber biases were 
approximately balanced. On days  2-4 (conditioning days), twice per day, mice were 
injected with vehicle or drug and subsequently paired with either the white or black 
chamber, where they were allowed to roam for 15 minutes. Vehicle-treated animals 
were paired with saline in both chambers and drug-treated animals  received saline in 
one chamber and nicotine in the opposite chamber. Pairing of the drug with either the 
black or white chamber was randomized within the drug-treated group of mice. On day 
5 (test day), mice did not receive an injection. They were placed into the center 
chamber for 5 minutes, the partitions were lifted, and they were allowed to roam freely 
for 15 minutes. Time spent in each chamber was recorded. 
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Figure 6.1 Experimental timeline for BXD phenotyping of nicotine CPP. Using the 
5-day paradigm illustrated above, 27 BXD strains were assayed for an acute reward-like 
phenotype, conditioned place preference for 0.5mg/kg nicotine or saline. 
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Several studies evaluating the role of α7 nAChRs in nicotine CPP were 
conducted.  We tested nicotine CPP (0.1 and 0.5 mg/kg) in α7 KO, KI, and WT mice 
using the procedure described above. In separate studies, C57BL/6J mice were 
pretreated with either saline or PHA-543613 (4.0, 8.0 and 12.0 mg/kg) 15 min before 
nicotine administration (0.1 or 0.5 mg/kg). Finally, C57BL/6J mice were pretreated with 
either saline or MLA (10 mg/kg), 15 min later, treated with PHA-543613 (12 mg/kg), and 
another 15 min later, treated with nicotine (0.5 mg/kg).  
A similar procedure was  used for cocaine CPP as  our positive control. We tested 
cocaine CPP (10 mg/kg) in α7 KO, KI and WT mice. Finally, C57BL/6J mice were 
pretreated with either saline or PHA-543613 (12 mg/kg), and 15 min later, received 
cocaine (10 mg/kg). Doses were chosen based on those previously shown to produce 
reliable CPP for nicotine (Walters, 2006; Grabus, 2006) and cocaine (Sora, 2001).
 Behavioral Data Analysis and Statistics. For nicotine-treated mice, preference 
scores were calculated as time spent in the drug-paired side on test day minus time 
spent in the drug-paired side during baseline. For saline-treated mice, preference 
scores were calculated as the average of the white side on test day minus the white 
side during baseline and the black side on test day minus the black side during 
baseline. None of the drugs used caused locomotor suppression in the mice at the 
doses used for these studies, therefore, time spent in either chamber was not 
confounded by this behavior. Statistical analysis of all behavioral studies was performed 
using one- or two-way analysis of variance (ANOVA), where appropriate. If a one-way 
ANOVA was significant, an appropriate post-hoc test was performed (Dunnett’s for 
comparisons vs. control and Tukey’s HSD for between-group comparisons when more 
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than two groups existed). Post-hoc p-values of <0.05 were considered to be statistically 
significant. 
 QTL Mapping, Correlations, and Heritability Calculations. QTL mapping and 
correlations were performed using BXD strain means  in GeneNetwork (Chesler, 2004) 
and R/qtl (Arends, 2010). Heritabilities for nicotine and saline CPP phenotypes were 
estimated using the intraclass correlation coefficient method at α=0.05 (Smith, 1957; 
Lynch, 1998) using the ICC package in R. 
 Quantitative Reverse-Transcriptase PCR, Microarrays, Data Analysis, and 
Network Generation. For qRT-PCR experiments, single nucleus accumbens (NAc) 
samples from 9-week old, untreated C57BL/6J, DBA/2J, α7 KO, and WT mice were 
micro-dissected on ice and immediately flash-frozen in liquid nitrogen using a protocol 
described previously (Kerns, 2005). Samples were homogenized with a Polytron® 
(Kinematica AG) and RNA extracted using a guanidine/phenol/chloroform method 
(STAT-60, Tel-Test, Inc.). Each RNA liquid layer was added to an RNeasy Mini Column 
(Qiagen) for cleanup and elution of total RNA. RNA quality and purity was determined 
using an Experion Automated Electrophoresis Station (Bio-Rad) and a Nanodrop 2000 
(Thermo Scientific). 1µg of RNA was converted to cDNA using the iScript cDNA 
synthesis kit containing random hexamers  (Bio-Rad) according to manufacturer’s 
instructions.  Primer sequences, Tm’s, amplicon sizes, and cDNA dilutions  used for 
each gene are listed in Table 6.1. Primer efficiencies were between 90-110% and each 
primer set resulted in only one PCR product. Data analysis was performed using the 2-
[∆∆CT] method (Heid, 1996). Statistical analysis of qRT-PCR data was performed using a 
Student’s t-test between the two strains tested.
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 Affymetrix Mouse 430A 2.0 microarrays were performed on α7 KO and WT single 
NAc samples from individual animals, n=5/genotype (sample collection and RNA 
extraction were performed as described above). All RQI values were >9.0, 260/280 
ratios were between 1.9-2.1 and 260/230 ratios were >2.0. Samples were randomized 
at all possible steps and 100ng of RNA input were used for each 16-hour I reaction. 
Remaining steps were performed according to the manufacturer’s  protocol. All 
microarrays passed each quality control measure and Pearson correlations of robust 
multi-array average (RMA) signals between single chips were ≥ 0.996. Pairwise 
significance-scores (S-scores) between KO and WT chips were generated using the s-
score package in R (Kerns, 2003). A one-class statistical analysis  of microarrays against 
a mean=0 and 100 permutations, was performed in the MultiExperiment Viewer (MeV, 
Boston, MA). A delta of 0.314, a false-discovery rate of 9.8%, and s-scores ≥ |1.5| were 
used to identify significantly differentially regulated genes. Gene network construction 
was performed using Ingenuity Pathway Analysis (Ingenuity, Redwood City, CA), which 
uses Fisher’s exact test to determine the probability of input genes belonging to the 
network by chance (Ingenuity Pathway Analysis, 2005). 
 Immunoblotting. Single nucleus accumbens (NAc) from untreated α7 KO and WT 
mice were microdissected and flash-frozen in liquid nitrogen as described above. 
Samples were triturated in 100uL of cold 1X LDS (Life Technologies, Grand Island, NY) 
containing 2X Halt protease and phosphatase inhibitor cocktail and 10mM EDTA 
(Thermo Fisher Scientific). Each sample was  passed through a 28g syringe until brain 
tissue was no longer visible upon quick spin centrifugation. Protein concentrations on 
the whole sample homogenates were determined using the bicinchoninic acid assay 
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(Thermo Fisher Scientific). Samples were balanced with 1X LDS, reduced with 50mM 
dithiothreitol and boiled for 10 minutes. For each antibody used herein, it was 
determined that 20µg of protein lie within the linear range of detection, thus  20µg of 
protein were loaded per lane on a 4-12% NuPage bis-tris gel (Life Technologies). Using 
a 1X MOPS running buffer, electrophoresis  was performed at 150V. The gel was 
transferred to a 45µm PVDF membrane at 10V for 24 hours using a freshly prepared 
transfer buffer containing 10% methanol. Coomassie staining of the gel and Ponceau 
staining of the membrane indicated efficient and even transfer. Prior to each primary 
antibody incubation, the membrane was blocked with 5% BSA in 1X wash buffer (TBS-
T containing 0.3% Tween 20 and 1.5M NaCl) for 1 hour at room temperature. Primary 
and secondary antibody catalog numbers, dilutions, and incubation times are provided 
in Table 6.2. Immunoblots were imaged on Kodak film using the chemiluminescent ECL 
prime reagent (GE Healthcare Life Sciences) and quantitated using ImageJ processing 
and analysis software (National Institutes  of Health). All proteins were normalized to the 
loading control, β-actin (ACTB).
Results
Genetic correlation analysis of nicotine CPP phenotypes in BXD mice.
 Following conditioning with either saline-saline (0.9%) or saline-nicotine (0.5mg/
kg) twice daily for 3 days, nicotine place preference scores (Figure 6.2, a) on test day 
(no drug present) for BXD strains follow a continuous distribution for these behaviors, 
indicative of a polygenic trait. Strains with negative scores are interpreted as having an 
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Figure 6.2. BXD strain distribution for place preference for 0.5mg/kg nicotine.  A, 
Following conditioning with either saline-saline (0.9%) or saline-nicotine (0.5mg/kg), 
nicotine place preference scores (black) on test day for BXD strains follow a continuous 
distribution, indicative of a quantitative trait. Progenitor strains, C57BL/6J and DBA/2J, 
show divergent phenotypes for this trait. Each point represents the mean ± SEM of 
n=6-12 mice per group. B, Transformed distribution, nicotine minus saline BXD strain 
means. (Behavioral studies performed by Tie Han and Lisa Merritt).
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aversion to nicotine and strains with positive scores showed a preference for nicotine. 
Of note, some BXD strains treated with saline appear to show preferences for one side 
of the CPP chamber, however, the within-strain variability is quite high. To remove 
possible confounds of the saline phenotype on our nicotine phenotype, we performed a 
subtraction of BXD strain means,  nicotine minus saline (Figure 6.2, b) and used this 
phenotype throughout the remainder of the paper. The progenitor strains, C57BL/6J and 
DBA/2J, show divergent phenotypes. The mean heritability for nicotine place preference 
was 18.7% (Table 6.3). Quantitative trait loci (QTL) analysis revealed suggestive 
behavioral QTL (LRS>9.2) for nicotine CPP on proximal Chr X (maximum LRS 10.4; 
18.79 Mb; see Table S1). Genetic correlation analysis with traits  within the 
GeneNetwork phenotype database (www.GeneNetwork.org) revealed that nicotine 
place preference phenotypes significantly inversely correlate to the number of 
cholinergic neurons in multiple dorsal and ventral striatal sections (Table 6.4), 
suggesting a link between the nicotine place preference and cholinergic signaling in the 
striatum. Nicotine preference scores also significantly correlated positively to 
consumption of a saccharin solution (Belknap, 1992) (an appetitive reward-like 
behavior), exploratory activity in an open field test following saline (Belknap, 1992), 
rearing behavior following morphine (Philip, 2010), and percent time spent in the light 
side of a light dark box following ethanol administration (Putman, 2008), See Table S2). 
Together, these findings  suggest that the genetic architecture underlying nicotine place 
preference is complex and likely consists of both genes overlapping with natural food 
reward and exploratory behaviors, as well as genes involved in other drug of abuse 
phenotypes. A full list of significant nicotine preference phenotype correlates is provided 
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GeneNetwork 
ID Phenotype Authors
Spearma's 
rho n Strains  p(rho)
10106
Central nervous system, morphology: 
Striatum cholinergic neurons, section 
11 [n neurons/section] -0.7356738 18 0.000268
10107
Central nervous system, morphology: 
Striatum cholinergic neurons, section 
14 [n neurons/section] -0.5443756 18 0.0180843
10110
Central nervous system, morphology: 
Striatum cholinergic neurons, section 
22 [n neurons/section] -0.6417141 18 0.0032019
Dains K, 
Hitzemann 
B, and 
Hitzemann 
R (1996)
Table 6.4 BXD place preference scores correlate inversely to the number of 
striatal cholinergic neurons. Within multiple sections of the striatum, the number of 
cholinergic neurons (Dains  et al. 1996) is significantly inversely correlated with nicotine 
place preference scores of BXD mice on day 5 of the CPP paradigm. All genetic 
correlations are Spearman correlations performed using GeneNetwork (GN ID = 
GeneNetwork Record ID, n = number of BXD strains used for correlations).  
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in Supplemental Table S2. 
Basal Chrna7 mRNA expression in the NAc is genetically inversely correlated with CPP 
nicotine reward-like phenotypes in the BXD panel of mice.
 The lack of robustly significant QTL for nicotine place preference scores may be 
due to large intra-strain variance, high environmental variance, as well as  the 
complexity of the behavioral assay. Furthermore, many genes or loci of small genetic 
effect underlying the CPP behavior, rather than one or few loci of large effect would 
likely mask detection of a significant behavioral QTL with the number of strains assayed 
herein. Despite this, we reasoned that this data could still be used to identify gene 
expression networks contributing to trait variation. We have previously generated basal 
genomic expression profiles across the mesolimbocortical dopamine pathway (NAc, 
PFC, and VTA) in many of the same BXD strains used for the studies here (Wolen, 
2012). Therefore, we correlated these expression patterns to the transformed CPP 
behavioral data (nicotine-saline). Correlating this  trait versus  gene expression in NAc, 
PFC, and A resulted in 2044, 2099, and 1253 probesets, respectively, showing 
provisional correlations (p<0.05) (See Supplemental Tables S3-S6). The further analysis 
of these expression correlates will be reported elsewhere, but for the purposes of this 
report, we simplified the data analysis  by surveying the results for nicotinic receptor-
related genes that also contained putative cis expression QTL (eQTL). We proposed 
that this might implicate specific nicotinic receptors not previously implicated in 
modulating CPP for nicotine. Correlates were filtered for genes containing only putative 
cis eQTL because cis eQTL occur most often from genetic variation within the gene 
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itself, have a larger effect size, and are the primary genetic drivers of variation, while 
trans eQTL have secondary or tertiary effects (Schadt, 2003; Drake, 2006). This 
analysis showed that only Chrna7 in NAc contained a cis eQTL that significantly 
correlated with the normalized CPP phenotype (see Table S7). Figure 6.3 depicts 
correlations between the normalized CPP phenotype and Chrna7 mRNA expression 
(Figure 6.3, a, probeset ID 1440681_at and 6.3, b, probeset ID 1450229_at) in each of 
the three brain regions of the mesolimbic dopamine reward pathway (VCU BXD NA, 
VTA and PFC, RMA saline datasets). Although preference scores correlated significantly 
to Chrna7 mRNA expression in both NAc (Pearson’s  r= -0.50, p=9.04E-3, probeset 
1446081_at) and PFC (Pearson’s  r= -0.51, p=9.07E-3, probeset 1450229_at), the cis 
eQTL only existed in the NAc for probeset 1446081_at, so we focused on this probeset 
for the remainder of analyses. Together, with the CPP correlation to cholinergic neurons 
in the striatum, these data suggest that strains  with low basal mRNA expression of 
Chrna7 in the NAc may be more susceptible to the reward-like properties of nicotine 
using the CPP test.
 Figure 6.4a-b depicts  the Chrna7 cis eQTL (probeset 1440681_at) present in the 
NAc across the BXD panel of mice. Since two probes  within this  probeset have single 
nucleotide polymorphisms (SNPs) between B6 and D2 mice that may have influenced 
cRNA hybridization to the oligonucleotide microarray, causing a false cis eQTL, we 
excluded those probes and re-performed interval mapping, which confirmed the putative 
cis eQTL (Figure 6.4, a-b). Microarray results were validated by performing qRT-PCR 
for Chrna7 from B6 and D2 NAc tissue samples (Figure 6.4, c). Genetic variation, 
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Figure 6.3. The nicotine place preference phenotype is genetically correlated to Chrna7 
basal mRNA expression in the nucleus accumbens, but not the prefrontal cortex, or 
ventral midbrain.  Preference scores (nicotine-saline) significantly correlate with basal 
Chrna7 expression (Chrna7 Probeset ID = 1440681_at, panel A) in the nucleus accumbens 
and prefrontal cortex (Chrna7 Probeset ID = 1450229_at, panel B), but not ventral midbrain 
(denoted as VTA). Correlation scattergrams (left of diagonal), univariate density plots  (in 
white, along the diagonal), and Pearson’s  r values (right of diagonal) are displayed. For the 
correlation scattergrams, the linear fits are plotted in red with 50% confidence intervals in 
blue. Each point represents the mean for a BXD strain. A blue r values denotes a significant 
correlation, while grey r values  are non-significant at an alpha = 0.05. All expression data are 
saline RMA values from the VCU BXD NA, PFC, and VTA Datasets, with probes containing 
SNPs between B6 and D2 genotypes removed.
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Figure 6.4. Genome-wide interval map for Chrna7 mRNA levels across the BXD RI 
panel. A, Following 2000 permutations, a suggestive cis expression QTL (blue solid 
line) exists on chromosome 7 for Chrna7 mRNA levels in the nucleus accumbens (VCU 
BXD NA Dataset Saline RMA Values, Probeset ID 1440681_at). A LOD score of 3.77 
(LRS of 17.38) denotes a significant QTL. The cis eQTL remained after removal of the 
probes containing SNPs between B6 and D2 mice (red dotted line). The DBA/2J 
genotype for Chrna7 increases its expression. B, An enlargement of Chromosome 7 
reveals  two possible QTL peaks driving the mRNA expression of Chrna7, of which the 
proximal peak harbors Chrna7 (at 70.24Mb). C, Quantitative, reverse-transcriptase PCR 
validation of microarray results. Basal mRNA expression of Chrna7 in the nucleus 
accumbens is significantly greater in D2 mice compared to B6 mice (*p<0.001, 
t[12]=5.068, n=7/gp, Student’s t-test). Each point represents the mean ± SEM.
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specifically, SNPs within the 3‘UTR (which may lead to increased or decreased miRNA 
binding at the seed region) and/or the 5‘UTR (which may alter promoter activity) of 
Chrna7 are strong candidates for differential regulation of the transcript abundance 
(Schadt, 2003hp) observed between B6 and D2 strains, and thus, among the BXD 
panel of mice. Alternatively, Chrna7 transcript levels in the BXD panel may be regulated 
by a putative enhancer, which has been mapped to a region within intron 4 of Chrna7 
(Stefan, 2005). It is  possible that the enhancer contains a SNP affecting promoter 
activation and subsequent transcription between B6 and D2 mice, strains  which are 
highly polymorphic (285 SNPs, Supplemental Table S8) within intron 4 of Chrna7.
Knock-out of the α7 nAChR increases sensitivity to, while gain-of-function or agonism of 
the α7 nAChR, abolishes nicotine CPP reward-like phenotypes in mice.
 We employed a series of pharmacological and genetic manipulations in mice to 
confirm the involvement of the α7 nAChR in nicotine CPP as expected from the inverse 
correlation between basal Chrna7 mRNA expression and nicotine CPP. First, α7 KO 
mice demonstrated significant preference for 0.1mg/kg nicotine versus saline control 
treatment (Figure 6.5, a). This  dose of nicotine does not routinely produce place 
preference in C57BL/6J mice (Walters, 2006), suggesting an increase in sensitivity to 
the reward-like properties of nicotine in CPP. However, this enhancement was not 
observed with 0.5 mg/kg of nicotine. In contrast, gain-of-function, α7 KI mice did not 
develop preference to nicotine at either 0.1 or 0.5 mg/kg, but WT littermates developed 
normal preference for 0.5 mg/kg nicotine (Figure 6.5, b). This follows the trend observed 
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Figure 6.5. Deletion of the alpha7 nAChR results in increased sensitivity to nicotine place preference 
and knock-in or agonism of the alpha7 nAChR prevents nicotine place preference. Panel A, on day 5 of 
the CPP paradigm, a significant increase in place preference scores for 0.5mg/kg nicotine was observed in 
both Alpha7 KO and WT  mice (oneway ANOVA, by Dunnett’s post-hoc vs. within-genotype saline 
FKO[2,20]=16.8854, *p<0.01, n=7-8/group, FWT[2,21]=24.0645, *p<0.01, n=7-8/group; 0.5mg/kg dose 
previously reported by Walters, et al 2006).  Alpha7 KO mice display place preference for 0.1mg/kg nicotine 
(oneway ANOVA, followed by Dunnett’s post-hoc vs. saline control, F[2,20]=16.8854, #p<0.05, n=7-9/group). 
This enhancement of preference for 0.1mg/kg nicotine was of significantly lower magnitude than preference 
for 0.5mg/kg nicotine (oneway ANOVA, Tukey’s HSD post-hoc, F[2,20]=16.8854, ‡p<0.01, n=7-8/group). A 
twoway ANOVA (F[5,41]=16.9029, n=7-9/group) revealed significant main effects of both dose (p<0.01) and 
genotype (p<0.05), but no significant interaction between dose*genotype (p=0.3371). Panel  B, On Day 5 of the 
CPP paradigm, only wildtype (WT) mice, but not alpha7 knock-in (KI) mice, show nicotine place preference for 
0.5mg/kg of nicotine.  A oneway ANOVA, followed by Tukey’s HSD post-hoc, revealed a significant effect of 
dose in WT mice (F[2,21]=12.1665, n=8/group, *p<0.01), but not KI mice (F[2,29]=0.0080, p=0.9920, n=8-16/
group). C, Place preference for 0.5 mg/kg nicotine was significantly higher than preference for saline in B6 
mice (oneway ANOVA vs. PHA0/Nic0, Tukey’s HSD post-hoc, F[1,12]=35.8629, #p<0.01, n=6-8/group). 
Pretreatment with the nAChR alpha7 selective agonist, PHA-543613 (PHA), dose-dependently blocks place 
preference for 0.5mg/kg nicotine. Significant blockade was observed at 8.0 and 12.0 mg/kg PHA (oneway 
ANOVA vs. PHA0/Nic0.5, Dunnett’s post-hoc, F[3,25]=10.4663, *p<0.01, n=6-8/group). D, For CPP for 0.5mg/
kg of nicotine, 12.0mg/kg PHA blocked preference and this was reversed by pretreatment with 10.0mg/kg of 
methyllycacontinine (MLA) (oneway ANOVA vs. PHA12/Nic0.5 alone, Tukey’s HSD post-hoc, F[1,13]=46.5249, 
*p<0.01, n=7-8/group). MLA alone did not alter nicotine preference. Each point represents the mean ± SEM. 
(Behavioral studies performed by Cindy Evans).
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for low or no preference in BXD strains having high basal mRNA levels  of Chrna7 
(Figure 6.2). Finally, the α7-selective agonist, PHA-543613, was able to dose-
dependently block preference in B6 mice for 0.5mg/kg nicotine (Figure 6.5, c), a dose 
that routinely produces place preference in this strain of mice (Walters, 2006). The 
highest dose of PHA-543613 (12.0 mg/kg) did not significantly alter preference scores 
on its own (data not shown, one-way ANOVA vs. vehicle, Tukey’s  HSD post-hoc, 
F[1,14]=0.5321, p=0.4778, n=8/group). Furthermore, Figure 3.5D shows that blockade 
of nicotine preference by PHA-543613 can be reversed using 10.0 mg/kg of the α7-
selective antagonist, MLA (oneway ANOVA vs. PHA12/Nic0.5, Tukey’s HSD post-hoc, 
F[1,13]=46.5249, *p<0.01, n=7-8/group). Also shown and previously reported, this dose 
of MLA was unable to block preference for 0.5mg/kg nicotine in B6 mice on its  own 
(Walters, 2006). 
 To control for possible learning deficits or enhancements in the gene-targeted mice 
and to determine if this effect was specific to nicotine, we tested cocaine CPP in α7 WT, 
KI, and KO mice. Mice of all three genotypes  developed similar place preference to 
10mg/kg cocaine (Figure 5.6, a-b), suggesting that not only are these mice responsive 
to pavlovian drug conditioning, but also that the α7 mechanism is nicotine-selective. As 
an additional control to rule out Chrna7 involvement in place preference for cocaine, we 
attempted to block preference in C57BL/6J mice with PHA-543613, but saw no 
attenuation of cocaine place preference compared to control (Figure 5.6, c).
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Figure 6.6. Alpha7 knock-in and knock-out mice develop normal place preference 
to a 10mg/kg dose of cocaine; pre-treatment with PHA in C57BL/6J mice does not 
alter cocaine place preference. Panels A and B, On Day 5 of the CPP paradigm, a 
significant increase in place preference scores for 10mg/kg cocaine compared to within-
genotype saline treatment was observed for all genotypes tested (oneway ANOVA, vs. 
within-genotype saline, Dunnett’s post-hoc, FKO[1,13]=83.3130, *p<0.01, n=7-8/group, 
FWT-A[1,13]=47.3111, *p<0.01, n=7-8/group, FKI[1,16]=23.6439, *p<0.01, n=9/group, FWT-
B[1,15]=13.8604, *p<0.01, n=8-9/group). Panel C, C57BL/6J mice develop robust place 
preference to 10mg/kg cocaine as previously reported (cite, year), (oneway ANOVA, vs. 
saline, Dunnett’s post-hoc, F[1,8]=23.0984, *p<0.01, n=5/group). Pre-treatment with 
PHA did not block cocaine place preference in C57BL/6J mice, C (oneway ANOVA, vs. 
within-group PHA, Dunnett’s post-hoc, F[1,14]=4.9642, #p<0.05, n=8/group). Each point 
represents the mean ± SEM. (Behavioral studies performed by Dr. Pretal Muldoon).
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Genetic interactions among Chrna7 and insulin-related genes in the NAc may contribute 
to preference for nicotine. 
 In order to explore possible mechanisms underlying the enhanced sensitivity to 
nicotine observed in α7 KO mice with the CPP test, contrasted to their WT counterparts, 
we performed microarray analysis on NAc samples from only α7 KO and WT mice, but 
not KI mice. Following statistical analyses and filtering, differentially regulated genes 
revealed the top significant network (p=1.0E-49) as  containing multiple genes involved 
in insulin signaling (Figure 6.7, a). We observed differential expression between α7 KO 
and WT mice in the insulin growth factor binding proteins, Igfbp2 and Igfbp6, as well as 
Ide (insulin-degradation enzyme). A study in rats had reported differential mRNA 
expression of Ide following nicotine treatment (Polesskaya, 2007) and furthermore, an 
allele within the Ide gene had been previously significantly associated with plasma 
cotinine levels in both European and African American smokers (Hamidovic, 2012), 
implicating a possible role for Ide in nicotine addiction. 
Furthermore, within the BXD panel of mice, we elucidated a co-expression 
network of Chrna7 and insulin-related genes in the NAc, which are significantly 
genetically correlated to each other as well as the normalized nicotine preference 
phenotype, suggesting novel and complex gene-gene interactions underlying place 
preference to nicotine (Figure 6.7, b). Finally, qPCR performed from α7 KO and WT NAc 
samples confirmed significant downregulation of Ide mRNA ((p<0.05, t[7]= 2.957), 
upregulation of Igfbp6 mRNA (p<0.05, t[7]=2.230), and a non-significant trend for 
differential regulation of Igfbp2 (p=0.11, t[7]=1.07, see Table 3.5). qPCR for gene, Ndn, 
which was upregulated in α7 KO mice likely linked to Chrna7, was performed as a   
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Figure 6.7. Knock-out of the α7 nAChR results in alterations to an insulin-related 
gene network. A, Top-ranked (p=1.0E-49) biological network of genes differentially 
regulated in the NAc between α7 KO and WT mice (red = upregulated, green = 
downregulated, colorless  = imputed gene, number below each gene = KO/WT s-score, 
red arrows denote insulin-related genes). B, Genetic correlation network performed 
using BXD mRNA expression data, displaying co-regulation of Chrna7 and multiple 
insulin-related genes in the NAc. (All correlations drawn are significant and used 
Pearson’s r, red = positive, blue = negative. bold = r ≥ |0.5|, solid = |.41| ≥ r < |0.49|).
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Gene
Normalized Relative 
KO Expression KO SEM
Normalized Relative WT 
Expression WT SEM p-value
Ide* 0.731 0.091 1.102 0.096 1.55E-02
Igfbp2 1.768 0.249 1.166 0.166 1.08E-01
Igfbp6* 1.549 0.144 1.071 0.136 3.58E-02
Ndn* 2.374 0.160 1.177 0.078 3.09E-03
Table 6.5. Quantitative RT-PCR confirms differential insulin-related gene expression in the 
NAc of α7 KO and WT mice. Basal mRNA expression of Ide is  significantly down-regulated in 
the NAc of KO mice compared to WT mice, while Igfbp6 is significantly up-regulated, and there is 
a trend toward up-regulation of Igfbp2. Ndn, a gene likely linked to Chrna7 on chromosome 7, 
was also confirmed to be up-regulated in KO mice. Each point represents the mean of  ± SEM 
(nKO=4 and nWT=5). All genes were normalized to the housekeeping gene, Gapdh.
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positive control. The elucidated expression networks and qPCR data suggest an 
increase in insulin signaling in both α7 KO and BXDs with low NAc levels  of Chrna7 
mRNA, thus perhaps these genes may be regulated by Chrna7.
Knock-out of the α7 nAChR results in basal increases in insulin signaling in the nucleus 
accumbens.
 To confirm functional differences in insulin signaling in the nucleus accumbens of 
α7 KO and WT mice, we performed immunoblotting for proteins  known to be involved in 
insulin signaling. Contrasted to our microarray data in which Ide mRNA was decreased 
in the NAc of α7 KO mice, we found that IDE protein was significantly upregulated 
compared to WT (*p<0.01, t[6]IDE=5.18), Figure 6.8. Additionally, we found a trend for 
decreased total INSR-β (insulin receptor, intracellular subunit) levels (p=0.113, 
t[6]INSR=1.87) and significantly increased phosphorylation of multiple sites of the INSR in 
α7 KO mice compared to WT mice (t[9]pIR(Y1158, Y1162, Y1163)/IR=4.60, t[9]pIR(Y932)/IR=4.49), 
Student’s t-test, nKO=6, nWT=5.
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Figure 6.8. Alpha7 knockout mice display differential basal expression of insulin-
related proteins in the nucleus accumbens. A, Representative immunoblots of nucleus 
accumbens samples from individual mice. IDE=insulin-degrading enzyme, 
pIR=phosphorylated insulin receptor (Y= tyrosine residue phosphorylated), INSR/IR=β 
subunit of the insulin receptor, ACTB=β-actin). B, Quantitation and analyses of 
immunoblot samples (nKO=6, nWT=5) by Student’s  t-tests revealed that IDE protein levels 
as well the degree of phosphorylation of the total insulin receptor were significantly 
increased in alpha7 KO mice compared to WT mice (*p<0.01, t[9]IDE=5.18, t[9]pIR(Y1158, 
Y1162, Y1163)/IR=4.60, t[9]pIR(Y932)/IR=4.49) while total insulin receptor levels showed a trend for 
being decreased compared to WT mice (p=0.113, t[9]INSR=1.87). All proteins are 
normalized to ACTB.
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Discussion
In this  study, we combined behavioral and expression genetics to identify 
candidate genes underlying nicotine’s reward-like behavioral response in mice. This 
implicated Chrna7 as  a candidate gene and we verified this assumption using gene-
targeted mice and pharmacological tools  for Chrna7. By extending our genomic analysis 
in α7 KO mice, we provide evidence that an insulin gene expression network in the NAc, 
regulated by Chrna7, may contribute to reward-like effects of nicotine CPP. 
Using the BXD panel of mice, we found that basal Chrna7 mRNA expression in 
the NAc was significantly negatively correlated to CPP for nicotine. Studies with the α7 
agonist, PHA-543613, reduced CPP for nicotine dose-dependently and MLA studies 
with the α7 antagonist, MLA, were able to reverse the attenuation of nicotine CPP. 
Behavioral analyses in α7 KI mice did not display nicotine CPP, but conversely, α7 KO 
mice were more sensitive to a low dose of nicotine, suggesting an increased perceived 
reward-like effect in these mice. Together, these behavioral data strongly implicated 
Chrna7 as a candidate gene modulating nicotine reward-like phenotypes in CPP.
Previous studies using α7 KO mice or an α7 antagonist in rats  have reported that 
the α7 nAChR is  not required for nicotine CPP (Walters, 2006) or self-administration 
(Brunzell, 2012), respectively. Additionally, it was reported that reductions in α7 nAChR 
activity due to antagonist administration into the NAc shell, as  well as  anterior cingulate 
cortex, increased the motivation of rats  to self-administer nicotine (Brunzell, 2012), 
suggesting that low or lack of α7 nAChR activity may modulate the use of nicotine. By 
surveying the BXD strains and including a lower dose of nicotine in our α7 KO studies 
for nicotine CPP, our studies have unmasked the first evidence that Chrna7 transcript 
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levels  in the NAc are both genetically regulated and may be an important factor in 
determining the magnitude of nicotine’s reward-like effects as measured by CPP. 
Although CPP and self-administration were originally thought to be isomorphic models 
of drug reward, that idea is no longer generally supported. Rather, it is commonly 
accepted that that self-administration is  a model of reinforcement, and CPP is a model 
of “reward” (and is  influenced by other factors  such as memory), thus each measure 
different components of drug-seeking behavior in animals  (Bardo, 2000). Since the 
CPP test measures contextual cues associated with a drug’s perceived “reward”, our 
data suggests that lower levels of Chrna7 mRNA in the NAc contributed to an altered 
(perhaps, enhanced) neural response to cue-related behaviors, allowing nicotine-
seeking behavior to persist.
 Using microarray analysis, we discovered that gene-targeting of the α7 nAChR 
results in up-regulation of an insulin-signaling network in the NAc. A genetic correlation 
network of insulin-related genes and Chrna7 was independently elucidated in the NAc 
across the BXD panel, thus validating that our microarray results are likely not due to 
developmental compensation in α7 KO mice. Insulin-degrading enzyme, Ide, mRNA 
was significantly decreased and previous rodent studies have demonstrated that both 
knock-out of this  gene (Farris, 2003), as well as  a mutation decreasing its catabolic 
activity (Fakhrai, 2000), results  in hyperinsulinemia and glucose intolerance. Based on 
these studies, we predict that in the NAc, α7 KO mice should have increased insulin 
signaling compared to WT mice. Insulin and insulin growth factor 1 (IGF1) are produced 
peripherally and can readily cross the blood brain barrier to elicit endocrine signaling 
events. IGF1 is also secreted locally by neuronal cells (neurons, microglia, and 
157
astrocytes) and participates in paracrine signaling within the brain. Insulin and IGF1 
signal through either of their receptors, INSR (Insulin receptor) or IGF1R (IGF1 
receptor), or, through a hybrid receptor formed from dimerization of the INSR and 
IGF1R receptors. Insulin binds to and activates  its receptor, which stimulates 
autophosphorylation of the intracellular β-subunit at tyrosine residues 1158, 1162, and 
1163 promoting receptor tyrosine kinase activity. This event stimulates phosphorylation 
of Y972, which creates recognition sites for insulin receptor substrates (IRS) (Draznin, 
2006). Recruitment of IRS can trigger two canonical signaling pathways, PI3K-AKT and 
Ras-ERK. A study performed on rat NAc slices  reported that insulin potentiates the 
effects of DA release in the NAc following cocaine administration and this was reversible 
using a PI3K inhibitor (Schoffelmeer, 2011). Additionally, a study in rat striatal cultures 
found that insulin receptor activation led to increases in DAT mRNA expression and 
transporter function that resulted in higher reuptake of dopamine (Patterson, 1998) and 
regulation of DAT was blocked in cell culture with a PI3K inhibitor, providing evidence for 
the PI3K-AKT pathway in insulin’s modulation of dopamine uptake (Carvelli, 2002). 
These studies suggest a negative feedback loop in which insulin promotes both 
dopamine release and dopamine reuptake via increasing DAT transcription. In fact, α7 
KO mice have been shown to have significantly higher levels  of and longer persistence 
of nicotine-induced DA release in the NAc compared to WT mice (Besson, 2012). This 
enhancement of DA release within the brain’s reward center in α7 KO mice may be one 
explanation for the increased sensitivity to low dose nicotine observed in the CPP test. 
 Our studies  also provide evidence of feedback regulation of insulin levels, in which 
Ide mRNA in α7 KO mice is lower, suggesting high insulin levels, but IDE protein levels 
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are higher compared to WT mice. Protein levels may be high to compensate for 
increases in insulin levels and/or due to protein-protein interactions  between insulin and 
IDE, thus stabilizing IDE protein.  Additionally, we found significantly higher activation of 
the INSR as well as a trend for decreased INSR protein levels in α7 KO mice, 
suggesting possible downregulation of the receptor due to this increased activation by 
insulin. Furthermore, our microarray experiment revealed higher transcript levels of 
genes for two insulin growth factor binding proteins, Igfbp6 and Igfbp2, in α7 KO 
compared to WT mice. The bioavailability and actions of IGF1 are tightly regulated by 
insulin-like binding proteins, IGFBP1-6. Upregulation of IGF binding proteins in the NAc 
of α7 KO mice may be the result of a compensatory mechanism acting to sequester free 
IGF in response to the increases in insulin to prevent hyperstimulation of insulin 
signaling pathways via the hybrid receptor.   
Taken together, these studies  provide evidence that Chrna7 modulates an 
expression network of insulin-related genes and their proteins, which may alter 
downstream dopamine signaling, leading to altered nicotine reward-like behaviors in 
mice. These studies are the first to elucidate the genetic interplay between Chrna7 and 
insulin signaling in the NAc and a role for such interactions in nicotine behavior. These 
genetic and protein interactions  have implications for uncovering new therapeutic 
targets for nicotine cessation pharmacotherapies. 
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Chapter 7 - Concluding Discussion and Future Studies
Discussion
! Within the alcohol addiction research field, the notion that an individual’s initial 
level of response to alcohol correlates inversely  to his or her later susceptibility  to 
becoming alcoholic (Schuckit, 1994; Schuckit, 1980), has been a key driver in the  study 
of the neurobiological and neurogenomic mechanisms underlying acute ethanol-
responsive behaviors. Together, with the extensive literature suggesting that acute and 
repeated drug use lay  the groundwork for rewiring the nervous system toward addiction, 
the overall hypothesis of this dissertation work was that identification of genetic variants 
modulating acute behavioral responses to ethanol and nicotine may allow us to better 
understand the neural mechanisms contributing to these early cycles of addiction. By 
using a genetical genomics approach in mice, we have identified and begun to confirm 
a role for two such candidate genes, Chrna7 and Nin.
! At this point, it is important to further discuss the relationship between the initial 
level of response with later drug abuse and/or chronic drug behaviors. To reiterate, it 
has been accepted that those with lower initial responses to alcohol, and thus a reduced 
perception of a “high” from the same dose as others with the same blood alcohol 
concentration, have a higher susceptibility of becoming alcoholic later in life (Schuckit, 
1994). However, the responses tested by Schuckit were very specific (ie, body sway) 
and subjective (as determined by a survey). Therefore, we must not generalize that a 
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“low level” of every type of drug response will correlate with dependence susceptibility. 
In fact, mouse correlation data presented in Chapter 2 (Figure 2.1) shows the exact 
opposite, in which phenotypic responses in the acute paradigms tested for alcohol and 
nicotine correlate positively with chronic dependence-like behaviors for these same 
drugs. This discrepancy with the human literature might be due to the manner in which 
the data were scored for each assay, but nonetheless, these data do show a 
relationship  between acute and chronic behaviors, suggesting that measuring these 
type of phenotypes in mice is complex. 
! Perhaps, the data should be interpreted differently. For example, B6 mice show a 
greater anxiolytic-like response in the LDB compared to D2 mice, yet they self-
administer ethanol to dependence, while D2 mice do not (Le, 1994), suggesting a 
positive correlation between the acute and chronic ethanol phenotypes. The low 
consumption of ethanol in D2 mice is thought to result from an aversion to the odor, 
taste, and/or mucosal irritation, which B6 mice do not demonstrate (Belknap, 1977). D2 
mice were reported to avoid ethanol, even when adulterated with saccharin, in a 
conditioned taste aversion test (Horowitz, 1975). However, B6 mice have also been 
shown to have lower blood ethanol concentrations than D2 mice administered the same 
dose which persists for up to an hour following administration (Grisel, 2002). This 
supports both a decreased metabolism of ethanol and higher brain concentrations of 
ethanol (ethanol is a small, water-soluble molecule which readily  diffuses through the 
blood-brain barrier) in D2 mice, thus perhaps, higher euphoric effects of ethanol. 
Unfortunately, these subjective phenotypes cannot be asked of rodents. One 
interpretation of this might be that D2 mice in fact have higher initial levels of response 
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to ethanol defined by Schuckit as “greater perception of a high” and in turn, this is 
manifested by a lower level of response in the LDB assay and consequently, an 
aversion to drinking. Following this line of thought, B6 mice might then perceive a 
dampened rewarding effect of ethanol since concentrations reaching the brain would be 
lower, leading to enhanced self-administration to compensate for the low brain levels. 
Interestingly  in support of this notion, B6 mice have been shown to turn over synaptic 
dopamine (DA) in striatal nerve terminals to its metabolite, 3,4-Dihydroxyphenylacetic 
acid (DOPAC), more rapidly  than D2 mice under basal conditions even though total 
striatal DA levels were not different between the two strains (George, 1995). 
Furthermore, DA and DOPAC levels assayed immediately following a limited-access 
ethanol consumption paradigm revealed that ethanol did not alter total DA levels in the 
striatum, ventral midbrain, or frontal cortex, but did significantly increase the ratio of 
DOPAC to DA only  in the striatum compared to naive mice (George, 1995). 
Pharmacological inhibition of one of dopamine’s metabolic enzymes, monoamine 
oxidase B (MAO-B), with selegiline resulted in significant decreases in drinking behavior 
in B6 mice, and this was reversed with co-administration of antagonists for either 
dopamine receptor 1 and 2 (George, 1995). Thus, B6 mice have a genetic 
predisposition resulting in dampened basal striatal DA function due to high rates of 
synaptic turnover, which may cause a decreased reward-like response to ethanol and 
thus, a propensity to consume high levels. 
! The acute ethanol studies performed here implicate a role for Nin in an acute 
anxiolytic-like response to ethanol in mice. As mentioned earlier, the main function of 
Nin is microtubule-anchoring and organization in the centrosome during mitosis, 
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however, this is unlikely its function in the acute response to ethanol. Rather, Nin might 
by eliciting its effects through its interaction with microtubules in synapses to contribute 
to neuroplasticity. Until recently, it was thought that microtubules were not involved in 
actively-forming dendritic spines, protrusions of varied shapes which receive most of the 
brain’s excitatory input at the post-synaptic density (PSD) of glutamatergic neurons. 
However, recent immunohistochemical labeling studies have confirmed the presence of 
dynamic microtubules in dendritic spines (Hu, 2008). The shape, composition, and 
microenvironment of dendritic spines are important in the synaptic transmission of and 
communication between neurons (Gray, 1959). As they are mainly found on 
glutamatergic neurons, the PSD of dendritic spines is largely comprised of N-methyl-D-
aspartate (NMDA) receptors, to which glutamate directly binds, eliciting excitatory 
neurotransmission and promoting spine formation (Carpenter-Hyland, 2007). Therefore, 
increased concentrations of NMDA receptors, along with the presence of dynamic 
microtubules and their associated proteins within dendritic spines, may suggest an 
increased likelihood of interactions between Nin and NMDA receptors at the synapse or 
an association between Nin levels and synaptic plasticity. Interestingly, within the NAc, 
the brain region where Nin expression is thought to mediate acute ethanol’s anxiolytic-
like response, Nin and Grin2b (NMDA, NR2B subunit) basal mRNA levels were found to 
be significantly inversely  correlated (Figure 7.1, a). In fact, non-centrosomal Nin has 
been found in much higher concentrations in neuronal cells than centrosomal-
associated Nin, and levels were higher in processes actively  undergoing axonal 
retraction or “pruning”, a process that serves to eliminate inappropriate axonal 
projections (He, 2002; Baird, 2004). Thus, Nin may perform a protective role during 
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Figure 7.1 - Basal NAc Nin mRNA correlations with Grin2b and ethanol 
consumption. Across the BXD panel of mice, basal mRNA expression of Nin and 
Grin2b were found to be significantly inversely correlated, a. (Pearson’s r= -0.385, 
p=0.01982, n=36 strains). Basal Nin levels in the NAc were also significantly correlated 
with two-bottle choice drinking behavior following three rounds of ethanol vapor in the 
CIE model, b. (Pearson’s r= -0.702, p=0.0212, n=10 strains).
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neurogenesis, disease, and/or injury to ensure “proper” synapse formation. Even more 
striking, the basal mRNA expression of Nin significantly  correlates to two-bottle choice 
drinking following three bouts of ethanol vapor in the chronic-intermittent ethanol model 
of alcohol dependence (Figure 7.1, b), implying that low Nin transcript abundance in the 
NAc may be a risk factor for later drinking behavior.
! Chronic administration of ethanol and other drugs of abuse has been shown to 
decrease dendritic spine density (Robinson, 1997; Chandler, 2006; Kauer, 2007) and 
investigation of alcoholic brain tissue samples revealed that chronic drinking 
significantly decreased both the number of dendritic spines in the NAc and caused 
dysmorphology of spines (Zhou, 2007), revealing a neurotoxic effect of ethanol. It has 
been shown that ethanol, a known negative allosteric modulator of the NMDA receptor 
with its allosteric site on the NR2B subunit (Wright, 1996), acutely potently inhibits 
NMDA signaling (Engberg, 1992), but chronically upregulates these receptors 
(Chandler, 1999). Furthermore, acute ethanol increases dendritic spine density in the 
CeA (Moonat, 2011), suggesting that increased excitatory  neurotransmission remains 
intact. The ethanol-induced upregulation of NMDA receptors is thought to occur as a 
homeostatic compensation to counteract the inhibition of NMDA receptor activity in 
order to maintain an intact neural network (Carpenter-Hyland, 2007). In fact, one of the 
three clinically-prescribed medications used to treat alcohol withdrawal symptoms, 
acamprosate, antagonizes the NMDA receptor to reduce glutamatergic surge and 
increased excitability leading to symptoms of delirium tremens following alcohol 
cessation (DeWitte, 2005). Thus, it appears that predisposition to genetic variants of Nin 
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could result in alterations of a glutamatergic amygdalar-striatal circuit following acute 
and/or chronic ethanol use.
! Taken altogether, acute ethanol, although a potent inhibitor of NMDA receptors, 
has been shown to increase dendritic spines in the CeA, suggesting homeostatic 
counteraction of this  NMDA inhibition through enhancement of excitatory output to a 
target brain region, such as  the NAc. Perhaps because individuals with high basal Nin in 
the NAc also have low levels of Grin2b  in the NAc, this excitatory neurotransmission 
from the CeA may result in an anxiolytic-like response of lower magnitude compared to 
individuals with the opposite Nin/Grin2b gene expression pattern. Chronically, ethanol 
and other drugs of abuse indirectly decrease dendritic spine densities and this 
dysregulation might contribute to altered and/or inappropriate synaptic connections. As 
the localization of Nin in retracting axons indicates  that it may play a role in correcting 
faulty dendritic spines, individuals with low Nin levels  may be at risk for an enhanced 
neurotoxic effect due to chronic ethanol. As  these neural connections become rewired 
with chronic ethanol use, local concentrations of Nin may not be high enough to 
maintain regulation, thus predisposing an individual toward addiction. A model of the 
interplay between Nin, ethanol, and anxiety is illustrated in Figure 7.2. 
 Overall, these studies strongly implicate both a role for neuronal Nin in an acute 
anxiolytic-like response to ethanol and suggest that genetic variants of Nin may be risk 
factors for chronic ethanol use. Additional studies discussed at length in Chapter 3 
strongly implicate Chrna7-mediated regulation of insulin signaling as a potential 
mechanism for eliciting nicotine’s reward-like phenotype. We report that genetic 
variation within Chrna7 might be a risk factor for smoking initiation and/or relapse. The 
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Figure 7.2 - Proposed interactions between Nin, ethanol, and anxiety. Acute 
ethanol has been shown to increase dendritic spines in the CeA, which would be 
expected to enhance excitatory output to the NAc. Perhaps this excitatory 
neurotransmission underlies the decreased anxiolytic-like response in individuals with 
high basal NAc Nin. Chronically, ethanol decreases dendritic spine densities and this 
dysregulation might contribute to altered and/or inappropriate synaptic connections. As 
Nin may play a role in correcting faulty dendritic spines, individuals with low Nin levels 
may be at risk for an enhanced neurotoxic effect due to chronic ethanol. As these neural 
connections become rewired with chronic ethanol use, Nin may not be abundant enough 
to maintain regulation, thus leading toward addiction.
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genetical genomics approach taken here illustrates the utility of inbred mice as  model 
organisms in the study of disease phenotypes. 
 
Future Studies
! This dissertation work has just begun to unravel the complex, yet intriguing, 
relationship  between alcohol use disorders and anxiety, thus future studies are 
warranted to further investigate these interactions. For example, we report that NAc Nin 
transcript levels might be important in the synaptic remodeling events which occur 
following both acute and chronic ethanol use. Although that mechanism is supported by 
Nin neuronal localization studies and a large body of literature connecting spine 
densities with anxiety and drug use, we have yet to provide direct evidence for this. To 
do so, a series of studies examining dendritic spine densities and/or type of spines after 
acute and chronic ethanol treatment might be performed in mice with either high or low 
basal NAc Nin levels, such as B6 and D2 mice. However, the diverse genetic 
backgrounds of these two strains may confound the results if epistatic interactions 
involved in spine remodeling or between Nin and another gene occur, so a better 
approach may be to use viral constructs, sh-Nin-lentivirus (or Cre-recombinase), to 
knockdown Nin in a strain (or a Nin-floxed mouse) with high basal NAc levels, such as 
were performed with D2 mice herein. 
! Currently, there is no Nin knockout mouse available and since genetic variants in 
Nin were found to be associated with skeletal dysplasia (Grosch, 2013) and dwarfism 
(Dauber, 2012), one might predict these mice may either not be viable or have severe 
cranial and limb  abnormalities. Alternatively, congenic strains of mice could be utilized in 
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which B6 mice are created with the D2 form of the Nin gene and vice versa. The B6 Nin 
genotype should increase the anxiolytic-like response to acute ethanol, as measured by 
PTS and PDT in the light. However, congenic strains of mice require years of breeding, 
the genomic changes are global rather than region-specific, and with the 
commercialization and ease of making viruses, it is simply more feasible to inject a virus 
stereotaxically to alter the expression of a gene. Furthermore, the viral approach can be 
used in strains of varied genetic background and multiple brain regions can be 
interrogated. 
! We have thus far, shown that knocking down Nin in the NAc increases acute 
ethanol’s anxiolytic-like response, manifested as a decreased latency to enter the light, 
a measure routinely interpreted as anxiolytic-like, as discussed previously. However, 
drinking behavior was not tested because D2 mice do not routinely  self-administer 
ethanol (Le, 1994). Knocking down NAc Nin in the B6 mouse strain and subsequently 
testing chronic drinking paradigms would solidify  a link between basal Nin and drinking 
susceptibility. Although this dissertation work suggests a role for neuronal Nin, 
potentially at the synapse, it may be important to determine the downstream effectors of 
Nin in the NAc which may contribute to dysregulation leading to the possibility of alcohol 
addiction. One way to do so would be to perform microarray expression analysis or 
RNA-Seq analysis on the NAc tissue of four groups of mice following the treatments: 
basal Nin + saline, Nin knockdown + acute ethanol, basal Nin + chronic ethanol, Nin 
knockdown + chronic ethanol. Comparisons within acute, chronic, and between acute 
and chronic would elucidate genetic perturbances and perhaps networks of genes 
responsive to Nin in each of those instances. Alternatively, as we are hypothesizing that 
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synaptic Nin may be the primary driver for the acute and chronic ethanol-responsive 
behaviors mentioned and Nin is expressed both within and outside of the synapse, 
synaptoneurosome preparations might be performed on the aforementioned groups 
prior to gene expression analyses to link the genetic changes observed with synapse 
expression of Nin. It may be important to understand the gene network(s) being 
modified by Nin, as altered basal expression patterns of genes may respond to ethanol 
differently (Farris, 2010), and may ultimately lead to a new therapeutic approach of 
targeting a central network hub gene or simply, a hub  of one node of a network which 
responds to a drug.
! If these experiments reveal a solid role for Nin in modulating ethanol-responsive 
behaviors, then studies ought to be performed to elucidate the mechanism of Nin 
regulation. As discussed in Chapter 5, B6 and D2 mice displayed different  pools of NIN 
isoforms in the NAc, suggesting functional differences between the two isoforms and/or 
enhancement of alternative splicing in the D2 strain. The smaller, ~150 and ~160KDa 
isoforms which were found at higher levels in D2 NAc, likely from an alternative splicing 
event in which exon 16 is skipped. As mentioned earlier, D2 mice have two non-
synonymous SNPs in exon 16 of the Nin gene, one of which is suggested to alter an 
ESE site and one which creates a new site, compared with the B6 gene. Together, 
these data suggest that D2 mice have increased alternative splicing activity, resulting in 
a greater concentration of NIN isoforms missing exon 16. To determine whether these 
SNPs are responsible for the alternative splicing events predicted, an experiment in 
which site-directed mutagenesis of Nin and subsequent cloning into an expression 
vector to create sequences having the B6 or D2 SNPs may be performed. Transfection 
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into a cell line, followed by immunoblotting, may reveal whether these SNPs are 
responsible for generating the altered pools of NIN isoforms between B6 and D2 mice. 
Alternatively, Nin expression may be differentially regulated by an intronic enhancer 
polymorphism, variant in the promotor region, or the 3‘UTR region, which may affect 
miRNA binding. 
! The relationship between Nin and Grin2b is intriguing. As acute ethanol is a 
negative allosteric modulator of NMDA receptors, one might predict that an antagonist 
of Grin2b, for example, ifenprodil, should result in an anxiolytic-like phenotype in the 
LDB. In fact, this antagonist was shown to increase social interaction in rats (Morales, 
2013). It follows then, that the magnitude of the responses should differ in B6 and D2 
mice in the same manner as ethanol, in which B6 mice might be expected to have a 
greater anxiolytic-like response to the drug.
! Some followup studies for the acute nicotine reward-like phenotype should 
certainly  include site-specific modulation of Chrna7 levels, followed by  CPP testing. As 
the relationship between its basal expression in the NAc and CPP phenotype were 
inverse, one would predict that knocking down Chrna7 in the NAc would produce an 
enhancement in nicotine CPP. That is, at the 1.0mg/kg dose which does not regularly 
produce CPP, knockdown of Chrna7 in the NAc should produce a preference 
phenotype. Additionally, based on our studies, further investigation into the interplay 
between Chrna7 and the insulin pathway is warranted. A neuronal role for insulin in not 
only disease, but substance abuse disorders, is newly  emerging, suggesting a role 
separate from its major peripheral role in glucose homeostasis (Ghasemi, 2013). 
Furthermore, as the heritability of nicotine dependence is modest, additional BXD 
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mapping studies for other relevant phenotypes should be pursued in order to better 
understand the genetic underpinnings of the disease.
! Altogether, this body of work has significant implications for both the nicotine and 
alcohol fields. We have not only confirmed roles for new QTGs in acute phenotypes for 
each drug, but we also propose that these acute behavioral responses are very 
important in the progression from acute to chronic drug use and as such, warrant 
adequate and careful investigation. By doing so, along with many others, we have 
demonstrated the validity of the “genetical genomics” approach to studying substance 
use disorders. With both the mouse and human genomes sequenced and now actively 
being characterized in terms of regulatory elements, the future of genetical genomics 
promises to be exciting and will ideally enhance our understanding of the molecular and 
genetic mechanisms of disease so that treatment by genotype may be the effective 
practice.
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